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Genetic and molecular variations are closely intertwined; while genetic factors drive phenotypic 
differences ranging from gene expression to organismal traits, phenotypic variations are the 
target of evolutionary selection, what eventually results in genetic changes. As technological 
advances have resulted in high-throughput assays for different molecular dimensions, it has 
become challenging to turn these large-scale data into meaningful insights and to delineate 
biological cause and consequence. In this thesis, I use computational modelling to detect and 
understand biologically meaningful associations between genetic variation and gene expression 
alterations. 
First, we use data across 27 human cancer types to probe associations between different 
genetic factors and gene expression levels. We describe the tumours' regulatory landscape that 
is highly heterogeneous across cancer types, and quantify the relationship between gene 
expression and various genetic features that characterise local and global mutational burden as 
well as distinct mutational processes. 
Next, we study the relationship between genetic and epigenetic variation and alternative 
splicing. This analysis extends studies of splicing events in bulk data to variability in splicing 
between single cells from the same tissue: We analyse DNA methylation and alternative splicing 
across single cells derived from one human donor to characterise splicing variation and its 
determinants across genes. Thus, we identify relevant genetic determinants of splicing in 
induced pluripotent stem cells as well as during their differentiation, and a significant 
contribution of DNA methylation to splicing variation across cells.  
Finally, we show how gene expression-mutagenesis screens can be applied to understand 
complex mutational signatures, using the cancer hallmark of DNA repair deficiency as an 
example. The molecular cause and consequence of homologous recombination repair 
deficiency are not yet fully understood. We explore genome-wide molecular aberrations caused 
by this repair deficiency beyond the few previously known genes. Our preliminary results point 
towards a genetically dominant effect of BRCA1 mutagenesis. 
Taken together, this thesis highlights novel dimensions of genotype-phenotype associations in 
highly heterogeneous molecular datasets. We describe the complex regulatory landscape 
across human cancer types, as well as molecular alterations and relevant epigenetic effects in 
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Genetic and molecular variation are strongly dependent on each other: Genetic factors drive 
phenotypic differences ranging from gene expression to organismal traits while phenotypic 
variations are under evolutionary selection what eventually results in genetic changes. In this 
introduction, we first review sources of genetic variation in the human genome, followed by 
different forms of molecular variation that can now be quantified in unprecedented numbers due 
to technological advances and the availability of high-throughput assays. Specifically, we 
describe in detail how total gene expression and alternative splicing can be quantified and serve 
as molecular proxies for protein expression (Section 1.1). 
The prevailing challenge in statistical genomics is the conversion of large-scale heterogeneous 
data into meaningful insights, including the predictability of molecular alterations and the 
associated delineation of biological cause and consequence. We focus on gene expression as 
molecular readout, and explore how the link between genetic and gene expression variation has 
been modelled so far, and how different sources of data have been integrated in previous 
analyses (Section 1.2): We introduce genome-wide association studies (GWAS) and 
quantitative trait locus (QTL) analyses, and explain how their statistical fundament, linear 
regression models, can be used to correct for known and hidden determinants of gene 
expression variability like batch effects, experimental confounders or population structure. We 
also give an overview of how complex machine learning methods can be employed to analyse 
non-linear associations in genomic data, using convolutional neural networks (CNNs) as 
exemplar.   
We then introduce human cancer as the central biological study system of this thesis (Section 
1.3). While the regulatory landscape of human cancers is highly heterogeneous, the relevance 
of the transcriptome for diagnosis and prognosis of the disease, and for the activity of mutational 
processes on the molecular level, has been well established.  
 
1.1 Functional consequences of genetic variation 
1.1.1 DNA and genetic variation 
The genome of an organism contains all necessary information to encode a living organism, and 
stores information about its evolutionary past. The genome of all living organisms and some 
viruses consists of DNA (deoxyribonucleic acid), a molecule composed of two antiparallel 
strains of polynucleotides kept together by hydrogen bonds. Each polynucleotide is composed 
of nucleotides, with each of them containing one of the four nitrogenous bases adenine ('A'), 
cytosine ('C'), guanine ('G'), and thymine ('T'). On a chemical level A and G constitute purines, C 
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and G pyrimidines, aromatic heterocyclic organic compounds that consist of one ring in the case 
of pyrimidines and of two rings in the case of purines. The hydrogen bonds that keep the two 
polynucleotide strands together operate between one purine and one pyrimidine base: A binds 
to C, and G to T. This makes the sequences of the two DNA strands complementary to each 
other (Alberts et al., 2009). 
The length and organisation of DNA differ between evolutionary taxa. Here, we focus on the 
nuclear DNA of eukaryotic organisms, which is organised into distinct chromosomes. Humans 
and most other mammals are diploid organisms, i.e., they have two homologous copies of each 
chromosome, one inherited from the mother and one from the father. Specifically, the human 
genome consists of 23 pairs of chromosomes, namely 22 pairs of autosomal chromosomes and 
one pair of allosomes. Whereas an allosome describes any chromosome that differs from the 
typical autosomes in, e.g., size or behaviour, the human allosomes constitute sex chromosomes 
that determine the genetic sex of human individuals. Human females have two copies of the X 
allosome, whereas males have one copy of the X and one of the Y allosome (Alberts et al., 
2009). Each chromosome contains protein-coding genes (approximately 1.5% of the whole 
genome) and inter-genic non-coding regions. Current estimates predict the presence of 19,000 
to 20,000 protein-coding genes in the human genome (Ezkurdia et al., 2014), with alternative 
splicing further diversifying possible function of each individual gene (Black, 2003; Section 
1.1.2). While these protein-coding regions are transcribed into messenger RNA (mRNA), the 
human genome also contains genes that are transcribed into non-coding RNA, which can be 
functional on its own (e.g., tRNA (transfer RNA) and rRNA (ribosomal RNA), which are key 
players of the translation process) (Palazzo & Lee, 2015). The human genome is approximately 
3.24G base pairs long (Venter et al., 2001; Lander et al., 2001). Every pair of human individuals 
share on average 99.5% of these base pairs (Levy et al., 2007).  
This leads us to genetic differences within a species: DNA sequence alterations that exist within 
an individual or between individuals within a population or between populations are called 
genetic variants. The alternative variants that occur at a specific genetic locus are called alleles. 
The genotype of an individual describes this individual's specific combination of alleles at a 
(normally diploid) genetic locus. In the case of diploid organisms, the genotype at a locus can 
hence be homozygous (i.e., with two copies of the same allele) or heterozygous (i.e., with two 
different alleles).  
The pool of genetic variation is large. Genetic variants can be categorised according to their 
length, their origin, their allele frequency, their functional effect, the type of chromosome they lie 
on, and if they are located in coding or non-coding stretches of the genome.  
The most common form of a genetic variant is the single-nucleotide variant (SNV), which 
describes the substitution of a single base pair (Frazer et al., 2009). SNVs can be of somatic 
origin, i.e., they originate from a de novo genetic mutation in somatic tissue, or of germline 
origin, i.e., they are inherited from parents to the offspring. The latter ones are referred to as 
single-nucleotide polymorphisms (SNPs). Variation in SNPs across individuals and populations 
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enables the inference of genetic population structure (Novembre et al., 2008). Most germline 
genetic variants in the human genome are assumed to be evolutionary neutral (Kimura, 1968), 
hypothesising that population differences have mainly arisen due to chance and stochasticity. 
Linkage disequilibrium (LD) describes the non-random association of SNPs at different genetic 
loci across individuals, and can serve as a readout for genetic processes that affect a 
population. Important evolutionary factors shape the LD of a genetic variant, including selection, 
recombination, mutation rate, and genetic drift (Slatkin, 2008). As the concept of LD relies on 
the assumption that those SNPs that are located close to each other tend to be inherited 
together (a phenomenon also known as 'gene linkage'), LD is affected by the distance between 
SNPs. In addition, LD patterns across the genome are influenced by the recombination rate: 
Genetic recombination during meiosis in eukaryotes can shuffle genetic material between 
homologous chromosomes and therefore create new genetic combinations in the offspring. 
Recombination enables alignment of chromosomes during meiosis to ensure proper 
segregation of chromosomes and avoid deleterious genetic disjunctions resulting in, e.g., 
aneuploidy (Hassold et al., 2007). Over several generations, recombination generates genetic 
diversity in populations due to new combinations of alleles (Slatkin, 2008).  
SNPs can be categorised according to their frequency in a population. If a genetic variant is bi-
allelic, its population-level frequency is described by its minor allele frequency (MAF). This 
allows categorisation of genetic variants based on predefined thresholds, e.g., into rare (MAF < 
0.05) and common (MAF ≥ 0.05) variants (Frazer et al., 2009). The minimum MAF of genetic 
variants that can be accurately assessed within a particular study cohort therefore strongly 
depends on the sample size of genetic cohorts, which is expected to continue to increase for 
many years (Roundtable on Translating Genomic-Based Research for Health, 2016).  
Whereas most SNPs are bi-allelic, larger genetic variants, so-called structural variants (SVs), 
often show more than two alleles in a population. SVs include short insertions and deletions 
(indels), larger copy-number (CN) changes due to insertions, deletions, and duplications, as well 
as inversions that range in size from kilo base pairs to whole chromosome arms (Frazer et al., 
2009). The functional relevance of somatic copy-number alterations (SCNAs) has hereby 
attracted more and more attention, particularly in cancer research where large genetic 
rearrangements have been shown to contribute to tumour development and progression (Wu et 
al., 2014). 
Genetic variants also differ in terms of their relative genomic position, i.e., they can lie in coding 
or non-coding parts of the genome. The functional consequences of protein-coding genetic 
variants can be inferred by determining if the variant affects the amino acid sequence of a 
gene's encoded protein or not. Non-synonymous variants alter the amino acid sequence of the 
downstream protein; synonymous variants don't alter the amino acid sequence due to the 
degeneracy of the genetic code. Non-synonymous variants can hereby cause nonsense 
mutations due to premature stop codons that result in truncated proteins, or missense mutations 
that lead to the incorporation of a different amino acid into the protein. Additionally, it has 
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become clear that many genetic variants in non-coding areas of the genome are functionally 
relevant, e.g., by modulating transcription factor (TF) binding efficiency, altering the DNA's 
spatial structure, affecting alternative splicing rates, or influencing the degradation rate of the 
mRNA. The functional classification of non-coding genetic variants is more difficult than the 
categorisation of coding variants since they might result in much more complex phenotypes 
than the alteration of a protein's amino acid composition. To make sense of all genome-wide 
genetic variation, many of the functional consequences of these non-coding variants for 
molecular variation and ultimately for the organismal phenotype have yet to be understood 
(Alberts et al., 2009).  
The next section describes the extent of molecular variation that can be assessed by existing 
technology and that can be used to understand the functional consequences of both, coding 
and non-coding genetic variants. 
 
1.1.2 Phenotypic effects of genetic variation 
The very first effect of different genetic alleles on a phenotype was described by Gregor Johann 
Mendel when he studied the discrete inheritance of dichotomous traits in plants (Mendel, 1866). 
This was extended to quantitative phenotypes by Francis Galton (1871) who observed that, 
opposed to dichotomous traits in plants, height was inherited in an averaged manner in humans. 
Traits such as height that do not follow discrete Mendelian inheritance are referred to as 
complex traits. By today, we understand that most organismal traits have a genetically complex 
architecture and follow heritability patterns as observed by Galton. The biostatistician and 
(eu)geneticist Ronald A. Fisher used mathematical approaches to combine Mendelian genetics 
with Darwinist natural selection hypotheses to explain Galton's observation by an additive 
genetic model (Fisher, 1918). The additive genetic model assumes small effects of a large 
number of genetic loci that ultimately result in the normal distribution of the affected quantitative 
trait (Charlesworth & Charlesworth, 2010). 
 
Levels of phenotypic variation 
While Mendel, Galton and Fisher relied on organismal traits for their studies, high-throughput 
assays now allow assaying a much broader range of phenotypes, and in particular molecular 
phenotypes. Possible molecular phenotypes range from direct DNA modifications to observable 
traits on the organismal level (Figure 1). Direct DNA modifications can concern the three-
dimensional structure of DNA and hence the chromatin accessibility, with regulatory impact on 
gene expression (Degner et al., 2012). Further, DNA can be affected by epigenetic 
modifications, heritable chemical or physical changes of the DNA that do not affect the actual 
DNA sequence. These include modifications of the DNA itself (most prominently DNA 
methylation, i.e., the covalent addition of a methyl group to cytosine) or of the histone proteins 
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that the DNA is wrapped around, resulting in structural changes of the chromatin. DNA 
methylation in promoter regions of genes can act to repress gene expression and therefore 
have a strong functional impact. The first expression level of genomic information is the 
transcriptome level. The number of transcribed RNA (ribonucleic acid) sequences per gene can 
hereby serve as a proxy of the gene's activity. Most genes can exert different functions via the 
mechanism of alternative splicing: Alternative splicing ultimately leads to different transcripts of 
a single gene, another level of gene expression complexity (see below). While some RNA is 
functional on its own (e.g., tRNA, rRNA; Section 1.1.1), most RNA (mRNA; Section 1.1.1) 
encodes proteins by translation of a sequence of nitrogenous bases into a sequence of amino 
acids. Further, the function of a protein itself can be affected by sequence or structural 
alterations, by modulation of its quantity, or by changes of its interaction partners. Notably, the 
protein group of TFs binds to regulatory genetic regions, affects the transcription levels of other 
genes and hence their proteomic output. Proteins are involved in a vast range of functions in 
living organisms, including cellular structure and transport, metabolism, response to stimuli and 
DNA replication. Their quantity and function translates into organismal phenotypes, including 




Figure 1. Different levels of molecular variation that can be modulated by genetic variation. 
While alterations of the epigenome and the DNA structure, gene expression, protein expression, 
and organismal traits can be directly caused by underlying genetic variation (solid arrows), 




In this thesis, we focus on gene expression, i.e., the transcriptome, as a molecular phenotype. 
In general, the transcriptome describes the complete set of transcripts in a tissue or cellular 
sample, and their respective quantity. As a precursor of protein expression, mRNA can serve as 
a proxy of gene expression levels. Multiple approaches have been developed to measure 
cellular mRNA levels, including hybridization- and sequencing-based approaches. In the case of 
hybridization-based methodology, reverse transcription (RT) is used to generate a 
complementary DNA (cDNA) template of the mRNA. When this cDNA template is being 
amplified with labelled hybridization probes via quantitative polymerase chain reaction (qPCR), 
fluorescence is emitted according to the oligonucleotides that are being incorporated. Based on 
the fluorescence signal, the genetic sequence of the original mRNA strand can be 
reconstructed. Alternatively, a hybridization microarray contains pre-defined probes for 
transcripts of every known gene of one or several species. Transcripts that are not known a 
priori can be detected with tag-based methods such as SAGE (Serial Analysis of Gene 
Expression); SAGE uses small tags that cover only fragments of a transcript as probes, and can 
therefore, opposed to hybridization microarray chips, also discover transcripts whose full 
sequence is unknown. However, a large proportion of the tags used by SAGE does not map to 
unique regions of a reference genome due to their short length, and can therefore not be used 
for transcript quantification. Further, tag-based approaches do not ensure the analysis of the 
entire transcriptome, and can generally not discover alternative splicing events (Wang et al., 
2009). 
RNA sequencing (RNA-Seq) based on next-generation sequencing (NGS) of the cDNA allows 
for genome-wide quantification of the transcriptome. After obtaining one (single-read RNA-Seq) 
or two paired (paired-end RNA-Seq) sequence reads per cDNA fragment, the sequencing reads 
are either aligned to a reference genome or are assembled de novo. From the number of RNA-
Seq reads that map to a particular gene an estimation of gene expression can be deduced. In 
this thesis, we use FPKM (fragments per kilo base per million reads mapped) for gene 
expression estimations. FPKM quantify the number of reads that are assigned to a given gene, 
normalised by gene length and the total sequencing depth (Wang et al., 2009). 
Opposed to the hybridization- and tag-based methods, NGS allows for identifying completely 
new genes, previously unknown genetic variants in the genes, variation in alternative splicing 
(see below), or post-transcriptional modifications. In addition, RNA-Seq can quantify the vast 
array of non-coding RNA molecules (Section 1.1.1). Altogether, sequencing-based assessments 
of the transcriptome deliver more detailed insights into gene expression variability than 
hybridization- or tag-based approaches. 
In this thesis, we quantify gene expression by RNA-Seq measurements of mRNA levels. 
Besides analysing total gene expression and its alterations across cell types and individuals, we 
also investigate alternative splicing variation. Alternative splicing is a molecular process that 
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only takes place in eukaryotic cells. Eukaryotic genes are discontinuous, and consist of protein-
coding exons and non-coding introns (Sharp, 1994). Exons are normally shorter than introns: In 
humans, 80% of exons are shorter than 200 base pairs whereas the mean intron length in is 
2600 base pairs (Sakharkar et al., 2005). The human genome project revealed that human DNA 
consists of surprisingly few exons (1.1% of the genome), whereas introns cover 24% of the 
genome (Venter et al., 2001; Lander et al., 2001). The number of genes was also found to be 
smaller than expected, with around 30,000 being identified in 2001, and 19,000 genes being the 
latest estimate at the time that this thesis is written (Ezkurdia et al., 2014). However, this 
relatively small number of genes can exert various functions in a large number of complex 
processes, since alternative splicing diversifies the functionality of each gene by including or 
excluding exons in the transcript (Black, 2003). Importantly, the amount of alternatively spliced 
genes has been shown to be correlated with phenotypic complexity in higher eukaryotes (Kim et 
al., 2007): Alternative splicing occurs in more than 95% of human genes, compared with 63% of 
mouse genes (Barbosa-Morais et al., 2012). While alternative splicing plays an important role in 
many regulatory functions like cell differentiation and diversification of neuronal wiring (Kelemen 
et al., 2013), it has also been found to affect the development of various diseases like autism 
spectrum disorder, spinal muscular atrophy and different cancers (Xiong et al., 2015).  
Splicing is carried out by the spliceosome, a ribonucleoprotein machinery. It consists of five 
small ribonucleoprotein complexes (U1, U2, U4/U6, and U5) (Wahl et al., 2009): U1 recognizes 
and binds to the 5’ end of the intron, whereas U2 binds to a distinct sequence within the intron. 
Binding of these complexes ensures recognition of the introns and of the ends of the retained 
exons (Matlin et al., 2005). Subsequently, the complexes U4 and U5 bind to the genomic region, 
U6 replaces U1, U4 is removed, and finally a transesterification reaction removes the introns 
and connects the adjacent exons (Fica et al., 2013). 
While different types of alternative splicing have been observed (Sammeth et al., 2008), the so-
called exon skipping within a cassette exon is the most frequently observed type. A cassette 
exon describes an alternative exon that is flanked by two constitutive exons separated by 
introns. The alternative exon can either be spliced out or retained in the transcript (Black, 2003). 
In this thesis, we will only focus on alternative splicing events at cassette exons. Alternative 
splicing at cassette exons can be quantified using RNA-Seq data by calculating the ratio of the 
number of transcript reads that include the alternative exon to the total number of transcript 
reads that map to the cassette exon (Black, 2003; Section 3.2.1).  
 
Genetic regulation of molecular traits 
While molecular phenotypes are interesting to study in their own right, modern genetics 
research, frequently also termed 'systems genetics', considers these traits as mediating factors 
between genetic variation and variability in observable traits (Figure 1). The rationale behind 
this is that intermediate phenotypes reflect the immediate consequences of genetic variation, 
which can reduce noise and allows for mechanistic insights into deregulated biological pathways 
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(e.g., Chen et al., 2016). Molecular phenotypes such as gene expression are hereby highly cell 
type-specific. Relevant associations between genetic variants and gene expression may 
therefore be missed if the most relevant tissue is not profiled (see Fairfax et al. (2012) who 
demonstrated substantial differences in genetic variant-gene expression associations between 
monocytes and B lymphocytes). In addition to cell type specificity, genetic variant-gene 
expression associations have also been shown to depend on the context of the tissue in 
question; e.g., Fairfax et al. (2014) discovered certain associations in monocytes only when the 
cells were induced with immune stimuli. These cell type- and context-specificities have provided 
a first insight into the complexity of associations between genetic and molecular variation. 
Therefore, defining molecular phenotypes as mediating factors of organismal phenotypes 
remains a difficult task. Also, not all associations between genetic variants and gene expression 
result in variation of an observable trait, and for many of the organismal traits no molecular 
mediators have yet been identified. However, some studies revealed individual cases of striking 
colocalisation between molecular and disease phenotypes, e.g., between inflammatory bowel 
disease and cell type-specific CARD9 expression, a gene that has been shown to have a 
regulatory role in cell apoptosis processes (Chen et al., 2016). 
Genetic variation can be associated with all levels of molecular variation, ranging from direct 
DNA modifications to organismal traits (Figure 1). These effects can be direct, e.g., by changing 
the sequential composition of RNA or proteins, or indirect, e.g., by altering regulatory genetic 
regions and therefore TF binding efficiency, or by modulating epigenetic modification, DNA 
structure and gene accessibility (Figure 1). The effect of a genetic variant can further be 
classified as cis, i.e., the genetic variant in question regulates the molecular phenotype of a 
neighbouring gene, or as trans, i.e., the genetic variant in question regulates the molecular 
phenotype of a different gene via intramolecular interaction, e.g., via affecting proteins like TFs. 
The latter mode of gene regulation often implies that the genetic variant is distant from the 
regulated gene and frequently located on a different chromosome (Yao et al., 2017). Epistasis 
hereby describes the interaction between genes in regulating a phenotype: One genetic locus 
can alter or even mask the effect of other genetic loci, complicating or hampering the study of 
regulatory effects. Exploiting the phenomenon of epistasis may, however, help identify 
previously unknown genetic variants and their regulatory effects (Cordell, 2002).   
Germline variants are known to be causal for gene expression changes. While the cause-effect 
relationship between these genetic variants and molecular phenotypes is therefore known, it is 
often difficult to identify the actually causal individual variant due to the LD structure of the 
genome (Section 1.1.1). In the case of somatic variants, even the cause-effect relationship 
between the genetic variant and molecular variation is often intractable: While somatic variants 
may affect gene expression, molecular mechanisms can also introduce de novo somatic 
mutations to the DNA, e.g., due to erroneous DNA replication or insufficient DNA repair.  
In the next section, we give an overview of the statistical models that this thesis applies to tackle 
the challenges presented by the analysis of genetic molecular datasets.  
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1.2 Integrative modelling of genomic and molecular 
variation 
1.2.1 Expression quantitative trait locus analyses 
GWAS link genetic variation to variability in organismal traits (Frazer et al., 2009); these studies 
perform under the assumption that a genetic variant that has been found to be statistically 
significantly associated with a trait is in strong LD with the actually causal variant. GWAS 
therefore leverage the LD structure of the genome to detect genetic loci responsible for a 
specific trait. QTL studies can associate genetic variants with tissue-specific molecular 
alterations across individuals; we here focus on expression QTL (eQTL) studies that associate 
genetic variants with tissue-specific gene expression (Schadt et al., 2008). QTL studies have, 
however, recently been extended to assess the effect of genetic variants on other molecular 
phenotypes, including DNA methylation (Gaunt et al., 2016), histone modifications (Grubert et 
al., 2015), chromatin architecture (Waszak et al., 2015), and protein expression (Stark et al., 
2014) (see Figure 1 for an overview of molecular traits that can be leveraged in association 
studies). 
A persistent challenge in eQTL studies is the strong dependence of associations between 
genetic effects and gene expression on the cell or tissue type and the context of the study 
(Section 1.1.2). Therefore, eQTL studies have to be realised in various cellular and 
environmental contexts to fully understand the associations between genetic and gene 
expression variation. Other environmental variables, such as age or sex of the individuals, might 
also have an impact on these associations. Hence, to understand true biological associations, 
these variables have to be accounted for in eQTL studies.  
The GTEx (Genotype-Tissue Expression) project started tackling these problems by obtaining 
gene expression profiles from a broad range of tissues of post-mortem human donors, and by 
collecting environmental variables of the same individuals (Lonsdale et al., 2013; The GTEx 
Consortium et al., 2015). In addition, projects like the Human Cell Atlas will result in an even 
more detailed classification of cell types by defining molecular cell types based on single-cell 
transcriptomic data (Regev et al., 2017) what will help identify truly cell type-specific 
associations. 
However, association testing between many molecular measurements and many genetic 
variants in multiple tissues and contexts entails an even larger multiple testing burden than in 
conventional GWAS. For this reason, eQTL studies have mostly been restricted to cis eQTL 
studies, mapping only proximal genetic variants to the expression of the respective gene since 
they are more likely to affect the molecular trait. Increasing the sample size of gene expression 
studies has already helped boost the statistical power of association studies (The GTEx 
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Consortium et al., 2015), but ideally samples from multiples studies could be pooled and 
analysed by one approach to alleviate the sample size problem.  
Data heterogeneity, particularly of large-scale or pooled studies, leads us to the problem of 
confounding factors across individuals that are often not well defined or unknown, leading to 
spurious association between genetic variants and gene expression and therefore reducing the 
statistical power to identify real associations (McClellan & King, 2010). Many approaches for 
solving this challenge in eQTL studies have been proposed; here, we will focus on linear 
(mixed) models, which have emerged as a robust method to control for confounding factors 
(Kang et al., 2008) and which have been implemented in a computationally efficient way (e.g., 
Lippert et al., 2014).  
 
1.2.2 Linear regression models in genomics 
Linear regression models a continuous variable yi as linearly related to C input variables, 
referred to as covariates, across N samples with i 𝜖 {1, 2, ..., N}: 
 𝑦! =  𝑥!"!!!! 𝛽! +  𝜓!  ,with 𝜓!  ~ Ν(0,𝜎!!)                                          (𝑖) 
 
The residual term 𝜓! accounts for deviations from the model due to noise or covariates that are 
not taken into account. In a simple linear model, these residual terms are assumed to be 
independent and identically distributed with variance 𝜎!!. The weights 𝛽! describe the magnitude 
and directionality of the effects of the model covariates xic on the phenotype yi. These so-called 
effect sizes can be estimated by a maximum likelihood approach (see below). We here denote 
matrices (including vectors) - as opposed to scalar values - by bold scripture or capital letters. 
By introducing Y, X, and 𝛃 (Y 𝜖 ℝ! ! !; X 𝜖 ℝ! ! !; 𝛃 𝜖 ℝ! ! !), and the identity matrix I 𝜖 ℝ! ! !, we 
can specify the probability distribution p of the data as follows: 
 𝑝 (𝑌|𝑋,𝜷,𝜎!!)   =     Ν(𝑌|𝑋𝜷,𝜎!!𝐼)                                            (𝑖𝑖) 
 
This probability p from equation (ii) is also known as the likelihood of the model ℒ(𝜷,𝜎!!). The 
maximum likelihood estimator (MLE) is then the set of parameters 𝜷 and 𝜎!! that maximises the 
likelihood (or typically the log likelihood, which is easier to estimate due to the mathematical 
properties of the logarithm). The MLE of these parameters, here denoted as 𝜷 and 𝜎 !!, can be 
defined by the following equation (iii):  
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 𝜷,𝜎 ! ! =  𝑎𝑟𝑔𝑚𝑎𝑥𝜷,!!!  ℒ(𝜷,𝜎!!)                                            (𝑖𝑖𝑖) 
 
The MLE values can be obtained by calculating the first derivative of the (log) likelihood with 
respect to the two parameters, and by then obtaining the set of parameters that will set this 
derivative to zero. It can then be proven that (v) solves (iv) and (vii) solves  (vi), resulting in the 
MLE values 𝜷 and 𝜎 !!: 
 𝛿 𝑙𝑜𝑔ℒ(𝜷,𝜎!!)𝛿 𝜷 𝜷!𝜷, !!!!!!!  =  0                                             (𝑖𝑣) 
 𝜷  =  (𝑋!𝑋)!! 𝑋!𝑦                                                        (𝑣) 
 𝛿 𝑙𝑜𝑔ℒ(𝜷,𝜎!!)𝛿 𝜎!! 𝜷!𝜷, !!!!!!!  =  0                                             (𝑣𝑖) 
 
𝜎!!  =  1𝑁  (𝑦 − 𝑋(𝑋!𝑋)!! 𝑋!𝑦)!  (𝑦 − 𝑋(𝑋!𝑋)!! 𝑋!𝑦)                     (𝑣𝑖𝑖) 
 
Here, we model the genetic variant and all other known ('fixed') factors as covariates in X 𝜖 ℝ! ! !. In genotype-phenotype association studies, we are, however, only interested in the 
effect of the genetic variant, from now on referred to as 𝛽: 
 𝑌 =  𝐺𝛽 +  𝑋𝜶 +  𝜓, with 𝜓 ~ Ν(0,𝜎!!𝐼)                             (𝑣𝑖𝑖𝑖) 
 
Here, we focus on one phenotype Y that can, e.g., describe the expression of one gene. The 
matrix G 𝜖 ℝ! ! ! contains the genotype of one genetic variant across all samples. Then, 𝛽 𝜖 ℝ 
denotes the effect of the one genetic variant, and 𝜶 𝜖 ℝ(!!!) ! ! denotes the effects of the 
remaining fixed covariates in X 𝜖 ℝ! ! (!!!).  
Hereby, the genotype has to be encoded according the assumed genetic model. Here, we 
assume an additive genetic model that proposes a genetic effect proportional to the minor (or 
major) allele count η (η 𝜖 {0, 1, 2}). However, some genetic effects might be modelled more 
accurately via the dominant or recessive genetic models that assume that either one copy of an 
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allele results in a phenotypic effect (dominant model), or that two alleles must be present to 
result in a phenotypic effect (recessive model).  
The concept of the linear model can be extended to the one of a linear mixed model that 
includes an additional covariate type, the random covariate. This covariate describes a random 
effect that is the realisation of a random variable of which we only model the distribution. A 
random effect is hence non-deterministic as opposed to fixed effects such as the ones 
represented by 𝜶, allowing to encode intractably large numbers of fixed effects as one random 
effect. Random covariates have been shown to capture subtle intrinsic data structure better than 
deterministic fixed covariates, and to yield calibrated association studies even in the case of 
complex data structures (e.g., Yu et al., 2006). In genotype-phenotype association studies 
across individuals, the population structure can be estimated based on a large number of 
genome-wide SNPs that have been shown to act as a reliable estimator of population structure 
(Kang et al., 2008). As accounting for a large number of SNPs as independent fixed effects 
would be intractable, we can model population structure u as a random covariate next to the 
fixed covariates: 
 𝑌 =  𝐺𝛽 +  𝑋𝜶 +  𝒖 +  𝜓, with 𝒖 ~ Ν(0,𝜎!!𝑹),𝜓 ~ Ν(0,𝜎!!𝐼)    (𝑖𝑥) 
 
Here, the genetic relatedness matrix 𝑹 quantifies the pair-wise genetic similarity between all 
individuals based on genome-wide SNPs. For example, the realised relatedness matrix 𝑹* can 
be calculated based on standardised genotypes of the matrix G 𝜖 ℝ! ! ! with N individuals and S 
SNPs: 
 𝑹∗  =  1𝑆𝐺𝐺!                                                                 (𝑥)  
 
The effects in a linear (mixed) model can then be estimated by maximising the likelihood of the 
model. For simplicity, we firstly introduce the maximum likelihood approach applied to a linear 
model. In this approach, the two following hypotheses concerning the effect of a genetic variant 
can be tested by comparing the likelihood of their underlying models: The null hypothesis H0 
assumes no effect of the genetic variant on the phenotype (𝛽=0), and the alternative hypothesis 
H1 assumes the significant presence of an effect (𝛽≠0). We can calculate the test statistic as a 
random variable that quantifies the evidence that H0 can be rejected. A typically employed test 
statistic is the log likelihood ratio (LLR), which directly compares the likelihood of both models. If {𝛽,𝜶,𝜎 !!} are the MLE of the parameters of H1, and {𝜶,𝜎 !!} the MLE of the parameters of H0, 
then the LLR can be calculated as follows:  
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𝐿𝐿𝑅 =  𝑙𝑜𝑔ℒ(𝛽,𝜶,𝜎 !!)  −   𝑙𝑜𝑔ℒ(0,𝜶,𝜎 !!)                                (𝑥𝑖)    
 
The P-value of the association between genetic variant and phenotype is then the probability 
that a test statistic sampled under the assumption of H0 is greater than or equal to the observed 
test statistic. According to a theorem by Wilks (1938), the test statistic 2xLLR asymptotes to a 𝜒2 
distribution with - in the case of one tested genetic variant - one degree of freedom. The P-value 
of the LLR can therefore be calculated via the cumulative density function of 𝜒2, here denoted 
as F: 
 𝑃(𝐿𝐿𝑅)  =  1−  𝐹(2𝐿𝐿𝑅;  1)                                              (𝑥𝑖𝑖) 
 
If the P-value is below a pre-defined significance threshold, H0 is rejected and a statistically 
significant association between genetic variant and phenotype is postulated. The significance 
threshold hereby models the expected percentage of false-positive associations, i.e., 
associations that reject H0 when it is true (type 1 error). Besides the false-positive associations, 
also false-negative associations, i.e., associations that reject H1 when it is true (type 2 error), 
might occur in association studies but are not controlled for by a manually set threshold. 
Instead, the statistical power of an association study assesses the rate of true-positive 
associations, i.e., the rate of accepting H1 when it is true.  
When conducting association tests across multiple genetic variants, the expected number of 
false-positive associations scales linearly with the number of tested variants. This problem is 
widely known as multiple hypotheses testing burden. Different methods to adjust nominal P-
values have been developed in order to ensure that the type 1 error rates remains controlled in 
this setting. The most straightforward approach to adjust P-values controls the family-wise error 
rate (FWER), i.e., the probability of having at least one false positive across all tests. One 
specific method that controls the FWER, the Bonferroni method, multiplies the P-values by the 
number of tests. This method is based on the assumption of independence of the conducted 
tests, an assumption that - especially in the case of complicated dependencies due to genetic 
structure in genotype-phenotype association studies - might lead to an overly conservative 
correction of P-values (Goeman & Solari, 2014). Another approach to adjust P-values for 
multiple testing is based on controlling the false discovery rate (FDR). Instead of controlling the 
probability of obtaining a false positive result at all, this approach controls the expected ratio of 
false positives across all tests. FDR-based multiple testing correction still assumes 
independence of tests but is less conservative in the magnitude of correcting P-values: E.g., the 
Benjamini-Hochberg FDR correction method multiplies the nominal P-values by the number of 
statistical tests similar to the Bonferroni method, but then divides these values by the ranks 
assigned to the P-values (with the smallest P-value having the smallest rank), hence alleviating 
the increase of the P-values and taking into account the intrinsic P-value pattern across 
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statistical tests (Benjamini & Hochberg, 1995). Throughout this thesis, we employ the FDR 
correction method of Benjamini and Hochberg to avoid an overly conservative adjustment of 
nominal P-values.  
Under the null hypothesis, P-values are uniformly distributed. For a first diagnostic visualization 
of the number of statistically significant associations across multiple associations, the quantile-
quantile plot (QQ-plot) shows deviations from the assumption of uniform distribution of P-values 
by comparing the observed P-values with the expected P-value distribution (-log P, 
respectively). These QQ-plots give a straightforward overview of how many associations have 
unexpectedly small P-values (i.e., are significant), and if the entire association study across all 
tests is calibrated, i.e., does not result in inflated or deflated P-values. To ensure that 
statistically significant associations are true and not a result of intrinsic data structure, the data 
can be permuted (e.g., the phenotype variable Y) and the resulting QQ-plot is expected to show 
correlation between observed and expected P-values.  
In the case of linear mixed models, computations associated with obtaining the MLE scale 
cubically with the sample size. Various approaches have been suggested to maximise the 
likelihood of linear mixed models while reducing the computational complexity (e.g., Kang et al. 
(2008); Lippert et al. (2011)). While description of all these approaches is beyond the scope of 
this thesis, we employ the approach by Lippert et al. (2011) that was later implemented within 
the LIMIX toolset (Lippert et al., 2014). Briefly, Lippert et al. (2011) compute the eigenvalue 
decomposition of the genetic relatedness matrix R once, and then use the decomposition to 
project all data into a space where phenotypic variables and covariates are uncorrelated. This 
transformed data can then be subjected to standard association analyses (Lippert et al., 2011). 
 
1.2.3 Convolutional neural networks in genomics 
The enormous amounts of molecular data that are now available thanks to new high-throughput 
technology also require more sophisticated and automated statistical tools. Different from linear 
regression models, machine learning methods enable the modelling of all sorts of relationships 
within high-dimensional data, including non-linear associations (Hastie et al., 2009). Machine 
learning methods can be 'supervised' or 'unsupervised'. In the case of supervised machine 
learning, regression and classification algorithms infer a function from labelled training data; the 
learnt features can then be used to predict labels for unknown samples. Examples of supervised 
machine learning algorithms include neural networks, support vector machines and random 
forests. In contrast, unsupervised machine learning algorithms do not require any prior 
knowledge. E.g., clustering and dimensionality reduction approaches like principal component 
analysis (PCA) or independent component analysis explore data structure by assessing intrinsic 
similarities between data points. 
Neural networks are especially valuable for large datasets with unknown confounding 
structures. A neural network first learns hidden features to then make accurate predictions. 
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Neural networks consist of layers of connected units, so-called neurons. Each unit represents a 
transformation of its input values. A neural network hereby consists of at least one input and 
one output layer with hidden layers in between. The depth of a neural network corresponds to 
the number of hidden layers, and its width corresponds to the maximum number of neurons in 
one of its layers. A deep neural network is a neural network with a large number of hidden 
layers.  
Deep neural networks represent powerful applications in genomics due to two advantages 
(Figure 2): First, the DNA sequence itself can serve as input. Whereas other machine learning 
approaches require feature extraction based on prior knowledge (e.g., k-mer counts), deep 
neural networks learn these features from the data. This does not only make deep neural 
networks applicable to large-scale data, but makes high-dimensional big data a prerequisite for 
training these models. Second, deep neural networks can capture any sort of dependency in the 
DNA sequence, not only linear relationships. This includes complex interaction effects between 
multiple layers of genomic data. For example, deep neural networks have already been applied 
to predict alternative splicing (Leung et al., 2014), binding of proteins to DNA and RNA 
(Alipanahi, Delong, Weirauch, & Frey, 2015) and epigenetic modifications (Kelley et al., 2016) 
from DNA sequence.  
Multidimensional inputs such as images can be analysed by a special type of deep neural 
network, the CNN. CNNs were originally inspired by work on the cat's visual cortex, which has 
simple neurons that respond to small motifs in the visual receptive field, and more complex 
neurons that respond to large composite motifs (Hubel & Wiesel, 1963). Here, we apply CNNs 
to the DNA sequence (Figure 2): First, DNA is one-hot encoded: One-hot encoding converts 
categorical to Boolean data, thus enabling the application of machine learning algorithms that 
require numerical data as input. After one-hot encoding of the DNA, each nucleotide represents 
one channel of an image-like representation of the DNA sequence. The central class of layers in 
a CNN is the convolutional layer, which consists of so-called filters of a predefined length that 
scan the one-hot encoded DNA sequence in a sliding-window approach and learn nucleotide 
motifs. A trained filter is activated according to how similar the DNA sequence within a window 
is to its learnt motif. Hereby, the two concepts of local connectivity and parameter sharing are 
essential to understand the advantage of a convolutional layer as compared to a fully-connected 
layer typically employed by traditional neural networks. Local connectivity means that each 
neuron is only connected to neighbouring neurons of the previous layer, defining the so-called 
receptive field of this neuron. The size of the receptive field depends on the length of the filters, 
i.e., the length of the sliding window. Parameter sharing means that each filter only learns one 
set of parameters that it will optimise across all locations of the previous layer. In the case of 
DNA sequence, each filter detects a unique sequence motif. These two concepts of a CNN 
ensure that it can handle high-dimensional data, what would not be feasible with fully-connected 
neural networks where the number of parameters would normally exceed the number of 
available training data. 
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The output of the convolutional layer is then transformed in a non-linear manner by processing it 
in a rectifier activation layer. This is followed by a maximum pooling step that reduces the 
dimensionality and provides a smoother representation of the data by setting the values of a 
certain pooling region to their maximum value. This assumes that the exact location and 
frequency of a certain feature described by a filter are irrelevant for the final prediction.  
The combination of these layers is repeated multiple times, i.e., the output of the maximum 
pooling layers is fed into another convolutional layer, and so forth. The combination of these 
layers and their individual architecture are described by the so-called hyperparameters of a 
CNN. In our example in Figure 2, we only illustrate one of these combined layers, reflecting the 
architecture of the CNN used in Section 3.2.4 of this thesis. The output of these layers is 
typically processed by (a) fully connected layer(s), which can reduce the dimensionality of the 
data. Finally, the last layer of the CNN predicts the output (either by classification or regression). 
In our example illustrated by Figure 2, this layer is a classification layer, and the output is the 
probability of alternative splicing, i.e., of skipping an alternative exon during transcription. As has 
been shown before (Leung et al., 2014) and as we show in this thesis based on a single-cell 
data (Chapter 3), the probability of alternative splicing can be predicted with a CNN based on 
the DNA sequence of the alternative exon and its neighbouring regions (Figure 2).  
While a training dataset is used to optimise a CNN with a specific architecture and 
hyperparameter set, an independent validation dataset is used to optimise the architecture and 
hyperparameters of the CNN. This includes optimising the type, number and order of the CNN 
layers described above. An independent test dataset is then used to assess the performance of 





Figure 2. Scheme of a CNN applied to a DNA sequence. Typically, the DNA sequence is one-
hot encoded and then processed by convolutional, non-linear, pooling and fully connected 
layers. A convolutional layer scans the DNA sequence with the help of filters in a sliding-window 
approach, and learns predictive nucleotide motifs. The output of a certain number of 
convolutional layers is then transformed by a non-linear activation function. The pooling layer 
reduces dimensionality of this output; here max-pooling summarises the values of a certain 
pooling region by its maximum value. The last element(s) of a CNN is/are typically (a) fully 
connected layer(s) that can reduce the dimensionality of the data further. The final layer of a 
CNN predicts the outcome. The schemes at the very left and right of this figure illustrate one of 
the many possible applications of CNNs to genomics, alternative splicing prediction of an 
alternative exon (orange genomic region in the DNA scheme on the left) that is flanked by 
introns and neighbouring exons both, upstream (blue genomic region) and downstream (green 
genomic region) of the exon itself (left scheme). This exon can either be skipped, i.e., spliced-
out, with probability p or retained, i.e., spliced-in, with probability 1-p (right scheme). The CNN in 
the scheme predicts the probability of splicing based on the DNA sequence of the alternative 
exon and its neighbouring region.  
 
1.3 Molecular deregulation in human cancer 
Cancer describes various diseases that can affect any body part, but have in common the 
abnormal growth of tumour cells, which may invade adjoining body parts and metastasise to 
other organs. The cause of cancer is manifold; besides germline predisposition (causal for ~5-
10% of all cancers), various environmental factors can lead to cancer. These environmental 
factors include exposure to chemical and physical agents, radiation, infection, as well as diet 
and lack of physical exercise. With cancer being the leading cause of human death worldwide, 
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its genetic and molecular characteristics have been studied in great detail, and have been 
leveraged for the improvement of prognosis and therapy (Weinberg, 2006).  
Cancer is now understood as an 'evolutionary' disease, mostly arising from a somatic mutation 
in a single cell of origin that enters rapid cell proliferation, accumulating additional alterations 
that can be beneficial in terms of survival and proliferation and lead to expansion of so-called 
'clones' of the tumour. Evolutionary forces like natural selection and genetic drift affect these 
clones and generate a highly heterogeneous population of cancer cells. Besides intra-tumour 
heterogeneity within tumour subpopulations, cancers are characterized by cancer type specific 
and patient-specific heterogeneity that is influenced by the germline variation of the individual 
patient. All this results in a highly heterogeneous regulatory landscape of cancer. Hereby, 
cancers harbour genetic variation from various sources: Besides patient-specific germline 
variants, cancers are characterised by somatic mutations that accumulate during cancer 
development and can stem from various different mutagenic processes, including endogenous 
factors like deficient DNA repair and exogenous carcinogens like viral infections, ultraviolet (UV) 
light or tobacco smoke. These mutations usually accumulate in specific genetic loci. E.g., 
certain TP53 mutations were observed across different cancer types in which they drive the 
activation of related oncogenic pathways (Cancer Genome Atlas Network et al., 2012). While 
somatic mutations can be located in or close to genes, i.e., in exonic, intronic or promoter 
regions, they also accumulate in the vast non-coding genomic region between genes 
(Weinberg, 2006).  
A wide range of cellular phenotypes that are relevant for cancer development and progression, 
including uncontrolled proliferation, immune evasion and metastasis, has been identified in 
human cancers (Hanahan & Weinberg, 2011). Gene expression can be leveraged to identify 
these cellular phenotypes and has been widely used to define molecular markers for cancer 
diagnosis and prognosis (e.g., van ’t Veer et al., 2002). However, gene expression levels in a 
cancer tissue - as well as its somatic mutational load and the patients' prognosis - strongly 
depend on the tissue-of-origin of the tumour (Li et al., 2017). Survival analyses based on gene 
expression profiles of deregulated genes have hence been conducted on a per-cancer-type 
level (Li et al., 2017). However, similar expression patterns of certain core cancer genes can be 
observed across multiple cancer types; hereby, expression of so-called tumour suppressor 
genes protects an organism from potentially harmful cellular mechanisms and inhibits cell 
growth and division. The overexpression of oncogenes, on the contrary, contributes to cancer 
development and progression. Tumour suppressor genes and oncogenes are therefore often 
differentially expressed between normal and tumour tissues (Liang & Pardee, 2003). For 
example, the application of gene expression arrays to normal and tumour tissues allowed 
identifying downstream gene targets of the tumour-suppressing TF p53 (Liang & Pardee, 2003).  
Extensive somatic genetic alterations have been suggested as causative agents of these 
extreme gene expression alterations (Knudson, 2002; Weir et al., 2004). Somatic mutational 
profiles may therefore be leveraged as proxy phenotypes of molecular processes. Importantly, 
 19 
mutational signatures have been shown to capture the activity of distinct mutational drivers in 
human cancers (Alexandrov et al., 2013; Petljak & Alexandrov, 2016). Hereby, mutational 
signatures delineate mutational processes by identifying genome-wide patterns of single-base 
mutations in a trinucleotide context. Nonnegative matrix factorization (NMF) can be used to 
extract these mutational signatures according to the approach by Alexandrov et al. (2013). In 
general, NMF is an approach to decompose and extract underlying features from complex 
multidimensional data (Berry et al., 2007). Briefly, in our case, a matrix A 𝜖 ℕ!! ! ! of somatic 
mutations in a trinucleotide context (i.e., the mutated base itself and its 3' and 5' neighbouring 
bases; c=96) across patients (s as number of patients) can be factorised into two nonnegative 
matrices, the signature profile matrix W 𝜖 ℝ!!! ! ! and the exposure matrix H 𝜖 ℝ!!! ! ! with k as the 
number of mutational signatures (Lee & Seung, 1999). Optimal decomposition, i.e., the optimal 
number of factors k, can be determined by comparison of cophenetic correlation coefficients 
and average reconstruction errors across possible values for k. Cophenetic correlation reflects 
how faithfully clustering can preserve pairwise distances between data points (Brunet et al., 
2004).  
For example, tobacco carcinogen-associated Signature 4 exhibits many CC>AA substitutions 
and a transcription-coupled strand bias for C>A mutations; Signature 1 has been associated 
with deamination of 5-methylcytosine to thymine, and has been shown to be correlated with a 
patient's age in a tumour- and cell type-specific manner (Alexandrov et al., 2013). In this thesis, 
we focus on mutational signature 3 that is associated with a failure in HR of DNA double-strand 
breaks and has been shown to occur in cancers with loss of BRCA1 and BRCA2 functionality, 
postulating an effect of BRCA1 and BRCA2 expression on mutation accumulation (Nik-Zainal et 
al., 2016). 
There is growing evidence for the relevance of the germline background of the patient for 
somatic mutagenesis (Helleday et al., 2014; 2014; Nik-Zainal et al., 2014). Most famously, 
deleterious BRCA1 and BRCA2 germline variants in breast, ovarian, pancreatic and prostate 
cancers have been shown to contribute to characteristic mutational patterns like long indels and 
short SVs (Nik-Zainal et al., 2016; Lu et al., 2015; Lord and Ashworth, 2016; Alexandrov et al., 
2013). Further examples include a germline CN alteration that deletes nearly the entire 
APOBEC3B gene to create an APOBEC3A/APOBEC3B fusion gene, and has been identified as 
a susceptibility variant in breast cancer patients. The novel gene fusion transcript has been 
shown to result in increased mutation load of the APOBEC-dependent mutational signature 
(Nik-Zainal et al., 2014). Further, increased activity of Signature 10, which is normally 
associated with a hypermutated phenotype in colorectal and endometrial cancers, has been 
linked to germline and somatic variants in the DNA polymerase epsilon, causing reduced 
replication fidelity and increased mutagenesis (Alexandrov et al., 2013). Moreover, patients 
harbouring specific germline variants in genes related to DNA mismatch repair (MMR) pathways 
show significantly increased indel rates in repetitive regions, a typical hallmark of MMR-deficient 
individuals (Karran, 1996).  
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To identify associations between germline and somatic variants and gene expression, previous 
integrative efforts (The Cancer Genome Atlas (TCGA; Cancer Genome Atlas Research Network 
et al., 2013); The International Consortium of Cancer Genomes (ICGC; Zhang et al., 2011)) 
obtained gene expression and exonic genetic variation data across patients and cancer types. 
First approaches identified genes that are recurrently altered by somatic mutations and whose 
mutation state is associated with gene expression levels. E.g., Masica and Karchin (2011) 
correlated mutation state and expression levels across genes to detect potential cancer driver 
genes. Ding et al. (2015) extended this approach to assess the impact of individual mutations 
within genes by analysing somatic mutations and gene expression across 12 cancer types: 
Their Bayesian hierarchical model predicts both, the probability that a recurrently mutated gene 
influences gene expression across patients, and the probability that an individual mutation 
influences expression in a specific patient. Like this, they identified 30 novel cis-modulated 
tumour suppressor genes, and somatic mutations in 150 genes that show trans associations 
with specific cancer-related expression networks.  
Non-coding genetic variation has been out of scope for these studies due to their restriction to 
whole-exome sequencing data. The role of the large number of non-coding somatic variants for 
cancer development therefore remains to be fully understood (Cancer Genome Atlas Research 
Network et al., 2013). The assessment of their functional consequences is rendered even more 
difficult by the fact that most somatic mutations are very rare or even private to individual 
tumours due to restricted sample sizes of existing cancer cohorts, making standard association 
studies (Section 1.2) impossible. Fredriksson et al. (2014) screened 14 cancer types for 
associations between somatic mutations in gene regulatory regions and gene expression 
changes. While they found many recurrently mutated promoter regions, they were only able to 
confirm TERT's promoter to be strongly associated with (increased) expression. This suggests 
that the effect of non-coding variation on gene expression has to be queried beyond the 
promoter regulatory region. Weinhold et al. (2014) have already shown that other genome-wide 
regulatory regions like 5' and 3' untranslated regions (UTRs) and distal enhancer regions as 
annotated by Ensembl (Hubbard et al., 2002) are recurrently mutated across different cancer 
types. Functional somatic mutations are, however, expected to be located across the entire 
genome, beyond Weinhold's functionally annotated genomic regions; their role in the molecular 
deregulation of cancerous cells remains to be determined (PCAWG Transcriptome Core Group 










The Pan-Cancer Analysis of Whole Genomes (PCAWG) study (Campbell et al., 2017) is an 
international initiative that aims to identify pan-cancer mutational patterns in more than 2000 
whole genomes (n=2,658) from 39 cancer types. In this section, I describe my contributions to 
the research of the PCAWG working group 3 for the integration of transcriptomic and genomic 
data. This working group focuses on the analysis of a subset of 1,188 whole genomes of the 
PCAWG cohort for which gene expression data is available. 
I led the studies to investigate associations between gene expression and mutational 
signatures, and the associated role of germline determinants. Besides, I collaborated on the 
PCAWG analyses concerning allele-specific expression, the effect of germline genetic variants 
on gene expression and the effect of somatic genetic variants on gene expression. While the 
entire PCAWG consortium and particularly PCAWG working group 3 were involved in this 
project, crucial contributions to the presented work have been made by Claudia Calabrese, 
Kjong Lehmann, Fenglin Liu, Roland Schwarz and Nuno Fonseca. Oliver Stegle, Alvis Brazma, 
Gunnar Raetsch, Zemin Zhang and Angela Brooks guided and supervised the analyses.  
Here, I present the results of my main project and my key collaborative efforts in the somatic 
variation and allele-specific expression studies. Other PCAWG-3 analyses I contributed to can 
be found in Calabrese et al. (2017), PCAWG Transcriptome Core Group et al. (2018), Waszak 
et al., (2017) and Campbell et al. (2017). 
All scripts will be available on github after peer-reviewed publication. The manuscript is currently 
under late-stage revision at Nature.  
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2.1 The functional relevance of somatic mutagenesis in 
cancer 
Cancer is characterised by extensive somatic genetic alterations that result in cellular 
phenotypes which are often relevant for disease, including uncontrolled proliferation, immune 
evasion and metastasis (Knudson, 2002; Weir et al., 2004). Such variations comprise SNVs, 
indels, and SVs such as SCNAs. Somatic mutagenesis is in part explained by environmental 
and intrinsic risk factors that are independent of the cancer itself, with growing evidence that 
somatic mutations have an early onset and occur during healthy ageing (e.g., Kennedy et al., 
2012). The prevalence and the consequences of somatic mutations are also increasingly linked 
to germline factors of the patient (Alexandrov et al., 2013; Karran, 1996; Nik-Zainal et al., 2014; 
Pleasance et al., 2010; Waszak et al., 2017). The relationship between germline mutations in 
MMR-related genes and increased somatic indel load in repetitive regions of the genome has 
been known for some time (Karran, 1996). Since then, several studies have implicated both rare 
and common germline variants in mutational processes and in the patterns of somatic variation. 
Alexandrov et al. (2013) have found associations between germline and somatic variants in the 
DNA polymerase epsilon and specific genome-wide somatic mutational patterns associated with 
hypermutation in colorectal and endometrial cancers. A very strong relationship between 
germline predisposition and somatic mutagenesis has been unravelled by Nik-Zainal et al. 
(2014) and concerns a germline deletion that removes nearly the entire APOBEC3B gene and 
fuses its remaining region to its neighbour, APOBEC3A. This germline variant leads to 
increased activity of the APOBEC-related mutational processes and to increased susceptibility 
to breast cancer (Nik-Zainal et al., 2014). Further, patients with breast, ovarian, pancreatic or 
prostate cancer that carry pathogenic germline variants in the BRCA1 and BRCA2 gene exhibit 
characteristic mutational patterns like long indels and short SVs (Nik-Zainal et al., 2016; Lu et 
al., 2015; Lord and Ashworth, 2016; Alexandrov et al., 2013). In pediatric medulloblastoma, 
germline TP53 mutations lead to massive chromosome rearrangements known as 
chromothripsis (Rausch et al., 2012). Most recently, Waszak et al. (2017) have integrated rare 
and common germline and somatic variants across 39 cancer types to uncover previously 
unknown relationships between these genetic factors. This study has emphasised the relevance 
of germline variants in cancer predisposition and DNA repair genes for mutational processes; 
e.g., protein-truncating germline variants in the MBD4 gene have been shown to cause 
increased activity of clock-like mutational processes, an effect that can be observed across 
cancer types.  
While these findings emphasise the relevance of associations between germline and somatic 
genetic factors, their combined interplay with molecular and cellular functions is not yet fully 
understood. Approaches that can shed light on this question include association analyses 
between genetic variation and molecular readouts such as gene expression levels. Previous 
efforts using exome-sequencing and transcriptomic data from TCGA (Cancer Genome Atlas 
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Research Network et al., 2013) and ICGC (Zhang et al., 2011) have identified associations 
between somatic variants in coding regions and gene expression. Although these studies have 
helped identify and characterise regulatory drivers, the role of the much larger number fraction 
of non-coding somatic variants is not yet fully understood (Cancer Genome Atlas Research 
Network et al., 2013; Kanchi et al., 2014). In addition, most somatic changes are rare or private 
to individual tumours and their functional consequences are difficult to study. Recent studies 
have begun to address this by identifying genomic loci that are recurrently altered by somatic 
mutations and associated with gene expression alterations (Section 1.3). Most work has, 
however, focused on the effects of variation in promoters of established cancer-genes, including 
TERT and BCL2 (Ding et al., 2015; Fredriksson et al., 2014; Smith et al., 2015; Weinhold et al., 
2014; Section 1.3). 
So far, a comprehensive analysis of associations between (non-coding) somatic variation and 
gene expression is missing. In addition, the potential regulatory effect of germline variants on 
the link between somatic mutations and gene expression remains to be fully understood. In the 
PCAWG transcriptome study, we assessed the local (cis) and genome-wide (trans) effect of 
these variants on gene expression across cancer types (Figure 3a). Our approach combined 
complementary strategies, including allele-specific expression (ASE) analyses, somatic and 
germline eQTL mapping and the analysis of gene expression associations with global somatic 
signatures (Figure 3b). This integrative analysis allowed us to derive a pan-cancer regulatory 







Figure 3. Integrative analysis of the gene regulatory landscape in human cancers. Overview of 
the sources of genetic variation considered in the analysis. For analyses of cis regulation, 
germline SNPs (blue) were individually tested for association with total gene expression using 
standard eQTL approaches. Due to their low recurrence in the cohort, somatic SNVs (red) were 
aggregated in burden categories depending on their position relative to the gene tested (e.g., 
promoter, 5' UTR, intron). Local SNV burdens were then tested for association with ASE 
globally across all genes, as well as with total expression on a per-gene level using eQTL 
approaches. Trans effects were estimated by testing total gene expression for association with 
mutational signatures. Window sizes were 1M base pairs for all somatic cis eQTL analyses and 





2.2 The PCAWG study 
The PCAWG initiative has derived a comprehensive map of genetic aberrations in 2,658 human 
cancers across 39 different cancer types (Campbell et al., 2017). We analysed the tumour 
whole-genome sequencing (WGS) and matched RNA-Seq data that were available for a subset 
of 1,188 patients, and carried out joint genetic analyses that integrate coding and non-coding 
somatic variation with germline variants to investigate regulatory effects on gene expression 
levels across altogether 27 cancer types.  
SNP, SNV and allele-specific SCNA calls from the 1,188 patients were obtained from PCAWG 
working group 1. Briefly, SNPs were derived from WGS data of the normal (blood) tissue of the 
respective patients; local SNVs, allele-specific SCNAs and mutational signatures were then 
derived from the tumour in comparison to the normal WGS samples. The 1,188 patients are 
spread across 27 cancer types and 29 project codes and include 899 carcinomas. The project 
code defines sequencing centre and cancer type of the respective sequencing study. All 
samples are primary tumours, except for 34 metastatic and 13 recurrent ones.  
Gene expression values (measured in FPKM; Section 1.1.2) were obtained from other members 
of the PCAWG working group 3 (Tophat2/Star gene expression; see PCAWG Transcriptome 
Core Group et al. (2018) for details). Gene expression data pre-processing was realised in 
collaboration with various members of the PCAWG working group 3. Genes with FPKM ≥ 0.1 in 
at least 1% of the patients (12 patients) were retained, resulting in 47,730 genes. Out of these 
genes, a subset of 18,898 protein-coding genes (based on Gencode version 19) was used for 
the subsequent analyses. We subjected the log2-transformed expression values to peer 
analysis to account for hidden covariates in this highly heterogeneous dataset (Stegle et al., 
2012). In order to balance number of covariates, statistical power and available sample size per 
cancer type, we followed the GTEx protocol and estimated 35 hidden peer factors to be used 
(Lonsdale et al., 2013). Peer residuals were then rank-standardised across patients.   
Building on these 1,188 consistently processed genomes and transcriptomes we derived a 
detailed regulatory map that considers different associations between germline and somatic 
genetic factors and gene expression (PCAWG Transcriptome Core Group et al., 2018).  
 
2.3 Associations between mutational signatures and gene 
expression 
Global variations in mutational patterns across individuals, for example due to generic 
environmental factors or exogenous damage, can be quantified using mutational signatures. 
These mutational signatures tag mutational processes specific to their tissue-of-origin and 
environmental exposure (Alexandrov et al., 2013). However, the pan-cancer relationship 
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between genome-wide mutational signatures and gene expression levels has not been studied 
yet, and the regulatory origin and/or effect of these signatures remains poorly understood. 
 
2.3.1 Methods 
NMF was performed by the PCAWG working group 7 per cancer type and across cancer types 
(Alexandrov et al., 2018). The final set of signatures were manually determined by the PCAWG 
working group 7 by including additional signatures from other datasets, validating particularly 
dominant signatures, and, where available, supplementing prior experimental evidence 
(Alexandrov et al., 2018). Alexandrov et al. (2018) extracted a vast range of different signatures, 
including globally distributed and clustered signatures, single base substitution, doublet base 
substitution, indel and composite signatures, and signatures derived with the help of different 
statistical tools. In this thesis, we focus on the canonical mutational signatures that are based on 
single base mutations and were extracted by SigProfiler, a tool that determines mutational 
signatures and their contribution in accordance with the signatures defined by the Catalogue of 
Somatic Mutations in Cancer (COSMIC; Forbes et al., (2008); Forbes et al. (2017); Alexandrov 
al. (2013)). With SigProfiler, Alexandrov et al. (2018) extracted 49 high-confidence single base 
substitution signatures across cancer types. 
In this analysis, we focused on a subset of 1,159 of our altogether 1,188 patients for which 
mutational signature profiles were available. Altogether, we used the 39 mutational signatures 
that were labelled according to the COSMIC system by Alexandrov et al. (2018) (version of the 
mutational signature set: PCAWG-7 beta 2 release). Gene expression data of 18,831 protein-
coding genes with FPKM ≥ 0.1 in at least 1% of the 1,159 patients was retained, and corrected 
for hidden peer factors as described above (Section 2.2). 
Signatures with zero variance and prevalence below 1% in their exposure across the 1,159 
patients were removed. Like this, we obtained 28 signatures. We then applied linear mixed 
models implemented in the LIMIX package (Lippert et al., 2014) to test for associations between 
the exposure to these signatures (from now on just referred to as 'signatures') and expression of 
all quantified protein-coding genes across all 1,159 patients. This entailed 28 x 18,831 
association tests between each signature and each gene. We queried the same associations in 
a subset of 877 carcinoma patients or a subset 891 European patients to assess robustness of 
the associations (Section 2.3.2 for details).  
In the linear mixed models, we accounted for known confounding factors by modelling them as 
fixed effects, and for population structure that we modelled as a random effect. Specifically, we 
accounted for sex, project code, per gene CN status, total somatic mutational burden (number 
of SNVs and indels) and sample purity (PCAWG Transcriptome Core Group et al., 2018). Per 
gene CN alterations were derived as the average CN across all CN alterations called within the 
annotated gene boundaries. Sample purity was obtained from PCAWG working group 11 who 
based their purity estimates on CN segmentation. The population structure was assessed via a 
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kinship matrix. This kinship matrix was calculated as an empirical patient-by-patient covariance 
matrix based on every 20th germline variant (PCAWG Transcriptome Core Group et al., 2018).  
The inclusion of the total somatic mutational burden per patient as fixed effect covariate allows 
for studying the relative effect of each mutational signature. The signatures are therefore 
negatively correlated with each other, a problem our model did not account for due to 
independent association testing of each signature. The problem of interdependencies between 
relative proportions of the whole data is widely known in the statistical analysis of compositional 
data (Aitchison, 1982). Aitchison (1982) suggested representing compositional data in a log-
ratio space by relating individual compositions to one representative, arbitrarily chosen 
composition. This relies on the assumption that various possible compositions are equivalent to 
each other when projected to a simplex, a space defined by the Aitchison geometry that 
compresses all equivalent compositions to unique compositions. When these representative 
compositions are projected into a two-dimensional space, independent ratios of the initial 
compositions are obtained - in our case ratios of mutational counts of different signatures - 
which can be used in independent association studies. As we are, however, not interested in the 
effect of ratios but in the effect of individual signatures onto gene expression, this approach is 
not valuable for a gene expression-signature association study. However, we emphasise that 
only an approach that handles relative signatures as compositional data ensures independence 
between signatures. The signature association studies presented in this thesis might therefore 
lead to spurious negative correlations introduced by the inherently negative correlations 
between relative signatures. Accordingly, Temko et al. (2018) have already discussed 
previously that analyses of a mutational signature in patients who also show evidence of other 
signatures can only approximate the contributions of this signature. 
 
2.3.2 Gene expression deregulation linked to mutational signatures 
We firstly investigated if the linear mixed model was calibrated and did not result in any spurious 
associations. We employed QQ plots to compare observed and expected P-value distributions. 
Under the null hypothesis of no associations, the resulting P-values of an association analysis 
should be uniformly distributed and follow the diagonal in a scatterplot of the ranked observed 
over the ranked expected P-values (-log10 P, respectively; Figures 4a-c for examples; see 
Section 1.2.2 for details). In our case where we tested associations between mutational 
signatures and many protein-coding genes (the majority of which are expected to have generic 
functions independent of mutational processes), we expected some significant associations that 
deviate from the diagonal in the QQ plot, but also many non-significant associations that follow 
the assumptions of the null hypothesis and are therefore located close to the diagonal in the QQ 
plot. 
Besides assessing the distribution of the nominal P-values of our association studies, we 
applied permutations tests by permuting the expression values per gene across patients. 
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Permutation (or randomisation) tests are statistical tests that obtain the distribution of the test 
statistic under the null hypothesis by calculating all possible values of the test statistic after 
randomisation of the data points (in our case, after rearrangement of patient IDs in our gene 
expression matrix). As we used the permutation test to study the calibration of our association 
analysis and not to assess an exact P-value, we restricted our permutation test to n=1,000 
random permutations. As permutations break up the true associations, the P-values of the 
permutated tests are expected to follow the assumptions of the null hypothesis, which assumes 
the absence of associations. Therefore, the P-values resulting from each permutation are 
expected to follow the diagonal in a QQ plot. Deviations from this expectation suggest that the 
statistical test is not well calibrated and either inflated or deflated due to un-accounted data 
structure (Section 1.2.2).  
The QQ plot of permuted P-values obtained from our model showed calibration of the analysis 
and the presence of true significant associations (n=1,000 permutation of the patient IDs in the 
gene expression matrix; only the result of one representative permutation test is shown; Figure 
4a). The nominal P-values, however, appeared to be inflated; hereby, cancer type is a known 
strong driver of mutational signature variability, and was therefore a likely candidate for creating 
spurious associations. Hence, we tested a different permutation scheme that accounts for 
cancer type related structure by permuting only patients within each cancer type. As the P-
values permuted according to this scheme also closely followed the diagonal in the QQ plot 
(assessed within the analyses of Section 4.2.2; see Figure 13e with a per cancer type 
permutation scheme versus Figure 13a with an across all patients permutation scheme), we 
however concluded that the associations detected in Figure 4a and in subsequent signature 
association studies were statistically valid.  
A volcano plot that compares significance and effect size of associations shows that several 
mutational signatures were strongly associated with the expression of multiple genes (Figure 
4e).  
Our cancer cohort is a heterogeneous dataset composed of patients with various different 
cancer types and from multiple ethnicities. Although we accounted for known confounding 
factors in our analyses and for hidden structure in our gene expression data, we wanted to 
ensure that our association analysis was robust and did not result in spurious associations due 
to more complex data structure. We therefore tested if the detected associations could be 
replicated in more homogeneous subsets of our cancer cohort. To still retain majority of the 
samples for each replication association study, we decided to focus on the subset of European 
patients to understand the potential confounding effect of ethnicity, and on the subset of 
carcinoma samples to understand the potential difference between carcinoma and lymphoma 
tumours. Both association studies were calibrated and resulted in statistically significant 
associations (Figures 4b-c). While both replication association studies resulted in slightly less 
significant associations than the original association study (FDR ≤ 10%; Figure 4d), the P-
values across individual signature-gene pairs were strongly correlated (Figure 4f for a 
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comparison between carcinoma and full association study, Figure 4g for a comparison between 
European based and full association study). The reduced power might therefore be attributable 
to the reduced sample size.  
After confirming the robustness of the linear mixed model analyses in these data subsets, we 






Figure 4. See next page for figure caption. 
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Figure 4. Quality control of the gene expression-mutational signature association studies. a-c. 
QQ plots of the P-values (-log10 P) of the linear mixed model associating expression of 18,831 
genes with 28 signatures across a. all 1,159 samples, b. 877 carcinoma samples, or c. 891 
European samples. Nominal P-values are shown in blue, permuted P-values are shown in red. 
Gene expression values are corrected for 35 peer factors. d. Plot of number of significant 
associations (log10 P) at different FDR thresholds (across all, carcinoma and European 
samples). e. Volcano plot of P-values (-log10 P) over effect sizes across gene-signature 
associations in the full dataset. Data points are coloured according to the mutational signature 
involved in the respective gene-signature association. f-g. Scatterplot of P-values (-log10 P) 
across gene-signature associations to comparison the full dataset analysis with the analyses 
performed on only f. carcinoma (Pearson correlation coefficients r=0.763), or g, European 
samples (Pearson correlation coefficients r=0.789), respectively. Data points are coloured 




Across all patients, this association study identified 1,176 genes significantly associated with at 
least one signature in altogether 1,388 unique associations after Benjamini-Hochberg multiple 
testing correction (FDR ≤ 10%, multiple testing was applied across all signature-gene pairs; see 
Supplementary Table 15 of PCAWG Transcriptome Core Group et al. (2018) for statistical 
results per signature-gene pair).  
The lymphoma/leukaemia-typical Signature 9 showed the largest number of associations 
(n=354), followed by the smoking-related Signature 4 (n=119). Whereas many of the remaining 
mutational signatures only affected a small number of genes (6 to 95 genes, with 6 genes in the 
case of Signature 34 and 95 genes in the case of Signature 7a, median number of genes across 
all signatures: 34.5), 18 signatures showed particularly prominent effects and affected the 
expression of more than 20 genes. While the vast majority of genes (85.8%) were associated 
with only a single signature (1,009 genes), 129 genes were associated with two, 32 with three, 
five with four and one with five signatures. 
Notably, the set of identified genes constituted a markedly different set of genes compared to 
associations with total mutational burden alone (total number of SNVs): When we correlated the 
P values (-log10 P) of the associations of the mutational burden with the respective signature-
specific P values, the absolute Pearson correlation coefficients always remained below 0.1 (see 
Supplementary Table 15 of PCAWG Transcriptome Core Group et al. (2018) for exact 
correlation coefficients). This confirmed that we discovered signature-specific molecular 
deregulation, which was independent of the total number of SNVs. 
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While some signatures have clear aetiologies and are well known in the cancer research field, 
others have not been fully characterised yet. To annotate these ambiguous signatures de novo, 
we considered the 18 signatures that were associated with at least 20 genes, and assessed 
functional enrichment using both, Gene Ontology and Reactome Pathways categories 
(Fabregat et al., 2018; Milacic et al., 2012). The gene enrichment was performed with the 
Bioconductor packages biomaRt (Durinck et al., 2009), clusterProfiler (Yu et al., 2012) and 
ReactomePA (G. Yu & He, 2016), considering the set of 18,831 protein-coding genes that were 
tested in the linear mixed models as background gene set. Benjamini-Hochberg multiple testing 
correction was applied across all categories per signature (FDR ≤ 10%; see Supplementary 
Table 15 of PCAWG Transcriptome Core Group et al. (2018) for all significant enrichments). 
We found that 11 signatures were enriched for at least one category (FDR ≤ 10%), revealing 
associations consistent with known aetiologies (Figure 5a). For example, lymphoma Signature 
9 was associated with 354 genes enriched for lymphocyte/leukocyte-related and immune 
response-related processes (P=1x10-6 for both categories), including TCL1A, LMO2 and TERT 
(P=1x10-10, 7x10-10, 2x10-9, respectively). The smoking Signature 4 was associated with 119 
genes enriched for biological oxidation processes (P=5x10-4). Processing of benzo[a]pyrene is a 
typical biological oxidation process that results in breaking down of this tobacco carcinogen. 
One of the associated genes was CYP24A1 (P=0.001, β=-0.193), a gene that is known to be 
down-regulated in tobacco-smoke exposed tissue (Figure 5b; Woenckhaus et al., 2006). The 
70 genes associated with APOBEC-related Signature 2 were significantly enriched for DNA 
deamination pathways (P=6x10-6; Figure 5a).  
Among signatures with unknown aetiology, our identified associations linked Signature 38 to 39 
genes enriched for melanin processes, vitamin D response and pigmentation (P=3x10-5; Figure 
5a). While Signature 38 has not been functionally annotated yet, it is strongly correlated with the 
canonical UV Signatures 7 across the patients of our cohort (e.g., correlation with Signature 7a: 
r2=0.375, P=5⋅10-40). Melanin synthesis causes oxidative stress to melanocytes (Denat et al., 
2014; Kvam & Tyrrell, 1999) and we found Signature 38 associated with the oxidative stress 
promoting gene TYR (P=1x10-4, Jimbow et al., 2001). A hallmark of Signature 38 are C>A 
mutations, also a typical product of ROS mediated by activity of 8-hydroxy-2′-deoxyguanosine 
(Valavanidis et al., 2009). This suggests that Signature 38 may capture DNA damage indirectly 
caused by UV after direct sun exposure due to oxidative damage (Premi et al., 2015), with TYR 
as a possible mediator of the effect (PCAWG Transcriptome Core Group et al., 2018). 
Signature 8 has been found to be prevalent in medulloblastoma (Forbes et al., 2017); our 
association studies linked this mutational signature to 25 genes enriched for ABCA-transporter 
pathways (P=0.011; Figure 5a). Whereas the PCAWG dataset does not contain any 
medullablastoma samples, this association might point towards a cancer type-independent 
relevance of Signature 8 that could be leveraged for drug repurposing: Drugs targeting the 
ABC(A) transporter pathways have already undergone clinical trials for treating 
medulloblastoma (Ingram et al., 2013), and preliminary results point towards a relationship 
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between ABC(A) transporter inhibition and decreasing radiation therapy and chemotherapy 
resistance. Specifically, Ingram et al. (2013) discovered that cells from medullablastoma cell 
lines that survived radiation exposure and were still carcinogenic in vivo showed elevated levels 
of different ABC(A) transporters. One of them, ABCA1, was also shown to be elevated in 
independent cell cultures obtained from medullablastoma patients. Ingram et al. (2013) then 
discovered that drugs like verapamil that inhibit multiple ABC(A) transporters led to radiation 
sensitization and had anti-proliferative effects in patient-derived medullablastoma cells. Ingram 
et al. (2013) also found that subtypes of ABC(A) transporters were associated with subtypes of 
medullablastoma, with, e.g., ABCA8 being associated with Sonic Hedgehog-dependent 
subtypes. The deregulation of ABC(A) transporters and with it the genome-wide pattern of 
Signature 8 might therefore constitute a possible genetic marker that could be queried for future 
diagnostic classification of medullablastoma subtypes. As a side note: Othman et al. (2014) later 
confirmed the potentially beneficial application of ABC(A) inhibitors to high-risk 
medullablastoma, and proposed a combinatorial treatment of chemotherapy and ABC(A)-
inhibiting drugs especially for metastasing tumours. Interestingly, the anti-proliferate effect of 
verapamil on medulloblastoma, pinealoblastoma, glioma, and neuroblastoma cell lines was 
already observed by Huber et al. (1988) although they were not yet able to understand the 
causative molecular mechanisms. Verapamil is commonly known as a calcium channel blocker 
that is, e.g., used for the treatment of high blood pressure; however, Huber et al. (1988) did not 
observe any alterations in calcium influx or efflux, suggesting - already at that time - a different 
underlying molecular process leading to anti-proliferation.  
In summary, there is strong evidence for an interplay between ABC(A) transporters and 
medullablastoma progression and metastisation. Given our association between these 
transporters and Signature 8 across cancer types and the previously known increased 
prevalence of Signature 8 in medullablastoma tumours, Signature 8 might constitute a 
biomarker for the potentially beneficial treatment with ABC(A) transporter inhibitors. However, 
as the key ABC transporter detected by both, Ingram et al. (2013) and Othman et al. (2014), 
were not contained in our list of protein-coding genes due to low gene expression levels across 
patients (Section 2.3.1), we were not able to state a direct relationship between the expression 
of these transporters and Signature 8.  
The enrichment of genes associated with other mutational signatures remained even more 
elusive. Age-related Signature 1 was associated with translational elongation and peptide chain 
elongation events (P=5x10-5 for both pathways; Figure 5a). While translational elongation 
describes a quite broad biological process, its role in oncogenesis has already been 
investigated. E.g, the eukaryotic translation elongation factor 1 alpha (eEF1A) gene was found 
to be overexpressed in metastatic compared to non non-metastatic cells and also plays a role in 
apoptosis regulation across cancer types (Lamberti et al., 2004). Our finding might therefore 
point towards an age-dependent role of regulatory mechanisms in protein synthesis for cancer 
progression.  
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Signature 18 has been commonly found in neuroblastoma (Alexandrov et al., 2013; Petljak et 
al., 2019) and was associated with damage due to reactive oxygen species (ROS; Viel et al., 
2017). We found Signature 18 to be associated with peptide cross-linking (P=6x10-6; Figure 5a) 
that in turn is known to be a product of excessive ROS production (Sharma et al., 2012). This 
might confirm the suggested link between Signature 18 and ROS on the gene expression level. 
Alexandrov et al. (2018) recently extended the catalogue of single base substitution mutational 
signatures to more than the 30 ones defined by Alexandrov et al. (2013) and Forbes et al., 
(2017). This catalogue links Signature 35 to chemotherapy treatment with platinum drugs (Boot 
et al., 2018). We found this mutational signature to be associated with platelet adhesion 
(P=6x10-4; Figure 5a). Platelet adhesion is known to create a favourable microenvironment for 
chemoresistance in gastric cancers (Saito et al., 2017). We therefore hypothesised that 
chemotherapy resistance after first treatments might not only arise from the selective survival of 
resistant clones, but possibly also from the de novo introduction of Signature 35 mutations. This 
hypothesis would however have to be supported by more detailed and extensive experimental 
evidence.  
 
2.3.3 Towards causality of associations between mutational 
signatures and gene expression  
While the analysis in Section 2.3.2 identified associations between somatic genetic variation 
and gene expression across cancer types, it is - unlike in association studies based on germline 
genetic variation - not clear a priori what is cause and what is consequence in these 
relationships. However, germline variants can act as an anchor of such analyses since they are 
inherently the causal part of any genetic association. To reduce the search space for genetic 
anchors and simultaneously identify likely causal germline players in these associations, we 
identified lead genetic variants of germline eQTL of signature-associated genes. The lead 
variant is the most significant SNP per eQTL and assumed to be likely causal for the variable 
gene expression, or at least in LD with the actually causal variant. By testing for associations 
between these variants and the mutational signatures that were associated with the respective 
genes, we could gain directed mechanistic insight into the relationship between gene 
expression and mutational signatures. This eQTL-based approach entailed substantially fewer 
tests than genome-wide germline analyses (e.g., Waszak et al., 2017), providing our analyses 
with a significantly reduced multiple testing burden. 
We firstly set out to perform cis germline eQTL mapping of all genes. Briefly, we employed 
linear mixed models in LIMIX (Lippert et al., 2014) to associate gene expression with local 
germline genetic variants, using a random effect to account for population structure and 
accounting for additional fixed effect covariates as described in the Methods (Section 2.3.1). In 
terms of gene expression, we used the gene expression residuals after correction for peer 
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factors (see Section 2.2 for a description of the peer factor analysis). In terms of local germline 
genetic variants, we considered common SNPs (MAF ≥ 1%) that were located proximal to 
individual genes (±100k base pairs from the gene boundaries). For each gene, we used the 
linear mixed model to test for statistical significance between these germline variants and the 
respective gene's expression. We used Bonferroni correction to adjust for the number of 
independent tests per gene; the number of independent tests was estimated based on local LD. 
Thus, we determined significant eQTL and their lead variants (Padj ≤ 5%). After applying this 
approach across all genes, we performed a global multiple testing correction according to 
Benjamini Hochberg across all lead variants, identifying 3,509 genes with a significant eQTL 
(FDR ≤ 5%). 
Among our 1,176 signature-linked genes, 197 genes had a germline eQTL, and these 197 
genes were uniquely associated with altogether 26 of our 28 tested mutational signatures. If a 
lead variant of a germline eQTL was also significantly associated with the signature the 
respective gene was associated with, it could be used to query the directionality of the gene 
expression-signature association by causal association analysis. We therefore tested the 
association between the lead variants of the 197 genes and the respective mutational 
signatures across 2,507 patients. These 2,507 patients constituted the subset of PCAWG 
patients for which mutational signature profiles, germline variant calls and all necessary 
covariates were available. We accounted for the same covariates as in the mutational signature-
gene expression association studies (Section 2.3.1). This entailed 197 association tests 
between 197 genetic variants and their corresponding signatures; P-values were adjusted for 
multiple testing following the Benjamini Hochberg procedure.  
Only the APOBEC3B eQTL lead variant rs12628403 was significantly associated with its 
corresponding signature, Signature 2, after multiple testing (P=5x10-7, FDR ≤ 10%, Figure 5c). 
This germline variant is a known risk variant for Signature 2 prevalence (Middlebrooks et al., 
2016).  
To investigate if we had found the shared and true causal germline variant for APOBEC3B 
expression and Signature 2, we performed proportional colocalisation analysis with Bayesian 
Model Averaging (BMA) (Wallace, 2013). This analysis tests if two molecular phenotypes, here 
gene expression and mutational signature, share a common causal genetic variant. Briefly, it 
tests the null hypothesis of colocalisation that assumes that the two phenotypes that share a 
causal variant have proportional regression coefficients against any set of variants that are 
close to the causal variant. An inherent problem of this analysis is the choice of the putatively 
causal variant. In our germline eQTL analyses, we had focused on the lead variant of the eQTL, 
i.e., the variant most strongly associated with gene expression. Using this lead variant as 
potentially causal variant, might, however, introduce bias in the regression coefficients of the 
proportional colocalisation analysis and lead to an increased likelihood of falsely rejecting the 
null hypothesis of colocalisation. We therefore decided to use the BMA approach that models 
various genetic variants that are close to our lead variant as potential causal variants and then 
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generates P-values averaged across all models. We used the implementation of proportional 
colocalisation analysis by the R-package coloc (version 3.1; Wallace, 2013). An intrinsic caveat 
of proportional colocalisation analysis is that the non-rejection of the null hypothesis can not be 
attributed to true colocalisation or to a lack of power (Wallace, 2013). Hence, while we were 
able to state that our colocalisation analysis suggested germline variant rs12628403 as a 
plausible genetic determinant of both, APOBEC3B expression and Signature 2 prevalence 
(P=0.398, i.e., the null hypothesis of colocalisation cannot be rejected), we were not able to rule 
out a lack of power as underlying cause.   
To study the relationship between gene expression and mutational signature in more detail, and 
to assess directionality of the effect between the germline variant rs12628403, gene expression 
of APOBEC3B and Signature 2, we performed causal mediation analysis (Baron & Kenny, 
1986; Preacher & Hayes, 2004). Briefly, mediation analysis hypothesises a causal chain 
between three variables and mathematically describes them as a set of linear regression 
models, which when fitted can be leveraged to estimate the mediation effect (Baron & Kenny, 
1986). We modelled the genetic variant as the causal variable, and considered two models that 
either assumed signature or gene expression to be the mediating variable and the respective 
remaining variable to be the outcome variable.  
We firstly used a structural equation model (function sem) from the R package lavaan (Rosseel, 
2012) to compare the statistical effects predicted by these two possible models. The total effect 
of the causal variable on the outcome variable (t) was modelled as the sum of the direct effect 
between the two variables (c) and the indirect effect between the two variables via the mediating 
variable. This indirect effect can be calculated as the product of the effect of the causal variable 
on the mediating variable (a) and the effect of the mediating variable on the outcome variable 
(b). Only if the following requirements of the fitted model are met, is mediation of the proposed 
mediating variable statistically possible: (i) The effects t and a have to be statistically significant, 
and (iia) either the effect c has to be non-significant or (iib) the effect size of c has to be smaller 
than the effect size of t. In the case of (iia), full mediation of the effect via the mediating variable 
can be assumed, whereas in the case of (iib) partial mediation can be assumed (Preacher & 
Hayes, 2004). Whereas requirement (i) was met by both our models at a significance level of 
α=5%, (iia) did not apply to either of them and (iib) only to the model that assumed gene 
expression to be the mediating variable. This result provided first evidence that gene expression 
acts as potential partial mediator between the germline variant and mutational signature. The 
partial character of the mediating effect was expected since mediating effects are rarely - if ever 
- fully mediating (Tingley et al., 2014).  
Next, we subjected this model to the mediate function of the R package mediation (Tingley et 
al., 2014) to assess significance of the average causal mediation effect and estimate its 
proportion by nonparametric bootstrapping (n=1,000 simulations). Briefly, the average causal 
mediation effect is the difference between total effect t and direct effect c which equals to the 
indirect effect defined by the product a x b. Further, by bootstrapping, i.e., repeated random 
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sampling of data points with replacement and computation of the desired statistic on the 
randomly sampled data points, an approximate distribution of the average causal mediation 
effect can be obtained to determine its significance (Preacher & Hayes, 2004). 
Our mediation analysis revealed a significant average causal mediation effect (P ≤ 2x10-16) and 
estimated that a remarkable fraction of 87.11% of the effect of the germline variant rs12628403 
conferred to the mutational signature by APOBEC3B expression. We were therefore able to 
state with high confidence that the effect of the APOBEC3B eQTL modulates Signature 2 
accumulation via APOBEC3B expression, i.e., that in this particular case, gene expression acts 




















Figure 5. See next page for figure caption. 
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Figure 5. Associations between mutational signatures, gene expression and germline variation. 
a. Summary of significant mutational signature-gene expression associations. Top panel: 
Barplot of total number of associated genes per signature (FDR ≤ 10%). Bottom panel: 
Heatmap of enriched Gene Ontology and Reactome Pathways categories for genes associated 
with each signature (-log10 Padj of enrichments; associations with FDR > 10% are coloured in 
white). b. Representative signature-gene association, depicting a negative association between 
CYP26A1 expression and Signature 4. c. Manhattan plots of associations between cis germline 
variants proximal to APOBEC3B (plus or minus 100k base pairs from the gene boundaries) and 
Signature 2 (top panel) and APOBEC3B gene expression level (bottom panel), respectively. 
The grey region denotes the gene body, the orange dot is the eQTL lead variant rs12628403. 
 
 
2.4 Wide-spread associations in somatic eQTL mapping 
While the mutational signature analyses revealed links between gene expression and somatic 
mutations, they were based on genome-wide accumulated somatic SNVs and could therefore 
not capture the effect of local somatic mutations on close-by genes. These local effects might, 
however, be important for gene expression alterations and hence for larger-scale phenotypic 
consequences like cancer progression and metastasis if the gene in question modulates these 
phenotypes. Therefore, as a complementary strategy, we considered the effect of local somatic 
variation (cis) on gene expression. To mitigate the low allele frequency of somatic SNVs, we 
aggregated somatic variants into local burdens in genic and non-genic regions, to then follow an 
approach similar to established germline eQTL analyses.  
 
2.4.1 Quantification of somatic mutation burden 
We used the set of high-quality consensus somatic calls provided by the PCAWG Technical 
Working group based on several core caller pipelines and MuSE (Campbell et al., 2017; Fan et 
al., 2016). On average, each patient harboured 22,144 somatic SNVs across the whole 
genome. Due to this low frequency of somatic SNVs and the resulting low recurrence of specific 
SNVs across the cohort, we aggregated the variants into somatic burdens of different genomic 
regions defined by gene annotations according to Gencode (version 19, Harrow et al., 2006). To 
map local effects of somatic mutations within the gene body, we generated a set of disjoint gene 
exons (cis exonic regions) by collapsing overlapping exon annotations into single collapsed 
exonic regions using bedtools (Quinlan & Hall, 2010). The set of disjoint introns was generated 
using bedtools by subtracting the collapsed exonic regions from the gene regions (cis intronic 
regions). To map local effects of somatic mutations in flanking features outside the gene body, 
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we binned the surrounding regions (±1M base pairs from the gene boundaries) into 2k base 
pairs windows overlapping by 1k base pairs ('cis flanking regions').  
We considered alternative strategies for aggregating somatic SNVs in burden regions: (i) a 
binary value that indicates presence or absence of SNVs, (ii) the aggregated burden as sum of 
SNVs, or as (iii) weighted burden, i.e., sum of variant allele frequencies (VAFs) of the SNVs. 
VAF is an important concept in cancer genomics since it can be used to estimate the fraction of 
a tumour that contains certain mutations. As a concept of intra-tumour heterogeneity, VAFs can 
be used to reconstruct the cancer evolutionary tree and tumour subpopulations (Hajirasouliha et 
al., 2014). While all burden definitions (i, ii, iii) resulted in calibrated association analyses, the 
latter (from now on referred to as weighted burden) had most power in mapping somatic eQTL 
and was therefore used for downstream analyses (see PCAWG Transcriptome Core Group et 
al. (2018) for details). This somatic burden was standardised across patients (to mean zero and 
standard deviation one).  
 
2.4.2 Variance decomposition of gene expression 
We firstly performed variance decomposition of the gene expression data in LIMIX. Specifically, 
we used variance decomposition to quantify the variability of gene expression explained by local 
and distal germline and somatic genetic variation. To do so, we modelled all genetic effects as 
random effects in a linear mixed model, accounting for known confounding factors as fixed 
effect covariates as in the mutational signature analysis (Section 2.3.1) and in addition for local 
somatic burden per gene. The following different measurements of germline variants and 
somatic burden were hereby modelled as genetic factors in the variance decomposition model: 
cis somatic intronic variants (weighted burden in introns), cis somatic exonic variants (weighted 
burden in exons), cis somatic flanking variants (weighted burden in regions of 2k base pairs 
overlapping by 1k base pairs within 1M base pairs from gene boundaries), somatic intergenic 
variants (weighted burden in regions of 2k base pairs overlapping by 1k base pairs outside the 
window of 1M base pairs), cis germline variants (germline variants within 100k base pairs from 
gene boundaries), genome-wide germline variants (i.e., genome-wide population structure), and 
local SCNAs. For each of these random effects, the data was mean-centered and standardised, 
and a linear kernel was computed and used as covariance matrix. The random effect model was 
fit to decompose gene expression variation across individual genes into the defined genetic 
components. The resulting variance components were normalized to a sum of one. 
This analysis identified SCNAs as the major driver of expression variation (27.3% on average, 
Figure 6a), followed by flanking somatic and germline variants. Notably, cis germline effects, 
although exhibiting smaller effects on individual genes, explained the largest proportion of 
variance for 11,905 genes, compared to 3,568 genes, for which somatic factors explained most 
variation (PCAWG Transcriptome Core Group et al., 2018).  
.  
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2.4.3 Cis somatic eQTL mapping 
We then tested for associations between the somatic burden and gene expression levels. 
Specifically, we associated the weighted somatic burden (Section 2.4.1) with gene expression 
(of 18,898 protein-coding genes corrected for 35 peer factors, Section 2.2) by employing linear 
models in LIMIX (Lippert et al., 2014). We accounted for the same confounding factors as fixed 
effects as in the variance decomposition analysis (Section 2.4.2). This analysis was conducted 
on all 1,188 patients, and on a subset of 899 carcinoma patients to replicate the analysis on a 
more homogeneous set of tumours. Only the somatic burden of recurrently mutated genomic 
intervals, i.e., with a burden frequency ≥ 1% across all patients (presence of burden in at least 
12 patients in the full cohort and 9 patients in the carcinoma cohort), was taken into account. 
Altogether, 18,708 of the genes had at least one mutated interval at that frequency. Each of 
these genes was tested for association with the weighted burden of all cis burden regions, i.e., 
cis exonic, cis intronic and cis flanking regions. After the analysis, Bonferroni correction was 
applied to correct for multiple cis windows tested within the same gene. Then, Benjamini-
Hochberg correction was applied to adjust the P-values of the lead genomic regions across 
genes. 
Genome-wide, this identified 649 somatic eQTL (FDR ≤ 5%) that were associated with the 
somatic burden of 567 unique regions. Among these, only a few (n=11) somatic eQTL were 
explained by somatic burden in exonic and intronic regions. These included genes with known 
roles in the pathogenesis of certain cancers, e.g., CDK12 in ovarian cancer (Bajrami et al., 
2014), PI4KA in hepatocellular carcinoma (Ilboudo et al., 2014), C11orf73 in clear cell renal 
cancer (Bhalla et al., 2017) and BCL2 and SGK1 in lymphoma (Hartmann et al., 2016).  
In general, the majority of associated genes (68.4%) were associated with flanking non-coding 
intervals (272 intergenic, 172 intronic regions of different genes). In contrast to known germline 
eQTL, the detected somatic burden-gene expression associations tended to be located distal to 
the transcription start site (TSS) of the respective gene (88% at ≥ 20k base pairs from the TSS), 
with on average larger effects of distal associations than associations proximal to the TSS 
(|β|=3.3 for distal associations versus |β|=1.4 for proximal associations). This finding points 
towards relevance of somatic mutations at distal regulatory elements that have probably been 
underestimated in the analysis of somatic regulatory networks in human cancers so far (Figure 
6b).  
We discovered that so-called cancer-testis genes were marginally more frequent among genes 
with somatic eQTL than expected (45/982, P=0.06, Fisher’s exact test). Cancer-testis genes are 
of interest for their known immunogenic properties (Scanlan et al., 2002) and exhibit high 





 Figure 6. Somatic eQTL analysis. a. Variance composition of gene expression. Average 
proportion of variance (y-axis) explained by different genetic factors (x-axis: SCNAs, somatic 
variants in flanking regions, germline variants, intronic somatic and exonic somatic variants). 
The numbers in parentheses behind the genetic factors indicate the number of genes for 
which the respective factor is the largest variance component, respectively. b. Breakdown of 
567 genomic regions that underlie the observed cis somatic eQTL by genomic region (flank. 
= 2k base pairs flanking region within 1M base pairs from the; flank.intergenic = flanking 
region in a genomic location without gene annotations; flank.intronic = flanking region 
overlapping an intron of a nearby gene; flank.others = flanking region partially overlapping 
exonic and intronic annotations of a nearby gene). c. Manhattan plot of nominal P-values of 
associations between TEKT5 expression (gene body highlighted in grey) and the somatic 
burden of flanking, intronic and exonic genomic regions. The somatic burden of the leading 
genomic region is associated with increased TEKT5 expression (inlet boxplot: log10FPKM+1 
over binarised somatic burden of the genomic region; P=2x10-6, β=0.221). The genomic 
region overlaps with an upstream bivalent promoter (red dot). 
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 We further observed an enrichment of somatic eQTL in bivalent promoters for cancer-testis 
genes (P=0.04, Fisher's exact test). Re-activation of poised promoters is known to be one 
mechanism of upregulation of developmental genes - including cancer-testis genes - in cancer 
(Bernhart et al., 2016), and our findings might point towards a re-activation by somatic mutation. 
One example is TEKT5, an integral component of sperm, that has been found to be aberrantly 
expressed in a variety of cancers (Hanafusa et al., 2012). We observed a positive association 
between TEKT5 expression and somatic mutational burden in a bivalent promoter site close to 
the 5' end of the gene (Figure 6c; PCAWG Transcriptome Core Group et al., 2018). 
 
2.5 Cancer-specific deregulation of allele-specific 
expression 
While the somatic eQTL analysis establishes associations between proximal (likely cis acting) 
genetic variants on gene expression, allele-specific effects allow for directly investigating 
haplotype-specific deregulation. We therefore extended the QTL-based somatic analysis to 
study the effect of somatic mutations in various genomic contexts on ASE, which provides an 
internally controlled readout that enables assessing differential regulation between haplotypes in 
the same patient (Korir & Seoighe, 2014). 
 
2.5.1 Allelic expression quantification 
To enable an allele-specific analysis, we firstly obtained phased germline and somatic variants 
from the PCAWG working group 11. Briefly, for assembling phased germline genotypes, the 
PCAWG working group 11 applied IMPUTE2 to the Sanger 1000G output for phasing of 
heterozygous germline variants (Howie et al., 2012). The IMPUTE2 output was corrected using 
results from the Battenberg CN calling algorithm (Davies et al., 2017), ascertaining that no 
haplotype switches occurred within regions of consecutive CN gain (Nik-Zainal et al., 2012). The 
resulting phased germline variants were arranged such that haplotype 1 always corresponded 
to the amplified alleles in regions with SCNAs. In cases where both co-occurred on the same 
read (10M variants, i.e., ~20% of all SNVs), individual somatic variants were phased to the 
nearest germline heterozygous site. We only considered SNVs that were phased to the 
respective germline variant by at least three reads (resulting in ~6M variants). 
We quantified ASE in tumour and the corresponding normal tissue (available for 150 patients 
across 13 cancer types) based on heterozygous germline variants in exonic regions, using the 
GATK ASEReadCounter algorithms for counting ASE reads (Castel et al., 2015). We 
considered RNA-Seq reads with a minimum mapping quality of 20 and a minimum base quality 
of ten. Only heterozygous variants with a minimum coverage of eight RNA reads were 
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considered for further analyses. The raw ASE read counts were then post-processed as follows: 
ASE sites were converted to BED files and aligned against the ENCODE 50mer mappability 
track to extract mappability scores for all sites. All sites with mappability scores unequal to one 
were removed. All sites with allelic read counts less or equal to one were removed to prevent 
genotyping error to influence ASE quantification. To maximise detection power, we then 
aggregated ASE counts across heterozygous sites within genes to gene-level ASE by 
leveraging phased germline variant maps. First, gene mapping was performed against 
ENSEMBL release 75 using the pyEnsembl library (Hubbard et al., 2002; Zerbino et al., 2018). 
Second, for each gene, we summed up the read counts on the respective haplotypes over all 
gene-specific ASE sites to gene-level haplotype-specific read counts. To allow for a robust 
assessment of gene-level ASE we only considered genes with at least 15 reads total, yielding 
4,379,378 gene-patient pairs across 1,120 patients and 17,009 unique genes across 
12,441,502 ASE sites. Per patient, this allowed us to quantify between 588 and 7,728 genes for 
both haplotypes (median=4,112). 
We then identified potential functional somatic and germline variants on each of the haplotypes 
that could be tested for cis regulatory associations. Due to the low frequency of somatic SNVs 
and the resulting low recurrence of specific SNVs across the cohort, we aggregated all phased 
SNVs into functional categories based on their genomic regions (see somatic eQTL analysis 
(Section 2.4.1)). Using the Variant Effect Predictor (VEP) tool (McLaren et al., 2016), we defined 
regulatory regions of each gene as functional categories (flanking (upstream, downstream), 
promoter, 5' UTR, exon, intron, 3' UTR). We additionally classified exonic SNVs as 
synonymous, missense, or stop gain variants, depending on their functional annotation by VEP. 
We integrated 'splice donor' and 'splice acceptor' variants into the general 'splice region' variant 
category and mapped 'stop retained' variants to the 'synonymous' variant category. We then 
mapped each SNV to the respective regulatory region of its nearest gene. Hereby, we only 
mapped SNVs that were located in a cis window of 100k base pairs from the boundaries of a 
gene; the remaining SNVs were discarded. We further divided the flanking (upstream and 
downstream) categories into disjoint categories using windows of the size of 10k base pairs 
from 10 to 100k base pairs from the gene boundaries. We used the relationship between the 
VAF of SNVs and SCNAs at the same genetic locus to determine whether SNVs occurred 
before (‘early’) or after (‘late’) the corresponding SCNA. As outlined in Section 2.4.1, VAFs can 
be used to estimate the fraction of a tumour that contains certain mutations, and can therefore 
be used to reconstruct the cancer evolutionary tree (Hajirasouliha et al., 2014). For final 
quantification of SNVs per functional category, we therefore computed a weighted cis mutational 
burden per functional category by aggregating SNVs to a total localised burden weighted by the 
VAF of each SNV (see somatic eQTL analysis (Section 2.4.1)).  
Finally, we calculated allelic expression imbalance (AEI) for each gene using a binomial test 
against the expected CN ratio modified by tumour purity. The CN-corrected P-values were 
adjusted for multiple testing using the Benjamini-Hochberg procedure. Significant AEI was 
called at FDR ≤ 5%. Importantly, this definition of AEI notably prevents the assessment of the 
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effect of copy neutral loss of heterozygosity that has been observed in various cancer types 
(Maciejewsky & Mufti, 2008) and should therefore be studied in future analyses. We found 
substantial differences in the fraction of genes with AEI between cancer types (median 
percentages between 14.2% in prostate adenocarcinoma and 46.8% in squamous cell 
carcinoma of the lung; P=2.2x10-13, Mann-Whitney-U-Test; Figure 7a), and between AEI in 
cancer and the corresponding normal tissue. Cancers with extensive chromosomal 
rearrangements, including lung, breast and ovarian cancers, were associated with most 
frequent AEI events (Figure 7a), which is consistent with previous reports that have implicated 
SCNAs in allelic deregulation in cancers (Ha et al., 2012; PCAWG Transcriptome Core Group et 
al., 2018). 
 
2.5.2 Decomposition of allele-specific expression determinants 
Motivated by the substantial difference in the fraction of genes with AEI between cancer types 
and between cancer and corresponding normal tissues (Section 2.5.1), we considered AEI to 
robustly identify the genetic elements that contribute to somatic deregulation of gene 
expression. We employed a generalised linear model to identify the determinants of AEI, 
accounting for known imprinting status, the germline eQTL genotype, local allele-specific 
SCNAs and the weighted mutational burden of proximal somatic SNVs stratified into functional 
categories (upstream, downstream, promoter, 5'UTR, intron, synonymous, missense, stop gain, 
3'UTR; Section 2.5.1). We accounted for genomic imprinting since it results in parental-
dependent gene expression; for doing so, we used a census of known imprinted genes collated 
by Morison et al. (2005). We additionally corrected for sample purity, local CN ratio, sex, cancer 
type, total somatic burden, gene length, length of the canonical transcript, the number of 
accessible ASE sites per gene and both, gene-level and sample-level read depth. Briefly, gene-
level CN ratio was obtained by averaging haplotype-specific CN states to mean haplotype-
specific CN ratio per gene and computing the major over total ratio of those averages.  
In aggregate, SCNAs accounted for 84.3% of the total explained variation, confirming our 
findings of the somatic eQTL analysis, followed by germline eQTL lead variants (9.1%), somatic 
SNVs (4.9% as sum of non-coding and coding SNVs) and imprinting status (1.7%; Figure 7b). 
While cumulatively, non-coding variants were more relevant than coding variants, somatic 
protein truncating variants ('stop gain' variants), which trigger nonsense-mediated decay, were 
the most predictive individually (Figure 7c). This observation confirms the importance of 
nonsense-mediated decay in cancer gene regulation (Lindeboom et al., 2016). SNVs within 
splice regions, 5' UTR and promoters were also strongly associated with AEI presence and we 
observed a global trend of decreasing relevance of variants with increasing distance from the 






Figure 7. ASE analysis. a. Distribution of the proportion of genes with significant AEI (FDR ≤ 
5%) (red) and SCNAs (blue) across patients for different cancer types. Cancer types with 
prevalent chromosomal instability (frequent SCNAs) exhibit most frequent AEI. b. Standardised 
effect sizes of a generalized linear model modelling the presence of AEI, taking SCNAs, 
germline eQTL, coding and non-coding mutations and imprinting into account. c. Relative 
contribution of different types of somatic mutational burden and other covariates to the likelihood 
of observing AEI. Significant covariates (FDR ≤ 5%) are highlighted in bold. 
 
 
Our model allowed for attributing AEI to germline SNPs, SCNAs and somatic SNVs by 
computing average scores derived from predicting AEI individually from SNPs, SCNAs and 
SNVs. Using the trained model for AEI, we hence set out to characterise sets of genes with 
strong allelic deregulation that can be attributed to these different genetic factors. We ranked 
genes according to average scores across the cohort, based on (i) the predicted AEI from the 
germline component and (ii) the predicted AEI from somatic components (SCNAs and SNVs). 
For comparison, we also considered (iii) the empirical AEI frequency in the cohort, and (iv) the 
burden of loss-of-function and gain-of-function mutations derived from genetic data only. When 
overlaying these ranked lists with known cancer genes (COSMIC catalogue; Forbes et al. 
(2017)), we found cancer genes to be enriched among genes with high somatic AEI score (P ≤ 
0.005, Gene Set Enrichment Analysis; Subramanian et al., 2005), but we observed no 
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enrichment amongst genes with recurrent AEI (P=0.99). As expected, genes with AEI due to 
germline eQTL were depleted for cancer genes (negative enrichment, P ≤ 0.001). Consistent 
with the traditional definition of cancer genes based on recurrent mutations (Forbes et al., 
2006), genes with recurrent loss/gain-of-function mutations were most strikingly enriched  for 
the COSMIC genes (P ≤ 0.001). In addition, the top 10% of genes of the somatic AEI scores 
were enriched for Gene Ontology categories with relevance to cancer, including chemotaxis, 
cell motility, locomotion and cell migration, which notably were absent when considering 
loss/gain-of-function mutations. These results suggest that somatic AEI could be used to 
prioritise regulatory variants to identify genes with roles in cancers, which extends previous 
observations in a single cancer (Ongen et al., 2014) to a pan-cancer setting (PCAWG 
Transcriptome Core Group et al., 2018). 
 
2.5.3 Assessment of allele-specific expression of potential cancer 
genes 
As we found cancer genes to be enriched among genes with high somatic AEI (Section 2.5.2), 
we specifically investigated genes that were primarily deregulated by SNVs or SCNAs. Of the 
4,007 genes in the upper quartile based on the prevalence of overall AEI across all tumours, 
1,843 genes exhibited SNV-linked AEI. When we ranked these genes based on the predicted 
AEI from SNVs, the top 10 genes were FBXO5, ASPM, PSCA, CDKN1A, KIF20B, TP53 and 
CLDN4, which have previously been linked to cancer (e.g., Wang et al., 2014) but also SYNE1 
and EXO1, genes that have not been prominently linked to cancer.  
SYNE1 controls nuclear polarity and spindle orientation, and acts upstream of NOTCH 
signalling in squamous lineage development (Lasorella et al., 2014). To understand the effects 
of the regulatory SNVs in detail, we applied a Combined Annotation Dependent Depletion 
(CADD) analysis according to Kircher et al. (2014), which scores deleteriousness of SNVs 
based on multiple annotations like conservation and functional effect. Notably, three melanoma 
cases in our cohort preferentially expressed deleterious missense mutations in SYNE1 
(elevated CADD scores > 25), likely leading to a relative decrease of gene expression in these 
tumours. Based on the GEPIA (Gene Expression Profiling Interactive Analysis) webserver 
(Tang et al., 2017), we also found that low SYNE1 expression was associated with worse 
overall survival in TCGA melanoma patients (log-rank P=0.002, hazard ratio=0.57), providing 
further support for its relevance in disease. 
EXO1 is known to be involved in MMR and recombination, and exhibited significant AEI for a 
deleterious missense mutation in a colorectal adenocarcinoma patient (CADD score 34). 
Similarly, TCGA colorectal adenocarcinoma patients with lower expression of EXO1 showed 
worse overall survival (log-rank P=0.022, hazard ratio=0.57), implicating EXO1 as a potential 
tumour suppressor in human colorectal cancer. Consistent with this finding, EXO1 knockout 
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mice exhibited defects in DNA damage response and increased carcinogenesis (Schaetzlein et 
al., 2013; PCAWG Transcriptome Core Group et al., 2018). 
Notably, we found cancer-testis genes (see Section 2.4.3) to be depleted when considering the 
full somatic score including SCNAs (25/476 cancer-testis genes in the top 10% of genes, 48 
expected, Chi-squared test, P=6x10-4), but enriched in the AEI score based on SNVs only 
(66/476 cancer-testis genes in the top 10% of genes, 48 expected, Chi-squared test, P=6x10-3). 
One potential explanation is that repressed cancer-testis genes have to undergo somatic re-
activation by SNVs before CN amplification. To elucidate this, we used the stratification of SNVs 
into the categories 'early' and 'late' (Section 2.5.1) and found strong over-representation of 
'early' SNVs in 329 out of 7,525 cancer testis gene-patient pairs (216 expected, Chi-squared 
test, P=4x10-14), what confirmed our hypothesis. 
In summary, we identified somatic and germline variation associated with allele-specific 
deregulation of genes across cancer types. We were able to demonstrate the power of ASE as 
an integrator of different sources of transcriptional deregulation in cis. Further, genes that 
showed ASE as a result of somatic mutagenic processes were enriched for both, known cancer 
genes and cell migration pathways, suggesting the utility of ASE analyses for the identification 
of candidate driver genes involved in metastasising processes. In particular, we found recurrent 
somatic reactivation of cancer testis genes, warranting further investigation into their role in 
carcinogenesis and tumour progression (PCAWG Transcriptome Core Group et al., 2018). 
 
2.6 Summary and discussion 
The regulatory landscape of cancer is highly heterogeneous, cancer type specific and 
influenced by the germline background. The prevalence of perturbations due to somatic 
mutations makes cancer a perfect model for studying regulatory dependencies, including 
regulatory dependencies of genes that are not subject to germline perturbations. Collectively, 
our analyses of the PCAWG genomic and transcriptomic data provided a comprehensive picture 
of this regulatory landscape, and of how different germline and somatic variations alter gene 
expression levels in a pan-cancer setting.  
First, we studied associations between gene expression association and mutational signatures. 
As mutational signatures capture global variations across individuals, they describe variation 
patterns distinct from local somatic variations. We investigated the utility of associations 
between mutational signatures and gene expression levels, thereby deriving de novo 
annotations of signatures with previously unknown roles. We produced comprehensive across-
tissue germline eQTL maps to carry out analyses that integrate germline and genome-wide 
somatic variation with gene expression. This allowed us unpick the molecular chain of events for 
the common APOBEC mutational process and its germline component. The APOBEC signature 
was however the only mutational process that we were able to associate with germline variation. 
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This might be due to the tissue specificity of mutational signatures that inherently reduces the 
effective sample size per signature analysis and might hence render the detection of the effect 
of (rare) germline variants impossible. In general, the strong tissue specificity of mutational 
signatures did not allow for an entirely cancer type-independent study of the molecular 
consequences of the signatures: Although we accounted for differences between cancer types, 
if in an extreme case a signature only occurs in one cancer type, associations will inherently be 
confounded with tissue type effects. It will therefore be important to conduct similar analyses for 
individual cancer types and in cohorts with more WGS samples. 
In terms of local somatic variation, we considered the effect of somatic mutational burden in 
different genomic regions on gene expression changes by building a systematic map of somatic 
eQTL. We accounted for variation in clonality as well as local hypermutations, thereby 
identifying likely causal associations between somatic burden and gene expression. However, 
this approach has limitations and we cannot rule out that a fraction of the associations we 
identified are due to technical or biological factors that jointly affect gene expression and local 
mutation rates. We also note that an analysis of cancer type specific somatic eQTL is currently 
not feasible with the given sample size. However, the somatic eQTL map will be a valuable 
resource to address a wide range of downstream analyses, providing a comprehensive 
overview of gene expression determinants in cancer and insights into the underlying biology. 
The systematic assessment of regulatory non-coding genetic variation significantly improves our 
understanding of the aetiology and functional implications of intra- and inter-tumour 
heterogeneity and the selective forces applied to these heterogeneous genomes. 
We then used ASE readouts for integrated modelling of local genetic variation to characterise 
genetic elements that have the largest regulatory effects. We demonstrated the extent to which 
AEI on the expression level follows allelic imbalance on the genomic level. A problem was that 
the considered phased somatic mutation set was based on read phasing, which has only been 
possible for around 20% of all SNVs and hence substantially reduced the size of our available 
dataset. Further, ASE readouts can only be derived in cases with at least one heterozygous 
germline variant in the gene in question, what reduced overall sample size once more and 
additionally hindered gene-level associations.  
Altogether, we showed that co-regulation of the same genes by multiple different types of 
variants is common in cancer, and we simultaneously reported the relative magnitudes of these 
different effects. Previous studies have been limited by the lack of WGS data, which is essential 
for identifying contributions of non-coding variants to gene expression variability. Indeed, our 
analyses of the currently largest cohort of matched tumour WGS and RNA-Seq data of 1,188 
patients identified previously underappreciated associations between somatic regulation in distal 
regulatory elements and gene expression, as well as de novo functional annotations of genome-
wide mutational signatures.  Finally, our results pointed towards non-coding somatic 
deregulation as an important functional driver of carcinogenesis beyond mutations of the coding 




3 Combined single-cell profiling of expression 
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Linker in this project. While I supervised Stephanie in analysing splicing ratios and applying 
deep learning modelling, my own work focused on understanding splicing variation across cells 
and on splicing category switches during stem cell differentiation. All work has been realised in 
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the scM&T-Seq data.  
All scripts are available as jupyter notebooks here: https://github.com/PMBio/scmt_splicing. The 
manuscript was published in Genome Biology (Linker, Urban et al., 2019). The deep learning 
component of this project was published as part of the kipoi project (Avsec et al., 2019) in 







RNA regulation is not limited to changes in total gene expression levels, and in particular post-
transcriptional changes affect the pool of gene products and proteins in the cell. One such 
modification is alternative splicing of RNA, which enables efficient gene encoding and 
contributes to gene expression variation by alternative exon usage (Black, 2003; Section 1.1.2). 
Alternative splicing is pervasive and affects more than 95% of human genes (Barbosa-Morais et 
al., 2012). Splicing is known to be regulated in a tissue-specific manner (Kelemen et al., 2013; 
Revil et al., 2010) and individual splicing events have been implicated in human diseases (Xiong 
et al., 2015). Bulk RNA-Seq data of cell populations has been used to identify and quantify 
different splicing events (Sammeth et al., 2008). These studies mostly focused on exon skipping 
at cassette exons, the most frequent alternative splicing event (Black, 2003; Section 1.1.2). 
Different genetic factors have been linked to splicing of cassette exons, including sequence 
conservation (Wainberg et al., 2016) and genomic features such as local sequence composition 
and length of the exon and of the flanking introns (Huang & Sanguinetti, 2017; Xiong et al., 
2015). Although there is some evidence for an epigenetic component of splicing regulation, this 
relationship is not fully understood and alternative models for the role of DNA methylation in 
splicing have been proposed (Maunakea et al., 2013; Shukla et al., 2011b; Yearim et al., 2015). 
The transcriptional repressor CTCF has been shown to slow down RNA polymerase II, resulting 
in increased exon inclusion rates. By inhibiting CTCF binding, DNA methylation can cause 
reduced exon inclusion rate (Shukla et al., 2011). Alternatively, increased DNA methylation of 
the MeCP2 pathway has been associated with increased exon inclusion rates. MeCP2 recruits 
histone deacetylases in methylated contexts; histone deacetylases are enzymes that remove 
acteyl groups from histones and therefore allow the histones to wrap the DNA more tightly. This 
interplay between MeCP2 and DNA methylation slows down RNA polymerase II and leads to an 
increased exon inclusion rate (Maunakea et al., 2013). Finally, the heterochromatin protein HP1, 
which serves as an adapter between DNA methylation and TFs, increases the exon inclusion 
rate if it is bound upstream of the alternative exon (Yearim et al., 2015). This might be due to 
heterochromatin formation that again slows down RNA polymerase II. However, when HP1 
binds to alternative exons, this results in increased exon skipping (Yearim et al., 2015). These 
alternative mechanisms point towards complex regulation of alternative splicing via combined 
effects of DNA sequence and DNA methylation, both proximal as well as distal to the alternative 
exon. These links are, however, difficult to study since this would require a model system with 
constant genetic background but epigenetic variation, which is hard to realise experimentally.  
While epigenetic variation can be found between different tissue types, the intrinsic variation 
between individual cells has not been exploited yet. However, single cells with the same genetic 
background constitute the perfect study system that enables analysing molecular single-cell 
variability as perturbation at the epigenetic level. While technological advances to perform RNA-
Seq in single cells have recently enabled analyses of splicing variation at single-cell resolution 
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(Huang & Sanguinetti, 2017; Song et al., 2017; Welch et al., 2016), no studies have linked the 
epigenome to the transcriptome yet. Here, we leveraged technological advances that enable 
joint profiling of gene expression and DNA methylation in the same cell (single-cell methylation 
and transcription sequencing (scM&T-Seq) by Angermueller et al. (2016)). Considering induced 
pluripotent stem (iPS) cells and differentiated endoderm cells, we studied associations between 
single-cell splicing variation and DNA methylation while taking into account the effect of local 
genetic variation across genomic splice sites (Linker, Urban et al., 2019).  
We considered iPS and endoderm cells since alternative splicing has been shown to change 
substantially between pluripotent and differentiated cells, and to play an important role in 
maintaining pluripotent homeostasis (He et al., 2015). Importantly, iPS cells resemble 
embryonic stem (ES) cells in terms of their molecular states including alternative splicing 
patterns (Chen et al., 2015).  They can be obtained by reprogramming differentiated cells to 
stem cells: While the pluripotency of cells depends on a vast network of genes and signalling 
molecules, the TFs OCT4, SOX2, and NANOG are known to control majority of these processes 
and modulation of their activity has allowed reprogramming of various cell types across species 
(Boyer et al., 2005). Similar to ES cells, iPS cells can then be differentiated into derivatives of 
any of the three primary germ layers (Medvedev et al., 2010). iPS cells therefore allow the study 
of molecular changes during the development of organs and whole organisms (Yamanaka, 
2012), and will potentially play an important role in cell therapy of human diseases (Medvedev 
et al., 2010). A thorough understanding of the molecular mechanisms of pluripotency and 
differentiation is hereby essential for any clinical application of iPS cells (Chen et al., 2015).  
 
3.2 The determinants of single-cell splicing variation 
3.2.1 Single-cell splicing variation during differentiation 
We applied parallel scM&T-Seq to differentiating iPS cells from a single donor ('joxm_1') of the 
Human Induced Pluripotent Stem Cell Initiative (HipSci) (Kilpinen et al., 2017; Streeter et al., 
2017). We profiled 93 cells in the iPS state, as well as following three days of differentiation 
towards definitive endoderm. After quality control (see Section 3.5 for details) this resulted in 86 
iPS and 59 endoderm cells, which were used for further analysis. In each cell we quantified 
cassette exon inclusion rates (scheme of a cassette exon with the central alternative exon 'A' in 
Figure 8a). The alternative splicing rate (PSI) was estimated as the fraction of reads that 
include the alternative exon versus the total number of reads of the cassette exon. We detected 
and quantified splicing for between 1,386 and 14,434 exons per cell (minimum coverage of five 
reads; see Section 3.5 for Methods, and Linker, Urban et al. (2019) Table S1/Additional File 1 
for read distributions of the transcriptome and methylation data across cells). We considered 
6,282 (iPS) and 4,096 (endoderm) cassette exons that were quantified by at least five reads in 
at least ten cells. 
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Initially, we investigated to what extent single-cell data is consistent with existing models of 
splicing variation. One canonical splicing model assumes that individual cells express only a 
single splice isoform ('cell model'), whereas the other existing splicing model postulates the 
presence of multiple isoforms in a given cell ('gene model'; Figure 8b). The question which 
splicing model describes splicing variation across cells best can not be modelled with bulk data 
(Faigenbloom et al., 2015; Shalek et al., 2013), and no study has tried to answer this question 
on a single-cell level yet. We therefore modelled the expected distribution of PSI assuming 
either the cell or the gene model. For the cell model, we modelled PSI variation as a bimodal 
distribution at the single cell level. In the case of the gene model, the limited number of 
transcripts per gene had to be taken into account. Assuming that each time a gene is 
transcribed, the probability of exon inclusion equals mean PSI; however, the limited number of 
transcripts leads to fluctuations in the actually observed PSI and the binomial distribution of 
isoforms is therefore restrained by an upper boundary of the standard deviation. To obtain this 
boundary, we calculated this standard deviation across cells by simulating the PSI (n=400 
simulation) of each cell as a binomial distribution.   
A comparison of mean and standard deviation of PSI in our data with these expected 
distributions ruled out the cell model, but we also observed deviations from the gene model, in 
particular for exons with intermediate levels of splicing (0.2 < PSI < 0.8; Figure 8c). An 
intermediate model might therefore describe our data best, e.g., a model that assumes 
differential alternative splicing behaviour between individual chromosomes. We also observed 
that iPS cells have splicing patterns that are more consistent with the gene model (percentage 
of cassette exons that follow the gene model) as compared to endoderm cells (P=8.x10-12, 
Mann-Whitney-U-test), suggesting an impact of cell differentiation on the splicing model and a 




Figure 8. Modelling of alternative splicing in single cells. a. Illustration of the sequence contexts 
per cassette exon (top) and the total numbers of genomic and epigenetic features extracted per 
sequence context (bottom). 'A' denotes the alternative exon, 'I1' and 'I2' correspond to the 
upstream and downstream flanking introns and 'C1' and 'C2' to the upstream and downstream 
flanking exons, respectively. Hereby, the 5' and 3' ends of the flanking introns are considered 
separately. b. Illustration of two canonical splicing models. The 'cell model' assumes that 
splicing variation is due to differential splicing between cells, with each cell expressing one of 
two splice isoforms. The 'gene model' corresponds to the assumption that both splice isoforms 
are expressed in the same cells. c. Observed cell-to-cell variation in PSI across cells (standard 
deviation) as a function of the average PSI across cassette exons in 86 iPS cells. Solid lines 
model the expected trend under the assumption of a cell model (black line) or a gene model 
(red line). Grey vertical lines mark intermediate ranges of splicing (0.2 < PSI < 0.8). 
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3.2.2 Splicing variability and methylation heterogeneity across single 
cells 
To identify locus-specific correlations between DNA methylation heterogeneity and variation in 
splicing across cells, we tested for associations between differences in DNA methylation levels 
and splicing rates across cells. Specifically, for each cassette exon, we tested for associations 
between splicing and variation in DNA methylation in each of seven sequence contexts (based 
on Spearman's rank correlation coefficient and probability; see Section 3.5.4 for details): the 
alternative exon, the 5’ and 3’ end of the two flanking introns, and the two flanking exons 
(Figure 8a). Genome-wide, this identified 424 cassette exons with methylation-splicing 
associations in iPS cells (out of 5,280 tested cassette exons, FDR ≤ 5%) and 253 associations 
in endoderm cells (out of 2,622 tested cassette exons, FDR ≤ 5%; Section 3.5). DNA 
methylation variation in the upstream alternative exon was most frequently associated with 
splicing variation (~60% of associations included the alternative exon), with approximately equal 
numbers of positive and negative associations. In iPS cells, 58% of all correlations were 
positive, in endoderm cells 55%. We identified positive associations as associations where 
increased DNA methylation was linked to increased alternative exon inclusion; a negative 
association meant that increased DNA methylation was linked to decreased exon inclusion. 
Most associations could be detected in more than one sequence context of a given cassette 
exon, always with consistent effect directions. Similarly, we observed largely concordant 
associations across the two cell types in our data (again based on Spearman's rank correlation 
coefficient and probability; Section 3.5). Among exons that were expressed in both, iPS and 
endoderm cells (n=3,743 cassette exons), 77% of the associations identified in iPS could be 
replicated on a nominal level in endoderm cells (P ≤ 5%, with a consistent effect direction), and 
89% of the associations identified in endoderm were also observed in iPS cells (P ≤ 5%, with a 
consistent effect direction). Genes with negative associations between DNA methylation in the 
three upstream regions and PSI were enriched for HOXA2 transcription factor binding sites 
(TFBSs; enrichment with G:Profiler (Reimand et al. (2016)) and P-value correction across 
categories according to Benjamini Hochberg; iPS: 78/118 query genes linked to HOXA2, 
Padj=6x10-4; endoderm: 60/90 query genes linked to HOXA2, Padj=9x10-3) (Linker, Urban et al., 
2019). 
 
3.2.3 Prediction of splicing at single-cell level 
To gain insights into the genetic determinants of splicing, we trained regression models that 
related genomic to splicing rates in single cells (Figure 9a). Briefly, we pooled splicing 
information from cassette exons across cells and trained separate regression models for iPS 
and endoderm cells. Initially, we considered 607 features that explain sequence composition 
(based on k-mers), sequence length and sequence conservation per sequence context of the 
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respective cassette exon and per cell ('genomic' features). We additionally considered an 
additional set of up to 826 features derived from DNA methylation, including an extended k-mer 
alphabet that takes the methylation status into account (that results in a five-letter code which 
differs between methylated (‘M’) and un-methylated (‘U’) cytosines), as well as DNA methylation 
average and variance (across CpG sites) in each of the seven sequence contexts of the 
cassette exon per cell. Methylation features were either incorporated on a pseudo-bulk average 
level ('genomic & mean methylation' features) or individual cell level ('genomic & cell 
methylation' features; see Section 3.5 for details). 
Notably, the model to predict single-cell splicing based on genomic features yielded comparable 
performance to previous attempts to predict splicing using bulk data (Xiong et al., 2015) and 
single-cell data (Huang & Sanguinetti, 2017; R2=0.706 and R2=0.670 for iPS and endoderm 
cells, respectively; assessed using ten-fold cross validation; Figure 9a). To facilitate the 
comparison with previous results using bulk RNA-Seq, we also predicted aggregate splicing 
rates across cells ('pseudo-bulk PSI'; bPSI), which resulted in similar prediction accuracies 
(R2=0.747 and R2=0.732 for iPS and endoderm cells, respectively). The inclusion of DNA 
methylation features increased the prediction accuracy slightly, with larger gains for cell-
matched DNA methylation information (Figure 9a, e.g., for iPS cells R2=0.719 and R2=0.729 for 
'genomic & cell methylation' versus 'genomic & mean methylation', respectively). In combination 
with our previous results regarding the relationship between alternative splicing and DNA 
methylation, these findings suggest that DNA methylation is most predictive of cell-to-cell 
variation in splicing at the same locus, whereas genomic features capture variation across 
different loci. While we found these observations to be consistent across iPS and endoderm 
cells, we replicated these findings in a second independent scMT-Seq dataset of mouse ES 
cells (n=80 cells; Angermueller et al., 2016; Section 3.5) where we yielded similar splicing 
prediction performance that also increased with the inclusion of methylation information. 
Next, to explore the relevance of these genomic and methylation features in individual cells, we 
used the prediction accuracy (Pearson R2) of single-feature regression models. Consistent with 
previous bulk studies (Wainberg et al., 2016; Xiong et al., 2015), this identified features derived 
from the alternative exon and its neighbouring sequence context, i.e., the 3’ end of the upstream 
intron and the 5’ end of the downstream intron, as most informative for alternative splicing. 
Within these sequence contexts, sequence conservation of the alternative exon was most 
informative (Figure 9b). Other high-ranking features included the k-mers CT, CTC and CCT of 
the alternative exon (Figure 9b), sequence patterns that show close resemblance to CTCF 
binding motifs. Although CTCF or CTCF-like motifs have previously been implicated in 
alternative splicing, these identified motifs were located upstream or downstream of the 
alternative exon and were associated with an increased splicing ratio (Brooks et al., 2011; 
Shukla et al., 2011b; Section 3.1). Here, we were the first to discover the importance of these 
motifs within the alternative exon, and their association with a decreased splicing rate. In the 
case of the previously known phenomenon, CTCF-like motifs are hypothesised to lead to 
increased exon inclusion because CTCF binding to intronic regions slows down the RNA 
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Polymerase II (Section 3.1). We might see a different direction in our dataset for multiple 
reasons; CTCF might not bind to exonic regions as efficiently as to intronic regions, or the RNA 
Polymerase II might not be slowed down by CTCF bound to the alternative exon, or our 
observed splicing patterns only occur at the particular cell differentiation stages we have 
studied. Our dataset does not allow us to confirm the molecular caused of this relationship 
between splicing and exonic CTCF-like motifs. Our hypotheses could, however, be tested, by 
ChIP-Seq profiling of the TF CTCF, or by single molecular analysis measuring RNA Polymerase 
II activity and dynamics (Weiss, 1999). Alternatively, the motifs we discovered might differ from 
the canonical CTCF binding motifs (in terms of extended motifs or orientation), a possibility that 
we could not rule out based on our k-mer data and that might explain the reverse effect of our 
motifs on exon inclusion.  
The relevance of the cell-specific features for splicing prediction was markedly consistent across 
iPS and endoderm cells (average R2 between weights across all iPS and endoderm cells 
R2=0.79). Despite the overall consistency in feature relevance, PCA applied to the feature 
relevance matrix across all (iPS and endoderm) cells identified subtle differences in feature 
relevance between the two cell types (Figure 9c): The first two principal components (PCs) 
clearly separate iPS from endoderm cells. These components primarily reflect variation in 
(un)methylated cytosine-containing k-mer composition of the downstream intron ('I2') (Figure 
9d). Consistent with this, a single-cell splicing model trained on genomics and methylation data 
from endoderm cells yielded only moderate prediction accuracy in iPS cells (R2=0.52), 
highlighting the relevance of these parameters for splicing models that account for DNA 
methylation information. Altogether, these findings pointed towards a combination of DNA 
methylation and sequence composition as main determinant of cell type-specific splicing 




Figure 9. Prediction of single-cell splicing variation. a. Prediction accuracy (R2 based on ten-fold 
cross validation, y-axis) of different regression models for predicting single-cell splicing rates in 
iPS cells and endoderm cells (x-axis). The genomic model is based on sequence k-mers, 
conservation scores and sequence lengths of sequence contexts (genomic features, dark blue). 
Other models account for average methylation rates across cells (genomic & mean methylation 
features, median blue), or cell-specific methylation rates (genomic & cell methylation features, 
light blue). Error bars denote ±1 standard deviation across four repeat experiments. b. Features 
ranked by relevance for predicting splicing in iPS cells as determined by single-feature 
regression models. The most relevant features are features of the alternative exon, and include 
a methylated k-mer. Error bars denote ±1 standard deviation of the feature relevance across 
cells. Methylation features are indicated in grey. c. PCA on all cell-specific feature weights as 
shown in (b). The first PC captures differences between differentiation states. d. The ten 
features with the largest contribution to the first PC of (c). Negative correlations are shown in 
red, positive ones in blue. Methylation features are shown in grey. 
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3.2.4 Deep learning modelling of splicing 
Whereas linear models require a priori definition of features that we here averaged per 
sequence context (e.g., average k-mer load of the alternative exon), other models can use more 
complex data like raw DNA sequence as input. We therefore considered if the application of 
CNNs (Section 1.2.3) to predict single-cell splicing based on raw DNA sequence would add new 
insights to our analyses, and improve our understanding of the complex relationship between 
DNA sequence, DNA methylation and splicing rates. When encoding our DNA sequences, we 
either used the standard four-letter code for the four DNA bases or the previously used five-
letter code that differs between methylated (‘M’) and un-methylated (‘U’) cytosines (Section 
3.2.3).  
CNNs have already been used to predict methylation rate, TFBSs and alternative splicing from 
DNA sequence (Alipanahi et al., 2015; Angermueller et al., 2017; Wainberg et al., 2016; Xiong 
et al., 2015; Section 1.2.3). However, no deep model for predicting splicing from DNA sequence 
(or DNA methylation) in single cells has been developed so far. Therefore, we set out to 
construct our own CNN that can predict splicing from DNA sequence (and DNA methylation) in 
a single-cell setting.  
For each cassette exon, a sequence window of ±400 base pairs around the centre of the 
alternative exon was used to train a CNN. This region was selected since the linear model 
predictions revealed the alternative exon to be the most relevant region for splicing predictions. 
In addition, most exons are shorter than 200 base pairs (Sakharkar et al., 2005), i.e., the region 
is chosen to include the whole exon as well as regions from the adjunctive introns. The DNA 
sequence was one-hot encoded, and subsequently multiplied with the conservation score of the 
region, as previously derived from BRIE (Huang & Sanguinetti, 2017; see Section 3.5 for 
details). The sequence conservation was taken into account since previous studies (e.g., 
Wainberg et al., 2016) and our first analyses pointed towards relevance of this feature for 
splicing regulation.  
In the CNN analyses, the same set of cassette exons was used as described in Section 3.2.1; 
one CNN per cell type was trained. Here, I only describe the analysis of the iPS cells, but the 
results in endoderm cells were comparable. Briefly, the transformed DNA sequences were used 
as input for a CNN to predict binary splicing, i.e., inclusion (PSI ≥ 1/3) or exclusion (PSI < 1/3) of 
the alternative exon. Hereby, the PSI threshold of 1/3 was chosen (instead of a mean threshold 
of 1/2) since it approximately balanced our positive and negative samples; imbalanced datasets 
have been shown to have a detrimental effect on the prediction performance of deep models 
(Buda et al., 2018). Our final CNN consisted of one convolutional layer (58 filters of length 10), a 
bias and rectification layer that obtains non-negative values by applying the rectified linear unit 
function, a maximum pooling step that compresses the data (pooling length of 8 base pairs) and 
an additional fully connected layer (50 nodes; Section 1.2.3 for details about CNNs). The 
convolutional layer is hereby the core component of a CNN, which acts as a feature extractor to 
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identify predictive DNA sequence motifs. When the filters of the convolutional layer slide over 
the DNA sequence in an overlapping manner, they assign a score to each position and hence 
create a list of scores that can be thought of as a position weight matrix (Stormo et al., 1982): 
The higher the score, the higher the similarity between the respective DNA sequence and the 
motif learned by the filter (Section 1.2.3).  
For training the CNN, we randomly split our dataset into training (60%), validation (20%) and 
test (20%) datasets considering cassette exons in a given cell. We did not split the dataset on 
the cell level since multiple cells shared multiple alternatively spliced genes, which may lead to 
inflated prediction performance. The model was trained until the weights converged (patience=3 
iterations; maximum number of iterations=100) using the training dataset. We then optimized 
across some sets of hyperparameters, using the validation dataset. Importantly, we chose the 
number of described hidden layers (see above) since other models with more hidden layers did 
not converge after 100 iterations. The weights of the model did also not converge when we tried 
to predict quantitative PSI. This might be due to a too small sample size that did not allow 
attributing quantitative PSI changes to base-level changes in the DNA sequence. The binary 
PSI, however, yielded a successfully trained model. 
For the four-letter encoded DNA, we obtained a CNN with an AUC (area under the receiver 
operating characteristic curve) of 0.908 using the test dataset (see Figure 10a for the receiver 
operating characteristic (ROC) curve). This performance is comparable to state-of-the-art CNNs 
that predict alternative splicing in bulk data (Wainberg et al., 2016), which was a motivating 
result given that single-cell data is inherently noisier than bulk data. The five-letter code CNN 
that distinguishes methylated and un-methylated bases achieved an AUC of 0.912 using the 
test dataset (see Figure 10b for the ROC curve). Inclusion of methylation information therefore 
seemed to improve predictability of splicing slightly, similar to what we had observed in the 
linear models. 
To our knowledge we here present the first CNN trained on single-cell splicing data, which 
additionally allows for inclusion of DNA methylation information. We showed that CNNs predict 
single-cell alternative splicing with good performance. Opposed to linear models that are based 
on a priori defined features, the CNN can further be queried for sequence motifs relevant for 
splicing modulation. These sequence motifs can be detected by studying which motifs of the 
input DNA sequences lead to the highest activation of a filter and by then using these motifs to 
build a consensus sequence according to Ding et al. (2017).  
To make the (five-letter code) model accessible to the scientific community we contributed it to 
the kipoi model zoo (kipoi.org), a framework for deep learning applications in genomics (Avsec 
et al., 2019). Within this framework, our model can now be employed to make regulatory gene 
predictions using genomic and epigenetic variation data of any single-cell dataset. Finally, our 
model can be combined with other deep learning models provided by kipoi or the user to 





Figure 10. Prediction of splicing rates with CNNs based on genomic sequences. a. 
Performance of the CNN based on only genomic information (four-letter code model), assessed 
by ROC curve and AUC. b. Performance of the CNN based on genomic and methylation 
information (five-letter code model), assessed by ROC curve and AUC. 
 
 
3.3 Prediction of splicing categories  
3.3.1 Prediction of splicing categories of individual exons 
Next, we set out to study variability in alternative splicing patterns across cells. To describe 
cassette exons by both, their splicing rate and the variability of this splicing rate across cells, we 
classified them into five distinct categories, using a scheme similar to the one described by 
Song et al. (2017): We considered 1) excluded, 2) included, and three intermediate splicing 
categories: 3) overdispersed, 4) underdispersed and 5) multimodal categories (Figure 11a; 
Figure 11b shows the category distribution according to Figure 8c). We then trained 
multinomial regression models to classify individual exons using features sets analogous to the 
ones considered for the quantitative regression models that predict splicing rates (see Section 
3.2.3). A model based on genomic features yielded a macro-average AUC across all five 
categories of 0.85 (Figure 11c), where again sequence conservation in different contexts was 
the most informative individual feature. Interestingly, we observed differences in the feature 
relevance across splicing categories: i) included and excluded exons, where the most relevant 
features were located in the alternative exon, and ii) the intermediate splicing categories, where 
features of the flanking exons were most informative. Predictions of included and excluded 
exons were most accurate on the individual category level (AUC=0.96 for included and 
excluded in iPS, AUC=0.94 for included in endoderm, AUC=0.96 for excluded in endoderm 
cells; see Figure 11d for individual and macro-average ROC curves). These prediction 
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accuracies exceeded previously reported results in bulk data (Xiong et al., 2015). Even higher 
accuracies were achieved when training a model to differentiate between included and excluded 
exons alone (AUC=0.99), whereas lower prediction accuracies were achieved for differentiating 
just the intermediate splicing categories from each other (AUCs=0.7 to 0.9 for all one-vs-one 
predictions). The inclusion of methylation features did not improve the prediction performance of 
these categorical models (Figure 11d).  
Consistent with this, we also found that a model based on DNA methylation alone did not yield 
accurate predictions although methylation contained some information for identifying 
underdispersed cassette exons (Figure 11d). We therefore investigated the distribution of DNA 
methylation patterns across splicing categories, observing distinct distributions of DNA 
methylation in the upstream exon of underdispersed cassette exons (Figure 11e). This effect 
was consistent, although less pronounced, in other sequence contexts (decreasing from the 
upstream to the downstream exon).  
 
 
Figure 11. Classification of cassette exons based on their single-cell splicing patterns. a. PSI 
distributions for five splicing categories, inspired by Song et al. (2017). The intermediate splicing 
categories that can only be distinguished if single-cell data is provided are highlighted by a grey 
frame. b. Variation of PSI (standard deviation) across cells as a function of the average 
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inclusion rate of cassette exons across 86 iPS cells, coloured according to their respective 
splicing category as defined in (a). The solid black line denotes the LOESS (locally weighted 
scatterplot smoother) fit across all cassette exons. c. Prediction performance of logistic 
regression for predicting splicing categories based on genomic features. The ROC curves and 
AUCs for each splicing category and for the macro average across all categories are shown. 
Splicing categories are coloured as in (a).  d. Prediction performance of the logistic regression 
models for all splicing category, based on either genomic features ('genomic', left), genomic and 
all DNA methylation features ('genomic & methylation', centre) or only DNA methylation features 
('methylation', right). The genomic model includes k-mers, conservation scores and sequence 
lengths of the sequence contexts. The genomic and methylation model additionally includes all 
DNA methylation features. The methylation model only includes average DNA methylation 
features per sequence context. Splicing categories are coloured as in (a). Error bars denote ±1 
standard deviation across four repeat experiments. e. Distribution of DNA methylation levels in 
the upstream exon ('C1') per splicing category. Methylation is relatively decreased in 
underdispersed exons. Splicing categories are coloured as in (a). 
 
 
We again investigated the consistency of these models between iPS and endoderm cells. To do 
so, we trained the genomic model on endoderm cassette exons and assessed this model’s 
predictions on iPS-specific cassette exons, which resulted in a prediction accuracy that was 
comparable within-cell-type prediction (macro AUC=0.82). However, inclusion of the DNA 
methylation features into the model resulted in a decline in the cross-cell-type prediction 
performance (macro AUC=0.54). Similar to the cross-replication analysis using models trained 
on quantitative splicing rates (Section 3.2.3), this emphasised the relevance of cell type-specific 
DNA methylation for accurately predicting splicing. The relevance of genomic information for 
splicing, on the contrary, seems to be more conserved and applies across cell types.  
Next, we assessed if the same splicing category analyses applied to the scM&T-Seq dataset of 
mouse ES cells would yield similar results. We observed that the performance for splicing 
category prediction was very similar to the performance in the endoderm and iPS cells (macro 
AUC=0.82, for both, the genomic and the genomic and methylation model). We observed the 
same distinct distribution of DNA methylation in the upstream exon of underdispersed cassette 
exons. However, the relationship between the DNA methylation levels and underdispersed 
category could not be confirmed by the mouse ES cells (Linker, Urban et al., 2019). 
 
3.3.2 Splicing category switches during cell differentiation 
Finally, we assessed changes in the splicing category switches between cellular differentiation 
stages. Similar to previous observations in the context of neuronal iPS differentiation (Song et 
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al., 2017), we observed that a majority (88%) of the cassette exons retained their category 
during differentiation (Figure 12a). Also, no cassette exon switches from included to excluded 
or vice versa were observed. Instead, the majority of the switching events (55%) were observed 
within the three intermediate splicing categories. The most prevalent event was switching to the 
multimodal category: 51% of the underdispersed and close to 45% of the overdispersed 
cassette exons in iPS cells switched to be multimodal after differentiation to the endoderm state.  
After observing these interesting patterns in category switches between the two differentiation 
stages, we set out to build a set of logistic ridge regression models based on genomic and 
methylation features to predict category switching ability of cassette exons during differentiation 
(Figure 12b for prediction performance). The model based on genomic features had limited 
power to predict category switches, and DNA methylation did not significantly improve the 
prediction. However, moderately better prediction performance was achieved for the switching 
behaviour of over- and underdispersed cassette exons. 
Lastly, we explored if DNA methylation had an impact on the switching behaviour between 
splicing categories. We assessed if DNA methylation changed within switching cassette exons 
during differentiation. The DNA methylation levels of cassette exons that switched category only 
changed slightly during differentiation. However, we observed that DNA methylation of the 
alternative exon of switching cassette exons differed from non-switching cassette exons at the 
iPS stage (Figure 12c). DNA methylation of cassette exons that would switch from an included 
or excluded state was increased in the upstream exon ('C1') in comparison to their non-
switching counterparts. In the case of switching overdispersed cassette exons, we observed 
higher DNA methylation levels within and in the vicinity of the alternative exon, again compared 









3.4 Discussion and conclusion 
This chapter describes the analysis of alternative splicing in single cells and the impact of both 
genomic and epigenetic factors. Our study focused on variation of splicing in cassette exons at 
two different stages of cell differentiation, and we used data from mouse ES cells to replicate 
the most relevant results. This chapter extends the scope of this thesis from general 
associations between genomic variation and gene expression (Section 2) to (i) the functionally 
relevant phenotype of alternative splicing, (ii) the study of single-cell instead of bulk data, (iii) the 
impact of epigenetic variation on molecular functions, and (iv) the application of more complex 
machine learning models like CNNs. 
First, we demonstrated that splicing events do not strictly follow either of the canonical cell or 
gene models of splicing variation across cells. Instead we found a substantial proportion of 
exons that were better described by an intermediate model (Figure 8a). We therefore 
Figure 12. Comparison of splicing category distributions between iPS and endoderm cells. a. 
Pie chart showing the number of category switches between iPS and endoderm cells (left 
panel). The zoom-in (right panel) shows details of different category switches. The outer pie 
chart shows the splicing category of each cassette exon at the iPS state and the internal pie 
chart shows the respective category at endoderm state. Non-annotated slices in the pie chart 
reflect <1% of the data. b. Performance of logistic ridge regression models that predict 
absence/presence of switching splicing categories between iPS and endoderm states. DNA 
methylation information improves prediction of the under- and overdispersed cassette exons. 
The categories are coloured according to (a). Error bars denote ±1 standard deviation across 
four repeat experiments. The horizontal dashed grey lines highlight slight differences in 
prediction accuracy of the under- and overdispersed categories between the models based on 
genomic or on genomic and methylation data.  c. DNA methylation changes associated with the 
observed category switches (x-axis). The top panel shows the iPS and endoderm splicing 
categories coloured according to (a). The bottom panel shows a heatmap of DNA methylation 
levels within the seven sequence contexts of a cassette exon at iPS state (y-axis). The colour 
of the cells denote the relative DNA methylation level, relating DNA methylation levels of 
switching to the DNA methylation levels of non-switching cassette exons. Significant changes 
(FDR ≤ 5%) in DNA methylation are marked with a star. DNA methylation of the alternative 
exon ('A') and of its vicinity is increased in cassette exons that switch from the overdispersed 
category. Cassette exons that switch from either included or excluded to any other splicing 
category show increased DNA methylation of the upstream exon ('C1'). 
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suggested a more complex model that involves both, within- and across-cell variability in 
splicing.   
We showed that genomic features of the cassette exon modulated single-cell splicing, as 
previously assessed in bulk data. We additionally identified predictive epigenetic features 
derived from DNA methylation profiles. Hereby, DNA methylation was most strongly linked to 
single-cell splicing ratios. When studying splicing variation in bulk populations ('pseudo bulk'), 
most of the information encoded in DNA methylation got lost. A reason may be that average 
methylation primarily reflects genomic features, in particular due to the strong correlation 
between DNA methylation and cytosine-related genomic features. However, the cell-to-cell 
heterogeneity of DNA methylation for the same loci does appear to contain predictive 
information of splicing beyond these bulk properties in the same cells. These results indicate 
that the relationship between splicing and DNA methylation is highly locus-specific. This might 
explain why DNA methylation improved prediction performance to a very limited extent when we 
predicted average splicing rates across single cells, or when we quantified splicing based on 
pseudo bulk data.  
Sequence conservation has already been described as an important predictor of alternative 
splicing in bulk transcriptome studies (Wainberg et al., 2016). We were able to confirm this 
relationship in single-cell data. Besides sequence conservation, the most relevant features to 
accurately predict splicing in our dataset were the k-mer motifs CTC, CT and CCT within the 
alternative exon (Figure 9b). These k-mers point towards involvement of CTCF. Previous work 
has already shown that CTCF motifs are linked to splicing by slowing down RNA Polymerase II, 
thereby leading to a higher chance of exon inclusion (Shukla et al., 2011). However, according 
to existing literature, these motifs are located in the flanking introns, and not in the alternative 
exon that we identified as a functional source of CTCF motifs. Moreover, there is also a known 
link between DNA methylation and CTCF motifs (Shukla et al., 2011): Methylation of CTCF 
binding sites can block CTCF and thereby result in decreased inclusion rates of an exon. In our 
analyses, we however found that the methylated equivalents of these k-mers were less 
predictive of splicing than the k-mers that were just based on genetic and not on epigenetic 
information. We therefore suggest a more complex involvement of DNA methylation in 
alternative splicing, which our models were not able to capture (Section 3.2.3). 
In addition to modelling splicing ratios, we considered categorical models of splicing to gain 
insights into variability of splicing across cells (Figure 11). The splicing categories considered in 
our model reflect both, overall splicing rate and splicing variability across cells. The splicing 
state of exons with included versus excluded splicing states could be predicted with high 
accuracy. In contrast, the intermediate splicing categories that are reflective of single-cell 
variability could only be predicted with lower accuracy. This might be due to the lower number of 
cassette exons assigned to these categories in our dataset and therefore smaller sample sizes 
when training regression models (multimodal n=506, overdispersed n=427, underdispersed 
n=110, versus included n=3,278 and excluded n=1,944 in iPS cells). Alternatively, this 
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decreased accuracy might reflect increased vulnerability to assay noise when studying 
intermediate splicing categories, as well as biologically more complex regulatory dependencies. 
As in the cell-specific regression models, we observed that DNA sequence conservation scores 
were the most informative features for predicting splicing. Interestingly, for intermediate 
categories, features of the genomic regions in the vicinity of the alternative exon rather than of 
the exon itself seemed to be predictive of splicing variability. Whereas DNA methylation did not 
contribute to improving the splicing prediction, we observed that DNA methylation levels of 
underdispersed cassette exons were significantly reduced in all genomic contexts, most 
significantly in the upstream exon. We hypothesised that the lower DNA methylation levels of 
underdispersed cassette exons give the sequence motifs more power to control splicing levels, 
i.e., that increased DNA methylation levels lead to more stochasticity in splicing. This hypothesis 
is supported by the effect direction of methylation features, which was opposed between 
overdispersed and underdispersed cassette exons. We finally observed that the methylation k-
mers were on average less informative of splicing than non-methylation features, potentially 
further supporting this hypothesis.  
By leveraging data from two cell types, we were able to assess the consistency of both, splicing 
prediction performance and the associated relevance of the genomic and methylation features, 
across cell types. The differences between features predictive of splicing between iPS and 
endoderm cells were primarily observed within the (methylated) k-mers, which is consistent with 
the known alterations of TF activity and DNA methylation between cell types. We were able to 
confirm the findings from Song et al. (2017) that only few cassette exons switch splicing 
categories during differentiation (Figure 12a). Additionally, as previously described in context of 
neural differentiation (Song et al., 2017), switches between included and excluded categories, 
and vice versa, were not observed. Instead, most of the splicing category switches occurred 
between the three intermediate splicing categories. Hereby, DNA methylation differences 
seemed to predate the switching ability. Using ridge regression, we were able to predict if a 
cassette exon would switch its splicing category between the cell types, but only with limited 
power (Figure 12b). Again, DNA methylation only seemed to be relevant for intermediate 
splicing categories: It slightly improved the predictability of switching in over- and 
underdispersed categories. 
The novelties of our analyses simultaneously revealed their main limitations. Single-cell 
sequencing approaches intrinsically deliver fewer reads than bulk data to quantify both, gene 
expression and DNA methylation levels. In our dataset, especially the genome coverage of the 
bisulphite-treated DNA remained low due to the low quantities of starting material. Using 
computational imputation, we were able to mitigate this effect to some extent. However, 
imputation strategies suffer from inherent limitations and especially our decision to set cytosines 
with no methylation information in their genetic proximity to an un-methylated state might have 
biased our analyses. 
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The intrinsic properties of single-cell data also affected the accuracy of our estimates of splicing 
ratios across cassette exons. We opted for a lenient threshold on read depth to determine 
splicing ratios in order to obtain more cassette exons to train our models, but this 
simultaneously rendered splicing ratios less accurate in comparison to deep-sequenced bulk 
data: The low read depth increases the chance of missing an isoform or cassette exon, an effect 
known as a dropout. Dropouts in single-cell RNA-Seq data can have a strong impact on fitting 
the cell- or gene-model: If an isoform were completely unobserved, this would decrease the fit of 
the gene model. On the contrary, erroneously sequencing multiple cells at once would decrease 
the fit of the cell model. Given, however, that our results were robust across cassette exons, cell 
types and species, the overall findings we reported are unlikely to be affected by these 
properties of single-cell data.  
In summary, we showed for the first time that alternative splicing and splicing variability across 
cells can be predicted from genomic and DNA methylation variation in single cells. We 
assessed the impact of DNA methylation and cellular features on cassette exon splicing, and 
were able to replicate our findings in two human cell types and mouse ES cells. We investigated 
stability and variance of splicing between the two cell types and, importantly, we showed that 
DNA methylation primes splicing switches during cell differentiation (Linker, Urban et al., 2019). 
 
3.5 Detailed experimental and statistical approaches 
3.5.1 Experimental procedures 
Single-cell transcription and methylation data was generated from a single donor from the 
Human Induced Pluripotent Stem Cells Initiative (HipSci) (Kilpinen et al., 2017; Streeter et al., 
2017), using the protocol for scM&T-Seq (Angermueller et al., 2016). Line joxm_1, an iPS cell 
line derived from male fibroblasts cells from the HipSci project, was cultured and triggered into 
differentiation towards endoderm. scM&T-Seq data was generated for 93 cells (together with 
one empty well as negative control and two 15-cell and 50-cell positive controls) at iPS and 
endoderm stage, yielding 186 cells for analysis. 
The joxm_1 IPSC line was cultured in LifeTechnologies Essential 8 media. For dissociation and 
plating, cells were washed with Dulbecco's Phosphate-Buffered Saline and dissociated using 
StemPro Accutase at 37°C for 3-5mins. Colonies were fully dissociated through gentle pipetting. 
Cells were washed with MEF medium (Hannan et al., 2013) and pelleted gently by centrifuging 
at 285xg for 5mins. Cells were re-suspended in E8 media, passed through a 40µm cell strainer, 
and plated at a density of 60k cells per well of a gelatin/MEF coated 12-well plate in the 
presence of 10µM Rock inhibitor – Y27632 [10 mM]. Media was replaced with fresh E8 free of 
Rock inhibitor every 24 hours post plating. Differentiation into definitive endoderm started 72 
hours post plating as previously described (Hannan et al., 2013). 
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During all staining steps, cells were protected from light. Cells were dissociated into single cells 
using accutase and washed with MEF medium as described above. Approximately 1M cells 
were re-suspended in 0.5mL of differentiation stage specific medium containing 5µL of 1mg/mL 
Hoechst 33342 (Thermo Scientific). Staining with Hoechst was carried out at 37°C for 30 min. 
Unbound Hoechst dye was removed by washing cells with 5mL FACS buffer (PBS + 2% BSA + 
2 mM EDTA with nuclease-free BSA and PBS). For staining of cell surface markers Tra-1-60 
(BD560380) and CXCR4 (eBioscience 12-9999-42), cells were re-suspended in 100µL of FACS 
buffer with enough antibodies to stain 1M cells according to the manufacturer's instructions, and 
were placed on ice for 30mins. Cells were washed with 5mL of FACS buffer, passed through a 
35µM filter to remove clumps, and re-suspended in 250µL of FACS buffer for live cell sorting on 
the BD Influx Cell Sorter. Live/dead marker 7AAD (eBioscience 00-6993) was added just prior to 
analysis according to the manufacturer's instructions and only living cells were considered when 
determining differentiation capacities. Living cells stained with Hoechst but not Tra-1-60 or 
CXCR4 were used as gating controls (Linker, Urban et al., 2019). 
 
scM&T-Seq 
As previously described in Angermueller et al. (2016), scM&T-Seq library preparation was 
performed following the protocols for G&T-Seq (single-cell genome and transcriptome 
sequencing; see Macaulay et al., 2016) and scBS-Seq (single-cell bisulfite sequencing; see 
Clark et al., 2017), with minor modifications as follows. G&T-Seq washes were performed with 
20µl volumes, reverse transcription and cDNA amplification were performed using the original 
Smart-Seq2 volumes (Picelli et al., 2014) and Nextera XT libraries were generated from 100-
400pg of cDNA, using 1/5 of the published volumes. RNA-Seq libraries were sequenced as 96-
plexes on a HiSeq 2000 using v4 chemistry and as paired end reads (with a respective length of 
125 base pairs). BS-Seq libraries were sequenced as 24-plexes using the same machine and 
settings, which yielded a mean of 7.4M raw reads after trimming (Linker, Urban et al., 2019). 
 
DNA methylation processing and quantification 
For DNA methylation data, scBS-Seq data were processed as described (Clark et al., 2017). 
Reads were trimmed with Trim Galore (Andrews, 2010; Krueger, 2011; Martin, 2011), using 
default settings for DNA methylation data and additionally removing the first 6 base pairs. 
Subsequently, Bismark (version 0.16.3) was used to map the bisulfite data to the human 
reference genome (version 38), in single-end, non-directional mode, which was followed by de-
duplication and DNA methylation calling using default settings (Krueger & Andrews, 2011). All 
but two single-cell libraries (alignment rate < 15%) yielded good alignment rates (mean 
alignment rate of 43%), with negative control wells having very low mappability (mean of 2%). 
Additionally, seven samples with a library size of less than 1M reads were removed. 
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To mitigate typically low coverage of scBS-Seq profiles (20-40% according to Angermueller et 
al., 2017), we applied DeepCpG to impute unobserved methylation states of individual CpG 
sites (Angermueller et al., 2017). DNA methylation profiles in iPS and endoderm cells were 
imputed separately, using the default settings of the method. Predicted methylation states were 
binarised according to DeepCpG probabilities as follows: CpG sites with a probability equal to or 
lower than 0.3 were set to 0 (un-methylated base), all methylation sites with a probability greater 
than 0.7 were set to 1 (methylated base). Intermediate methylation levels were handled as 
missing. After imputation the methylation data was mapped to the human reference genome 
version 37 to match the expression data (see below), using the UCSC lift-over tool (Kent et al., 
2002). 
We integrated the imputed methylation information into the DNA sequence by distinguishing 
methylated (‘M’) and un-methylated (‘U’) cytosines. Cytosines without methylation information 
after imputation were assigned the value of the closest cytosine with methylation information. If 
there was no methylation information within 900 base pairs around the cytosine, its state was 
set to un-methylated (Linker, Urban et al., 2019). 
 
Gene expression and splicing quantification 
For single-cell RNA-Seq data, adapters were trimmed from reads using Trim Galore using 
default settings. Trimmed reads were mapped to the human reference genome build 37 using 
STAR (version 020201) in two-pass alignment mode, using the defaults proposed by the 
ENCODE consortium (Dobin et al., 2013).  
Expression quantification was performed per cell type using Salmon (version 0.8.2), using the 
'SeqBias', 'gcBias' and 'VBOpt' options on transcripts derived from ENSEMBL 75 (Patro et al., 
2017). Transcript-level expression values were summarized at gene level (estimated counts) 
and quality control of RNA-Seq data was performed using scater (McCarthy et al., 2017). Cells 
with the following transcriptomic features were retained for analysis: at least 50k gene-level 
counts from endogenous genes; at least 5k genes with non-zero expression; less than 90% of 
counts come from the 100 most highly expressed genes in the cell; less than 20% of counts 
come from ERCC spike-in sequences; a Salmon mapping rate of at least 40%. 
Of the 192 cells, 86 (iPS) and 59 (endoderm) cells passed quality control in terms of both DNA 
methylation and gene expression data. Exon splicing rates in individual cells were quantified 
using BRIE (Huang & Sanguinetti, 2017). BRIE calls splicing at predefined cassette exons and 
quantifies splicing using exon reads in single-cell data. By default BRIE combines a prior based 
on sequence features with a likelihood calculated from RNA-Seq reads within a mixture-
modelling framework. As our aim is to model the local and global determinants of splicing, we 
used splicing rate estimates based on the observed data at individual exons only. We quantified 
splicing for between 1,386 and 14,434 exons per cell (minimum coverage of five reads per 
cassette exon), and finally considered 6,282 (iPS) and 4,096 (endoderm) cassette exons that 
were detected in at least ten cells for further analysis.  
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We quantified PSI in three different ways, namely via the actual single-cell splicing rate (PSI), 
thepseudo bulk splicing rate (bPSI) or the variance of the splicing rate. To derive bPSI values 
per cassette exon, we aggregated the PSI values per cassette exon. The variance of splicing 
ratios per cassette exon was defined as the standard deviation of PSI across cells (Linker, 
Urban et al., 2019).  
 
Replication cohort 
To replicate our results, we processed the mouse ES single-cell scM&T-seq data (n=80 cells) 
presented in Angermueller et al. (2016). We preprocessed the aligned RNA and DNA 
methylation data to quantify splicing following the same protocols that were applied to the 
human data, with the following changes: GRCm38 was used as a reference for imputation, 
genome and transcriptome annotations were based on Gencode v18 ('GRCm38.p6.genome.fa' 
as genomic, 'gencode.vM18.annotation.gff3' as transcriptomic reference, available 
at ftp://ftp.ebi.ac.uk/pub/databases/gencode/Gencode_mouse/release_M18/ [August 2018]), 
and conservation scores were taken from 'mm10.60way.phastCons.bw' [August 2018] 
downloaded from UCSC (Kent et al., 2002).  
Out of the 80 cells, 12 cells did not pass quality control on the transcriptome data. Cells with 
less than 500k sequenced reads and cells that had less than 80% of the reads aligned to the 
genome were removed. Additionally, four cells did not pass quality control on the DNA 
methylome data. Cells with less than 1M reads aligned and a Bismark (Krueger & Andrews, 
2011) mapping efficiency below 7% were discarded. These filters yielded 68 cells that were 
used for the splicing analysis and 64 that were used for DNA methylation-related analyses. In 
these cells, we quantified between 649 and 1,433 cassette exons per mouse ES cell (minimum 
coverage of 5 RNA-Seq reads); in the replication analysis, we considered 2,194 exons that were 
supported by at least one cell. 
 
3.5.2 Definition of sequence features and splicing categories 
The genomic features used to predict the splicing ratios and its variance were based on the 
features described by both, BRIE (Huang & Sanguinetti, 2017) and Xiong et al. (2015). The 
following features were calculated for five sequence contexts of each cassette exon (i.e., the 
alternative exon, the two neighbouring exons and the two introns between the exons): the (log) 
length, and the strength of the splice site motifs at the exon-intron boundaries. The strength of a 
splice site motif was defined as the similarity between this splice site motif and known splice 
motifs. Additional features were calculated for seven sequence contexts (i.e., the alternative 
exon, the two neighbouring exons and the 5’ and 3’ boundaries of both introns): conservation 
scores according to PhastCons (Siepel et al., 2005) and k-mer frequencies (with k ≤ 3). The k-
mers reflect the percentage of nucleotides in the context that match the respective specific 
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motif. For these features, only the two boundary regions of the introns (300 base pairs length) 
were used since intron length is highly variable and the boundaries are the most relevant 
contexts for splicing. 
In addition to the genomic features, we defined DNA methylation features for each of the seven 
sequence contexts. We considered cell-specific methylation levels per context and extended the 
k-mer features by considering un-methylated ('U') and methylated ('M') cytosine. For the bPSI 
model, we included the mean frequencies of the k-mers that contained 'M' or 'U' across cells 
and the mean and standard deviation of the seven sequence contexts across cells per cell type. 
In bulk RNA-Seq data, splicing events can be broadly categorised into two major categories: 
included and excluded. Leveraging the single-cell information, we defined more fine-grained 
splicing categories that reflect both, splicing rates and splicing variability across cells (inspired 
by Song et al. (2017): 1) excluded (mean PSI < 0.2), 2) included (mean PSI > 0.8), 3) 
overdispersed, 4) underdispersed and 5) multimodal. The later three categories describe the 
extent of splicing variation across single cells, since cassette exons with intermediate average 
splicing rates (here 0.2 ≤ mean PSI ≤ 0.8) exhibit substantial differences in splicing variance. To 
assign intermediate cassette exons to these three splicing categories, we calculated the 
distribution of the distance between the observed and the expected variation in PSI per cassette 
exon and cell type. The expected variation was calculated by a scaled binomial standard 
deviation, using mean PSI as scaling factor (Faigenbloom et al., 2015). We then defined 
cassette exons with PSI deviating from the expected PSI beyond the upper boundary of the 
third quartile + 1.5x interquartile range (IQR) as overdispersed. This boundary corresponded to 
PSI > 0.016 in iPS and PSI > 0.022 in endoderm cells. Likewise, we defined underdispersed 
cassette exons as exons with a PSI smaller than the lower boundary of the first quartile - 1.5x 
IQR. This corresponded to PSI < -0.032 in iPS and PSI < -0.039 in endoderm cells. The 
remaining intermediate cassette exons were assigned to the multimodal category (Linker, Urban 
et al., 2019).  
 
3.5.3 Prediction of splicing ratios and categories 
We applied linear ridge regression to model PSI and bPSI and (multi-class) logistic ridge 
regression to model the splicing categories. The models are based on only the genomic 
features or on both genomic and DNA methylation features. The performance of linear models 
was evaluated using Pearson R2 between predicted and observed splicing rates. For the multi-
class prediction models, we applied a one-versus-rest scheme and reported the per-category 
and macro-average AUCs. To determine the most relevant individual features, we additionally 
trained regression models with a single feature at a time. In the case of the linear models, we 
reported Pearson correlation (both, R and R2) per feature. In the case of the logistic models, we 
reported the absolute weight multiplied by the standard deviation of the feature, and the AUC 
per feature. We assessed performance and parameters of models by using a ten-fold cross-
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validation with fixed training-validation splits across experiments. To assess variability of 
prediction performances, we repeated the cross-validation procedure four times with different 
fixed training-validation splits. Error bars indicate ±1 standard deviation of the statistic in 
question (AUC or R2) (Linker, Urban et al., 2019).  
 
3.5.4 Relating DNA methylation heterogeneity to splicing 
We applied Spearman correlation to link splicing at a single locus to variation in DNA 
methylation across cells. The test was performed and corrected per sequence context within the 
cassette exon. We only considered cassette exons where both, variation in splicing and DNA 
methylation, were observed in the relevant sequence contexts. In total, 5,280 cassette exons 
were tested for iPS and 2,622 for endoderm cells. The P-values obtained from the test were 
adjusted for multiple testing using the Q-value package in R (Bass et al., 2015; Storey, 2010). 
The gene enrichment of cassette exons which were significantly associated with DNA 
methylation was then performed with G:Profiler (Reimand et al., 2016), using all observed 
cassette exons per cell type as background gene sets (Linker, Urban et al., 2019).  
 
All Software and scripts of this project are available as jupyter notebooks 




4 Transcriptome-guided decomposition of 
homologous recombination repair deficiency 
 
Contributions 
This project was realised under supervision of Sebastian Waszak and Oliver Stegle. While I was 
responsible for data pre-processing, statistical and downstream analyses, Sebastian Waszak 
contributed key ideas and advice on statistical analyses. The work took place in regular 
exchange with him and Oliver Stegle.  
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4.1 Introduction 
4.1.1 Homologous recombination repair deficiency 
DNA double-strand breaks are one of the most serious damages for genomic integrity (Jackson 
& Bartek, 2010). The two distinct mechanisms of non-homologous end joining (NHEJ) and 
homologous recombination repair (HR) repair the majority of DNA double-strand breaks in 
eukaryotic cells. NHEJ repairs in the following way: So-called Ku proteins recognise double-
strand break fractions of genes and activate the DNA dependent protein kinase catalytic 
subunit, leading to activation of more enzymes, polymerases and of the DNA ligase IV. While 
this mechanism is already prone to error due to the lack of a template that could be used for 
faithful repair, the Ku-independent NHEJ, called microhomology-mediated end joining (MMEJ), 
always results in sequence deletions (Jackson & Bartek, 2010).  
HR is, on the contrary, able to achieve faithful repair. As it uses sister chromatid sequences as 
templates, it is however restricted to the S/G2 cell cycle states, while both NHEJ and MMEJ are 
operative during the entire cell cycle. After double-strand break generation, various proteins of 
the MRE11-RAD50-NBS1 complex generate single-stranded DNA at the location of the break, 
what in turn initiates the invasion of the undamaged template, catalysed by RAD51, BRCA1 and 
BRCA2. This is followed by the activity of polymerases, nucleases, helicases and ligases that 
faithfully repair and close the double-strand break. Besides direct DNA repair, HR also 
contributes, in interaction with the Fanconi Anaemia protein complex, to the de-stalling of 
replication forks and the repair of interstrand crosslinks (Jackson & Bartek, 2010). 
In the last decade, HR deficiency (HRD) has received increasing attention in cancer research. 
Tumours with HRD have been found to be particularly responsive to cisplatin therapy and 
Poly(ADP-Ribose)-Polymerase (PARP) inhibition (PARPi; Fong et al., 2009). On a molecular 
level, PARP is responsible for the repair of single-strand breaks; in its absence, these breaks 
are not repaired before replication, leading to the accumulation of double-strand breaks during 
cell cycle progression. As double-strand breaks cannot be faithfully repaired in HR-deficient 
tumours, cancer cells accumulate more and more damage due to unfaithful repair until the 
genomic damage ultimately leads to cell death. As BRCA1 and BRCA2 are core genes of the 
HR pathway, cancers with loss-of-function mutations or promoter methylation of BRCA1/2 are 
very sensitive to platinum and PARPi therapy. So far, mainly breast, ovarian, and pancreatic 
cancers with a BRCA1/2 mutation have been treated with these therapies. However, also 
cancers without BRCA1/2 alterations that share key signatures of HRD such as mutations in 
other HR-involved genes have shown similar sensitivity to these therapies (Waddell et al., 
2015). Here, we refer to the presence of HRD in a tumour with BRCA1/2 wildtype as 
'BRCAness', describing a phenocopy of BRCA1/2 alterations that renders a tumour HR-deficient 
and therefore sensitive to cisplatin and PARPi treatments (Lord & Ashworth, 2016). 
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While around 20% of high-grade serous ovarian carcinoma tumours carry BRCA1/2 alterations, 
a further 30% show HRD with some of them having mutations in alternative HR-involved genes 
like PALB2 and RAD51. Several brain, breast and prostate cancers that harbour mutations in 
the DNA repair gene PTEN also showed signs of HRD. Further, patient-derived xenografts from 
ATM-mutated tumours were found to respond to PARPi (Evans et al., 2017); ATM has been of 
particular significance since it is frequently mutated in many cancer types, including gastric, 
bladder, lung, renal and endometrial cancers (Lord & Ashworth, 2016). Based on this collective 
evidence, Nik-Zainal et al. (2016) suggested that more comprehensive HRD biomarkers that go 
beyond BRCA1/2 mutations are needed for the identification of HRD in human cancers (Nik-
Zainal et al., 2016), hypothesising that this might increase the potential number of patients that 
could benefit from treatment with cisplatin/PARPi (Polak et al., 2017). 
While mutations in multiple genes have been associated with BRCAness, most importantly 
PTEN, PALB2, RAD51B, BRIP1, CHEK2, FANCI, RAD51C, and ATM, the molecular 
mechanisms that underpin BRCAness are not understood. In particular, it is not known if all 
mutations of BRCAness genes have similarly strong effects, and whether some of these 
mutations are conditional for BRCAness. In addition, we don't understand the cancer type 
specificity of these genes' effects, and how they interact with BRCA1/2 alterations. Finally, 
previously unknown genes may be associated with HRD and their perturbation may lead to 
sensitivity to cisplatin/PARPi treatment (Lord & Ashworth, 2016; Nik-Zainal et al., 2016).  
 
4.1.2 Molecular signatures of homologous recombination repair 
deficiency 
HRD has been linked to genetic signatures, like accumulation of mutational signature 3 
(Alexandrov et al., 2013; Nik-Zainal et al., 2016). The link with Signature 3 has recently been 
confirmed by Polak et al. (2017) who showed that bi-allelic inactivation of BRCA1/2 leads to 
accumulation of this mutational signature. However, not all HRD- and Signature 3-positive 
tumours harbour these mutations. Polak et al. (2017) showed that these BRCA1/2-wildtype 
patients with Signature 3 mutations partially harbour RAD51C genetic and epigenetic mutations, 
and PALB2 germline lesions. Therefore, Polak et al. (2017) proposed these alterations as 
alternative sources of BRCAness, and Signature 3 as a molecular readout of HRD.  
Nik-Zainal et al. (2016) assessed the relationship between HRD and signatures of genome-wide 
rearrangement patterns; in this thesis, we refer to these signatures as SV signatures as 
opposed to the canonical single base substitution signatures (Section 2.3). Nik-Zainal et al. 
(2016) found that almost all tumours (91%) of their breast cancer study with loss-of-function 
mutation or hypermethylation of BRCA1 harboured an increased amount of SV Signature 3. SV 
Signature 3 is strongly associated with relatively short tandem duplications (<10k base pairs), 
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what suggests inactivation of BRCA1 to be associated with this mutational phenotype (Nik-
Zainal et al., 2016). 
In addition, Nik-Zainal et al. (2016) found that many cancers with BRCA1 and/or BRCA2 
mutations showed accumulation of SV Signature 5 that is defined by small deletions (<100k 
base pairs) . However, some tumours without BRCA1/2 alterations were also enriched for 
Signature 3 and SV Signature 5 and further resembled BRCA1/2 mutants in gene expression 
patterns (as assessed by hierarchical clustering), possibly pointing towards a contribution of 
other genes to an HRD-like phenotype. Some tumours without BRCA1/2 mutations, however, 
showed different patterns of gene expression, despite extensive signs of Signature 3 and SV 
Signature 5. An alteration in other genes involved in DNA double-strand break pathways like 
ATM, ATR, PALB2, RAD51C, RAD50, TP53, CHEK2 and BRIP1 could not explain these 
mutational patterns. Due to these observations, a combined diagnostic score of (SV) signatures 
and indel patterns was suggested as an alternative or extension to the existing assessment of 
HRD (Nik-Zainal et al., 2016). Indel patterns were involved since long indels (>10 base pairs) 
have been shown to be enriched in HR-deficient tumours due to increased NMEJ and MMEJ 
(see Davies et al., 2017). 
Besides (SV) signatures, other molecular features have been used to define HRD. Most 
recently, Knijnenburg et al. (2018) defined a HRD signature across 33 cancer types in TCGA, 
taking into account various genomic features like loss of heterozygosity, large-scale state 
transitions, and number of telomeric allelic imbalances scores using SCNAs. Using Bayesian 
ridge regression on gene expression data to predict their HRD score, they found contributions of 
various gene mutations in BRCA1/2, RAD51B, RAD51C, TP53, MLH1, MSH2, and TCEB3 to 
HRD, and proposed a potential cisplatin/PARPi sensitivity of tumours from various cancer types. 
Mutations in one of those genes, the tumour suppressor gene TP53, have already been shown 
to co-occur with BRCA1 mutations (Lord & Ashworth, 2016). Another approach, HRDetect, used 
lasso logistic regression and identified six signatures that can distinguish BRCA1/2-deficient 
from sufficient cases, including microhomology-mediated indels, Signature 3, and SV 
Signatures 3 and 5 (Davies et al., 2017).  
While the mutational and epigenetic factors that underpin HRD have been studied in detail (e.g., 
Alexandrov et al., 2013; Davies et al., 2017; Nik-Zainal et al., 2016; Polak et al., 2017), the 
relationship between HRD and transcriptional profiles in the corresponding tumours remains 
elusive. An understanding of the molecular processes that are associated with HRD could 
improve the precision of detecting HR-deficient tumours and therefore increase the potential 
number of patients that can be successfully treated with cisplatin/PARPi. In addition, a better 
understanding of protein pathways linked to HRD could help develop new targets for therapy; 
this has become particularly important considering the development of PARPi resistance in 
originally HR-deficient tumours through demethylation of BRCA1 or RAD51C promoters 
(Montoni et al., 2013). 
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Among the few existing studies that have considered transcriptional profiles associated with 
HRD is Larsen et al. (2013), who derived a transcriptional signature that is able to predict 
BRCA1/2 germline mutation status in breast cancers. This approach is based on a support 
vector machine classifier trained on the expression data of gene sets that maximally segregate 
between BRCA1/2 and sporadic tumours. A classification of all breast cancer samples, 
however, distinguished breast cancer subtypes according to the PAM50 classification (Parker et 
al., 2009) rather than BRCA mutation state. This makes sense since BRCA1/2 mutation states 
are strongly correlated with breast cancer subtypes. For example, a vast majority of BRCA1 
mutants exhibit the basal phenotype and are 'triple-negative', i.e., they test negatively for 
oestrogen and progesterone receptors, and human epidermal growth factor receptor type 2 
(HER2), which normally mediate cell growth (Lord & Ashworth, 2016). While subtype-specific 
BRCA1/2 state predictions achieved better accuracy and were replicable across datasets, 
Larsen et al. (2013) did not (i) study the functional relevance of the maximally separating genes 
to explain the molecular basis of HRD, (ii) check for cancer subtype-specific effects of these 
genes, nor (iii) search for genes that might be associated with HRD beyond canonical BRCA1/2 
germline cases.  
Later, Wang et al. (2017) used the same dataset to propose a BRCA score per patient based on 
the expression of 600 genes that segregated BRCA1/2 mutants. This score accounted for 
clinical covariates like breast cancer subtype, and pointed towards the importance of CN 
alterations rather than expression of HRD-related genes in BRCA wildtype tumours. 
Another transcriptomic study of HRD by Peng et al. (2014) artificially introduced HRD in breast 
cancer cell lines by RNA-mediated inactivation of known HR-related pathways, and then defined 
a transcriptional signature based on the top genes separating between parental and HR-
deficient cell lines. While Peng et al. (2014) showed that these genes were enriched for cell 
cycle and DNA replication control, the resulting transcriptomic changes were later shown to 
probably be a general consequence of the reduced proliferation rate of the cell lines after RNA-
mediated inactivation (Wang et al., 2016). 
These existing transcriptomic approaches for analysing HRD have in common that they used 
the expression level of genes that are highly predictive of BRCA1/2 mutation state or HRD, in 
order to investigate patterns that differ between HRD-positive and -negative tumours. However, 
no molecular mechanisms of BRCA1/2-independent HRD, i.e., BRCAness, have been 
suggested, and, to the best of our knowledge, no transcriptome-wide pan-cancer studies of 
both, HRD and BRCAness, have been conducted so far.  
 
4.2 A PCAWG gene expression-mutagenesis screen  
As the role of gene expression in understanding and detecting HRD and BRCAness across 
cancer types might have been underappreciated, we set up an expression-mutagenesis screen 
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to analyse molecular aberrations of HR-deficient tumours in the PCAWG dataset. We first 
assessed the importance of gene expression for HRD detection in tumours while taking 
differences between cancer types into account. We then studied these gene expression-HRD 
associations to explore the molecular basis of BRCAness by adjusting for mutational and 
epigenetic alterations and germline predisposition of the BRCA genes. 
This gene expression-HRD study is based on linear mixed models (Section 1.2.2) and is guided 
by the gene expression-mutational signature screens of Section 2.3. The study is based on the 
WGS and RNA-Seq datasets of 1,159 patients of the PCAWG cohort that we used in Chapter 2, 
and that span 27 human cancer types (see Sections 2.2 and 2.3.1 for a detailed description of 
the dataset). 
 
4.2.1 A molecular marker of homologous recombination repair 
deficiency 
First, we had to define putatively HR-deficient samples in the PCAWG dataset. We hereby 
considered the following potential molecular markers of HRD that were quantifiable in the 
PCAWG dataset: Signature 3 (see Alexandrov et al., 2013; Nik-Zainal et al., 2016; Polak et al., 
2017); long indel (>10 base pairs) count that is increased in HR-deficient tumours due to 
increased NMEJ (see Davies et al., 2017), and short deletions and tandem duplications (<10k 
base pairs) that are the characteristics of HRD-associated SV Signatures 3 and 5 (see Nik-
Zainal et al., 2016).  
Briefly, we designed a combined biomarker to postulate HRD presence or absence based on 
evidence of an increased number of long indels and short SVs. We chose these molecular 
markers since their relationship with HRD can be explained in a mechanistic manner: Long 
indels are the result of non-faithful repair of DNA double-strand breaks due to the lack of HR, 
and short SVs are strongly correlated with BRCA1 down-regulation (Nik-Zainal et al., 2016). 
Whereas Signature 3 has previously been used as a marker for BRCA deficiencies, it does not 
provide mechanistic insights into the origin of the mutational patterns due to its definition by 
statistical decomposition (NMF; see Section 2.3.1), and is therefore less robust against potential 
correlated factors that are not directly linked to HRD. We defined patients with an increased 
ratio of long indels of more than 15%, and at least one increased ratio of short SVs of more than 
10% (either tandem duplications or deletions) as HRD-positive. With these criteria, we identified 
102 HRD-positive patients amongst our cohort of 1,159 patients. We encoded these HRD-
positive patients as '1' in a binary HRD score; HRD-negative patients were encoded as '0'.  
An explorative analysis of this set of 102 putative HRD-positive patients revealed known HRD-
related signatures: The majority of our HR-deficient cases were ovarian or breast cancer 
patients, with 46 ovarian and 30 breast tumours. Breast and ovarian, together with prostate and 
pancreas, cancers are known to be the cancers that show HRD most frequently. Of the breast 
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tumours, the majority (n=25) showed the basal signature subtype; this subtype is known to be 
particularly prone to HRD (Lord & Ashworth, 2016; Chartron et al., 2019; Telli et al., 2018). 
The remaining patients had pancreatic (n=7), liver (n=3), bladder (n=3), stomach (n=3), uterine 
(n=2) cancer or lymphoma (n=2).  
Amongst the 102 patients, 14 HR-deficient patients had a deleterious germline BRCA1 mutation 
(out of altogether 16 patients with a deleterious germline BRCA1 mutation; P ≤ 2x10-16, 
hypergeometric test), 6 a deleterious germline BRCA2 mutation (out of 12; P=2x10-4, 
hypergeometric test), 13 a hypermethylated BRCA1 promoter (out of 13; P ≤ 2x10-16, 
hypergeometric test), 7 a hypermethylated RAD51C promoter (out of 19; P=7x10-4, 
hypergeometric test), 23 a somatic BRCA1 mutation (out of 23; P ≤ 2x10-16, hypergeometric 
test) and 4 a somatic BRCA2 mutation (out of 4; P=6x10-5, hypergeometric test). As somatic 
mutations, we considered missense, frameshift, stop gained, splice acceptor, splice donor, start 
lost, and inframe deletion mutations. In addition, 36 patients showed significantly decreased 
BRCA1 expression (FPKM < 0.5, out of 289; P=0.009, hypergeometric test). Altogether, known 
HRD-related genetic, epigenetic and gene expression alterations are strongly enriched in HR-
deficient patients as compared to all patients.  
Deleterious BRCA1 germline mutations are known to have a strong effect on HRD development 
(Lord & Ashworth, 2016). We had, however, detected two patients with BRCA1 germline 
mutations that were HRD-negative according to our HRD score. One explanation might be that 
a secondary alteration has re-established BRCA1 functionality early on. Both patients did not 
show any evidence of Signatures 3 mutations either, strengthening our hypothesis. Indeed, the 
two patients (one liver, one cervical cancer) did not show remarkably decreased BRCA1 
expression (FPKM < 0.5).  
This first exploration gave us confidence that we were able to distinguish HR-deficient from HR-
sufficient patients with the help of our newly defined HRD score. 
 
4.2.2 Molecular deregulation in homologous recombination repair 
deficient tumours 
Leveraging our newly defined HRD score, we assessed associations between HRD and gene 
expression levels. Initially, we trained a linear mixed model (implemented in LIMIX (Lippert et 
al., 2014)) to associate the binary HRD score with expression levels of 10,959 protein-coding 
genes (filtered for minimum expression FPKM ≥ 1 in at least 50% of the patients), accounting for 
genetic relatedness of the patients, cancer type, sex, age, and sample purity. As previously 
(Section 2.2), we considered 35 peer factors in the analysis, thereby adjusting for heterogeneity 
in the gene expression data (see Figure 13a for quality control). As stated beforehand (Section 
2.3.2), the P-values of a permutation analysis within each cancer type delivered uniformly 
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distributed P-values, suggesting a calibrated analysis and no strong effect of cancer type on our 
detected associations (Figure 13e). 
Altogether, this association analysis identified 834 genes as differentially expressed between 
HRD-positive and HRD-negative tumours (FDR ≤ 10%). We repeated the same analyses 
considering the presence or absence of Signature 3; P-values between the two analyses were 
strongly correlated (Pearson correlation coefficient R=0.59; b), indicating consistent 
associations with gene expression profiles between the two molecular HRD classifications 
despite the divergent classification of 7% of the samples (12 patients classified as HR-deficient 
by our HRD score, and as HR-sufficient by Signature 3 presence; 66 patients classified as HR- 




Figure 13. See next page for figure caption. 
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Figure 13. Quality control of HRD-gene expression screen. a. QQ plot of P-values (-log10 P) 
from a linear mixed model association test between the HRD score and gene expression levels 
of 10,959 genes across 1,159 patients. Nominal P-values are shown in blue, P-values from a 
permutation experiment are shown in red. Gene expression values are adjusted for 35 peer 
factors. The association between the HRD score and BRCA1 is shown in orange. The ten most 
significant genes are annotated. b. Scatterplot of P-values (-log10 P) of the linear mixed model 
association study between Signature 3 (y-axis) and gene expression levels, against P-values (-
log10 P) of the linear mixed model association study between HRD score (x-axis) and gene 
expression levels. BRCA1 is highlighted in orange, the five most significant genes per 
association study are annotated, and the FDR threshold of 10% is indicated as dashed grey 
lines. c. Data decomposition by the first two of 35 peer factors. Peer factors 1 and 2 segregate 
the different cancer types. d. QQ plot of the P-values (-log10 P) of the linear mixed model 
associating HRD with gene expression of 10,959 genes across 1,159 patients. Nominal P-
values are shown in blue, permuted P-values are shown in red. Gene expression values are 
adjusted for 50 peer factors. The association between the HRD score and BRCA1 is highlighted 
in orange. The ten most significant genes are annotated. e. Since cancer type is known to be a 
strong driver of mutational signature variability, the permutation experiment from (a) was 
repeated, but patients were only permuted within each cancer type. Nominal P-values are 
shown in blue, P-values from a permutation experiment are shown in red. The permuted P-
values still closely follow the diagonal of the QQ plot.  
 
As expected, our analysis identified significant associations with canonical HR-linked genes, 
including BRCA1 (P=9x10-5, β=-0.470), RAD51 (P=0.002, β=0.381) and PTEN (P=0.001, β=-
0.383) (Section 4.1.2). Other expected positive controls, in particular BRCA2, had been 
excluded from the analysis due to low expression across patients. To systematically investigate 
the relationship of the identified gene set with known HRD-related genes, we compared our 
results to genes reported by Zimmermann et al. (2018) who undertook CRISPR (clustered 
regularly interspersed palindromic repeats) gene editing screens to identify genes that might 
be involved in PARPi resistance. In three cell lines, namely HeLa, RPE1-hTERT, and 
SUM149PT, they identified 64, 61, and 116 genes, respectively, for which knockdown 
resulted in increased PARPi sensitivity. As these genes are candidates for causing HRD, we 
overlaid our total gene set of 10,959 genes with their total gene set of 15,463 genes, 
resulting in 9,259 genes. We then studied the relationship between their PARPi sensitivity-
related genes and our HRD-associated genes. Hereby, we either considered the genes they 
had identified per cell line, or the union of genes they had found across cell lines. This 
enrichment analysis identified a significant enrichment of our gene set in their SUM149PT-
related gene set (P=0.023; hypergeometric test). We did not find any significant enrichment 
for the gene sets related to the other cell lines, or for the combined gene set (α=5%). In the 
case of SUM149PT, we overlapped the HRD-related genes common to both analyses, 
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namely 688 genes of our gene set with their 95 PARPi sensitivity-related genes. Twelve of 
these genes, including the genes BRCA1, RAD51, and FANCI, were contained in both gene 
sets. Interestingly, SUM149PT is a cell line derived from a BRCA1-hemizygous triple-
negative breast cancer, a cancer subtype that is known to be particularly prone to HRD (Lord 
& Ashworth, 2016; Chartron et al., 2019; Telli et al., 2018). 
To obtain more insight into the functionality our gene set of 834 genes, we performed gene 
enrichment with Gene Ontology (Ashburner et al., 2000). The 834 genes were indeed 
dominantly enriched for cell cycle pathways: Gene set enrichment analysis (Subramanian et al., 
2005) found positive enrichments of cell cycle and checkpoint related process, DNA replication, 
P53-independent DNA damage, cyclin-associated events, and condensation of prophase 
chromosomes. One of the cell cycle checkpoint genes that we interestingly found to be 
downregulated in HRD-positive tumours was RAD17 (P=4x10-5, β=-0.562). The 
phosphorylation of this chromatin-binding protein by the ATR/ATM pathway is required for 
cell cycle arrest in G2 upon DNA damage. As such, it is believed to be an important 
checkpoint after DNA damage (Post et al., 2003). We hypothesized that if RAD17 was 
downregulated in HRD-positive tumours and hence not available in sufficient quantity, 
molecular signalling leading to early cell cycle arrest might be disrupted and - instead of cell 
death or senescence - more DNA damage could accumulate. This involvement of RAD17 in 
HRD might point towards indirect effects of cell cycle regulation in HR-deficient tumours. The 
relevance of cell cycle control during replication for HR has been known since Jackson & 
Bartek (2010) have discovered that fast replication leads to skipping or diminution of HR activity. 
We additionally performed TFBS enrichment analyses to gain more insights into the 
deregulation of cell cycle processes. Like this, we hoped to identify master regulators of our 
deregulated cellular processes that might not be obvious on the gene expression level. We 
therefore applied the iRegulon tool (Janky et al., 2014), which searches for enriched 
transcriptional regulatory networks (so-called regulons).  
Briefly, iRegulon uses cis-regulatory sequence analysis of a gene set to detect these underlying 
regulons. The predictions are based on more than 10k known TF binding motifs and 1,120 
experimental ChIP-Seq tracks (provided in the form of position weight matrices), that are 
employed to search for putative and experimentally validated TF binding up to 20k base pairs 
around the TSS of each gene. Motif enrichment for any TFBS is measured using a ranking-and-
recovery process: First, all background genes are ranked for each motif by scoring for 
homotypic clusters across ten vertebrate species. Then, during recovery of the set of input 
genes, enrichment of these genes in each of the motif-based rankings is determined by an AUC 
that is retrieved from the cumulative recovery curve for the input set, along the whole-genome 
ranking of each motif. The final AUC is computed based on the top 3% of the rankings for all 
motifs. The AUC is then normalised across the AUCs of all motif rankings to the so-called 
enrichment score (ES) of each motif. The ES indicates how large the proportion of the input 
genes is that can be recovered in the top 3% of a motif-specific ranking. Janky et al., (2014) 
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propose to use an ES cut-off of 3 that corresponds to a FDR threshold of between 3% and 9% 
(Janky et al., 2014). 
In our HRD-associated gene set, the only strong enrichment (ES ≥ 3) we found was for ETS 
motifs (assessed by ES per TF, e.g., ES(ETV6)=6.12). The ETS TF family is defined by its 
binding to the ETS domain, a structurally highly conserved winged helix-turn-helix motif. 
Although there are ETS subfamilies with specific functions, the inappropriate functioning of ETS 
TFs in general is assumed to be essential for the development of certain cancer types 
(Sharrocks, 2001).  
In total, 563 out of our 834 (67%) genes were potentially regulated by ETS TFs. We 
hypothesised that perturbation of ETS TF binding and of its regulatory network might be a 
consequence of HRD or vice versa. Therefore, we tested for associations between HRD and 
gene expression of the altogether 18 ETS TFs which binding sites we had found to be enriched 
in our dataset, using linear mixed models as above; ELF5 was the only gene that was 
differentially expressed between HRD-positive and -negative cases (P=0.001, β=0.481). ELF5 
is an interesting tumour suppressor TF that has been associated with aggressiveness of 
tumours (Sizemore et al., 2017); it represses Snail2 expression, which in return induces 
epithelial-mesenchymal transition and metastasis in breast cancer (Chakrabarti et al., 2012). 
However, ELF5 is generally overexpressed in luminal breast cancers and confers endocrine 
resistance (Kalyuga et al., 2012). Increased aggressiveness of tumours due to enhanced 
carcinogenesis and metastatic spread after ELF5 overexpression has also been observed in 
mouse models (Gallego-Ortega et al., 2015). Hence, the role of ELF5 seems to be ambiguous: 
At low levels it helps to repress epithelial-mesenchymal transition, at high levels it increases 
aggressiveness and metastisation of tumours. Considering this ambivalent role of ELF5 in 
cancer progression, the relatively weak statistical power with which we were able to associate 
ELF5 expression with HRD, and the quite low expression of ELF5 in our dataset, we concluded 
that this relationship would require an experimental validation. Such an approach was, however, 
outside the scope of this thesis. 
In addition to the lack of association between expression of ETS TFs and HRD, we could also 
not detect any correlation between their expression and BRCA1 expression. The enrichment for 
ETS TFs motifs might hence stem from increased activity of the proteins, and not from 
increased expression. To assess ETS activity, we used known high-confident interactions 
between 16 ETS TFs and genes based on TF motifs to calculate a mean ETS activity score with 
the help of the Dorothea software (Garcia-Alonso et al., 2018). We then used this activity score 
as phenotype in a linear mixed model to associate it with our HRD score. This only detected one 
candidate ETS TF whose activity was associated with HRD, namely ETV6 (out of 16 associated 
genes, FDR ≤ 5%). Interestingly, ETV6 has previously been identified as recurrently rearranged 
genomic region in breast cancers by Nik-Zainal et al. (2016). However, no expression changes 
were discovered by this study, and the significance of this finding therefore remained elusive. 
ETV6 was also identified as a short tandem duplicator hotspot by Menghi et al. (2018). As our 
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HRD score is partially based on the ratio of short tandem duplications, the observed ETV6 
activity change could be attributable to an increase in tandem duplications, an effect cumulating 
in hotspots like the one of the ETV6 gene.  
In summary, we found some evidence for a relationship between HRD and increased ETS 
activity. To elucidate this relationship, we set out to replicate our HRD-ETS TF associations in a 
more homogenous subset, namely in just the breast cancers of our previously analysed dataset 
(n=87). Hereby, it has to be taken into account that the molecular state of breast cancers is 
modulated strongly by their hormone and growth factor receptors. E.g., DNA damage repair is 
affected by estrogen concentrations (Caldon, 2014). Hereby, strong differences can be detected 
between breast cancers that test positive for estrogen, progesterone, or HER2 receptor. This 
necessitates stratifying the patients according to these molecular subtypes. We used the 
PAM50 classification system for stratification (Parker et al., 2009), which is based on known 
molecular differences between basal, normal, Luminal A, Luminal B and HER2-enriched breast 
cancers, and which has implications for prognosis and therapy sensitivity (Caan et al., 2014). 
We therefore analysed gene expression-HRD associations based on all PCAWG breast cancers 
while taking PAM50 classification into account. Altogether, 232 genes were significantly 
associated with HRD (FDR ≤ 10%), 151 of which were also associated with HRD in the full 
PCAWG analysis. The 232 genes were, however, only weakly enriched for ETS binding motifs 
(ES across ETS TFs < 2). Due to the small sample size of the analysed dataset, we were not 
able to determine if the reduced enrichment for ETS TFBSs was due to decreased power, or if 
the more homogenous dataset resulted in a true biological disappearance of binding site 
enrichment, pointing towards data heterogeneity as source of the ETS TFBS enrichment. 
To distinguish between these two possibilities, we repeated the analyses in an independent 
cohort of 560 breast cancer patients from Nik-Zainal et al. (2016). Here, Signature 3 was the 
only available biomarker of HRD. We therefore associated the binary signature (signature count 
> 0 was set to 1, i.e., presence of signature) with gene expression changes (gene expression 
pre-processing as in PCAWG dataset, see Section 2.2). We then employed a linear model 
based on 252 patients and 8,972 genes. We only considered the 252 patients for which 
mutational signatures, gene expression data, sample purity, age, gender and PAM50 
classification were provided, and 15,064 genes that were observed in all 252 patients. The 
genes were then filtered to overlap with our previously used set of 10,959 genes (Section 4.2.2), 
resulting in the final number of 8,972 genes. Altogether, 45 genes were significantly associated 
with Signature 3 (FDR ≤ 10%), with BRCA1 being the only HR-related gene. As expected, 
BRCA1 was downregulated in HR-deficient samples (P=2x10-4, β=-0.690). Of the 45 genes, 20 
contained ETS binding motifs what led to a substantial enrichment of ETS TFBSs, with a 
maximum of ES(ETV6)=4.93. We therefore concluded that the enrichment of ETS TFBSs in 
HRD-related genes was a true biological finding that applied across cancer types. Without the 
inclusion of the PAM50 classification in our linear mixed model, no significant genes were 
detected at all, emphasising the importance of subtype stratification. 
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As Nik-Zainal et al. (2016) had identified ETV6 as a recurrently rearranged genomic region in 
their dataset, we additionally specifically investigated the tumours with ETV6 rearrangement in 
their dataset. Here, we focused on 553 samples with available mutational signatures. Three of 
these samples harboured fusions, and four deletions in the ETV6 genomic region. Two of the 
three fusion and three of the four deletion samples showed evidence of Signature 3 (of 
altogether 153 samples with positive Signature 3; P=0.02 for a combination of fusion and 
deletions, hypergeometric test). This signal was even stronger when we considered quantitative 
Signature 3 counts (P=0.003, Mann-Whitney-U-Test), with the top 30%-quantile samples of 
Signature 3 (n=168) comprising all seven ETV6 fusion and deletion tumours. As this pointed 
towards a contribution of ETV6 genomic rearrangements to HRD, we investigated the same 
relationship in the PCAWG dataset. However, only two PCAWG samples showed ETV6 fusions. 
While one of these samples was HRD-positive, and additionally a basal breast cancer with 
decreased BRCA1 expression, this was quite weak evidence for an interplay between ETV6 
rearrangements and HRD due to the small sample size. However, we found 16 ETV6 deletions, 
5 of which were HRD-positive (P=0.010, hypergeometric test). The PCAWG study therefore 
provided further evidence of an association between ETV6 genomic rearrangements and HRD. 
However, with such small numbers of rearrangement events and without longitudinal data of 
cancer progression, we could not infer if these rearrangement contributed to HRD, or if HRD led 
to the accumulation of these mutations.  
In the cohort of 560 breast cancer patients from Nik-Zainal et al. (2016), neither gene 
expression nor activity of ETS TFs was associated with Signature 3. We therefore concluded 
that although the ETS regulatory network had an effect on HRD, individual ETS TFs only 
exerted a weak effect. Altogether, our analyses pointed towards a potentially interesting 
involvement of TF network deregulation in HRD progression, a signal that can be followed up in 
larger and more homogenous datasets that will probably be acquired in the future.  
In summary, the functional assessment of our set of HRD-associated genes pointed towards 
deregulation of generic cell cycle processes and potential involvement of ETS TF activity.  
 
4.2.3 Effects of data heterogeneity 
Whereas we found interesting functional enrichment of the 834 HRD-associated genes (Section 
4.2.2), we did not discover any enrichment for DNA repair or HR pathways. Furthermore, overall 
surprisingly many genes (7.6% of all tested genes) were significantly associated with our HRD 
score, while of the 16 genes that Knijnenburg et al. (2018) defined as core HR-associated, only 
BRCA1 and RAD51 were significantly associated. On the one hand, HRD might truly affect 
many genes and broad pathways, and known HRD-related genes might exacerbate their effect 
via different mechanisms than transcriptomic changes. On the other hand, the deviation of the 
detected gene expression deregulation from known molecular HRD signatures let us doubt 
whether our gene set truly described deregulation related to HRD. Therefore, we decided to 
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investigate in detail if the detected gene expression associations were truly related to HRD or if 
they could be explained by hidden sources of variation in our data. We did so by investigating 
how modelling variable numbers of hidden confounding factors in the gene expression data 
would affect our HRD-gene expression association analyses.  
We firstly assessed which sources of variation were captured by the 35 peer factors we had 
initially adjusted for (Section 4.2.1). We therefore correlated all peer factors against all known 
patient covariates (assessed by Pearson correlation coefficients and P-values; we here define 
significant correlations as correlations with a nominal P-value < 10-5). The most significant 
correlations were found between cancer types and altogether 23 peer factors. Separation of 
cancer types by the 1st and 2nd peer factor is shown in Figure 13c. A strong cancer type effect is 
hereby expected since gene expression profiles differ substantially between tumours of different 
tissues of origin. Multiple other significant correlations with age, sex and sample purity were 
found. For altogether five peer factors, we did not find significant correlations with any known 
covariate, suggesting that these peer factors modelled unknown hidden structure of the data.  
This reveals an inherent problem of estimating confounders in highly heterogeneous data: How 
can the number of hidden factors an analysis should optimally adjust for be determined when 
some of the confounding covariates and the true signal are unknown? If the number of peer 
factors is too large, we correct for molecular signal that might be causal for HRD. If the number 
of peer factors is too small, we detect spurious associations with HRD that can be explained by 
sub-structure of the data, e.g., by molecular cancer subtypes.  
To systematically investigate the effect of different number of peer factors on our results, we 
repeated the HRD-gene expression association analyses with different numbers of peer factors 
(ranging from np=10 to np=300 with a step size of 10). In general, we observed a substantial 
effect of the number of peer factors on our analysis (e.g., in terms of number of significant 
genes). As individual gene-HRD associations varied strongly in P-value and effect size, we 
compared functional enrichments of the significant gene sets in order to understand the effect of 
the number peer factors (Figure 14). We firstly assessed how enrichment of the significant 
genes (FDR ≤ 10%) for the Gene Ontology category 'DNA repair regulation' varied across the 
different number of peer factors np. We chose this functional category since we expected true 
HRD-related genes to be enriched for it, while preventing a too narrow definition of HRD-related 
processes solely based on previously discovered associations. The strongest enrichment for 
'DNA repair regulation' was identified for np=50 peer factors (Figure 14a). The majority of the 
analyses with np>70, however, did not result in any significant genes (FDR ≤ 10%). This might 
introduce a bias into enrichment analysis with enrichment for a specific category depending 
strongly on the significance threshold arbitrarily chosen in the association analyses. We 
therefore conducted gene enrichment of the top 120 (~1%) of all genes per peer factors (genes 
sorted according to increasing P-value). The enrichment for the 'DNA repair regulation' category 
remained similar across numbers of peer factors (Figure 14b), confirming that the different 
functional enrichments were not only due to a lack of power in some of the analyses.  
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To ensure that the gene set of the optimal number of peer factors (np=50) did not maximise 
enrichments for other random pathways as well, we decided to repeat the peer factor-
dependent enrichment analysis across a complete set of independent pathways. As the 
organisation of Gene Ontology as a directed acyclic graph inherently defines ontologies in 
dependence to each other (Ashburner et al., 2000), we used the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) annotation of proteins with altogether 530 pathways (Kanehisa et al., 
2016). Again, we used the top 120 (~1%) of all genes per gene set to avoid bias due to 
arbitrarily chosen significance thresholds. As we were only interested in the relative enrichment 
of genes across pathways, we did not apply multiple testing correction across pathways what 
would have resulted in no significant enrichment at an FDR of 5%. Even based on nominal P-
values, only few KEGG pathways were enriched for at least one gene set (P ≤ 0.1; Figure 14c). 
The two most significant pathways were 'Homologous Recombination' and 'DNA replication'. 
Both were enriched at np=50 and np=60 (P=0.03 and P=0.04, respectively; Figure 14c). These 
enrichments point towards HRD-related processes: Homologous recombination constitutes a 
central mechanism of HR that allows for faithful repair of DNA double-strand breaks by sister 
chromatid invasion. HR further depends on DNA replication since it requires sister chromatids to 
be available during S and G2 phase of the cell cycle. Enrichment for cell cycle regulation was 
only detected to be significant at np=20 (Figure 14c). We note that this observation differs from 
our previous Gene Ontology enrichment that showed cell cycle regulation enrichment at np=35. 
This difference might be due to the inherent difference between Gene Ontology categories and 
KEGG pathways, or due to the different gene sets used: In the latest analysis we only used the 
top 1% (n=120), whereas the Gene Ontology enrichment was based on all significant genes 




Figure 14. Functional enrichment of HRD-associated genes in dependence of the number of 
peer factors. a. Enrichment (-log10 P) of HRD-associated genes (FDR ≤ 10%) for the Gene 
Ontology category 'DNA repair regulation' across peer factors.  b. Enrichment (-log10 P) of HRD-
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associated genes (top 120 genes sorted according to increasing P-value) for the Gene Ontology 
'DNA repair regulation' across peer factors. c. Heatmap of the enrichment (-log10 P) of HRD-
associated genes (top 120 genes sorted according to increasing P-value) for all 530 KEGG 
pathways across peer factors; only KEGG pathways with P ≤ 0.1 for at least one gene set are 
shown. The heatmap visualises P-values > 0.1 as P=1. 
 
 
Based on these observations, we considered 50 peer factors as optimal number of peer factors 
that maximised the HRD signal in the gene expression data (in the case of both, GO and KEGG 
functional categories). The number of significant genes (FDR ≤ 10%) dropped considerably: 
Instead of 834 genes in the analysis with 35 peer factors, we now detected 110 genes (Figure 
13d). The most significant gene in the np=50 analysiswas EXD3 (P=2x10-7, β=-0.631), a gene 
that is involved in 3'-5' exonuclease activity (Ashburner et al., 2000). Within cancer research, its 
overexpression has been associated with lower risk in endometrial cancer (Uhlén et al., 2005), 
but it has not yet been linked to HRD.  
As expected, the gene set was enriched for HRD-related pathways since the number of peer 
factors had been determined with the objective to maximise this enrichment: After multiple 
testing across pathways, the genes were enriched for the Gene Ontology categories 'Double-
strand break repair' (P=2x10-4) and 'Strand displacement' (P=4x10-4), the KEGG pathways 
'Homologous recombination' (P=5x10-4) and 'DNA replication' (P=1x10-3), and also for BRCA1-
binding TFs (P=3x10-5). We were also able to replicate our findings concerning enrichment of 
ETS TFBSs, although with weaker signal (e.g., ES(ETV6)=3.16) than in the association analysis 
that was based on 35 peer factors (Section 4.2.1). 
To directly compare our association analyses that adjusted for 35 and 50 peer factors, 
respectively, we correlated the resulting P-values across genes (Figure 15a). The correlation 
plot clearly shows an increased number of significant genes in the analysis with 35 peer factors, 
partially due to a shifted FDR threshold due to different P-value distributions. The correlation 
plot, however, also shows that the association results across genes are strongly correlated 
(Pearson correlation coefficient R=0.607; Figure 15a). We concluded that both analyses 
seemed to describe the same molecular process, with the analysis based on 35 peer factors 
tagging a larger number of genes and emphasising more general deregulation on the cell cycle 
level, and with the analysis based on 50 peer factors defining a more precise molecular basis of 
HRD.  
When comparing significant HRD-related genes between the two analyses with np=35 and 
np=50, we found BRCA1 (P=3x10-4, β=-0.441) and RAD51 (P=4x10-5, β=-0.500) to be significant 
in both analyses, but PTEN to be only significant in the analysis with np=35. While BRCA1 and 
RAD51 are direct players of the HR pathway, PTEN has been shown to have an indirect effect 
in BRCA1-deficient tumours: It usually antagonises the PI3K/ALT3 pathway that itself leads to 
cell proliferation and differentiation and is known to be aberrantly active in tumours with BRCA1 
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mutations (Minami et al., 2014). As such, PTEN normally acts as a cell cycle checkpoint that 
allows HR to take place (Mansour et al., 2018). Therefore, the significant association with PTEN 
at np=35 that disappears at np=50 is another indicator that the former analysis describes cell 
cycle deregulation indirectly associated with HRD whereas the latter one tags more precise 
HRD-core processes. Accordingly, a known DNA damage repair gene that was not discovered 
with 35 peer factors, but with 50 peer factors, is the DNA topoisomerase TOP3A (P=5x10-4, 
β=0.424). While all DNA topoisomerases are involved in DNA repair pathways due to their 
ability of breaking DNA and changing its topological state, TOP3A has been shown to be 
particularly important since it is able to process different DNA repair intermediates (Yang et al., 
2010).  
Taking all evidence together, we decided to rely our following analyses on 50 peer factors; this 
approach seemed to define HRD in a more precise way, what might facilitate our assessment of 
BRCAness-specific gene expression effects. However, we were not able to rule out that the 35 
peer factors may describe the true HRD process more accurately, following the assumption of a 
broad effect of HRD on cell cycle regulation.  
Our analyses emphasises the relevance of adjusting for an appropriate number of confounding 
factors before conducting association analyses on highly heterogeneous datasets. Here, we 
proposed a systematic approach to detect the optimal number of peer factors that takes into 
account prior knowledge of the biological processes in question. While the numbers of peer 
factors of the two analyses we investigated in detail were quite close to each other (np=35 and 
np=50, respectively) and the P-values of the associations across genes were strongly correlated 
(Pearson correlation coefficient R=0.607), the set of significant genes at the same FDR 
threshold differed considerably. We therefore showed that biological conclusions depend on the 
choice of both, the number of confounding factors and the significance threshold. This is an 
important topic that should be discussed in every statistical analysis of heterogeneous datasets.   
 
4.3 Alternative pathways of homologous recombination 
repair deficiency 
4.3.1 Molecular differences between BRCA-dependent and BRCA-
independent cases  
To elucidate the molecular basis of HRD in BRCA-independent, i.e., so-called BRCAness 
cases, we considered the HRD-association analysis (with correction for 50 peer factors; Section 
4.2.3) and modified it to search for BRCA-independent signal. Importantly, we only defined 
tumours as BRCA cases that (i) harboured known BRCA1/2 alterations and (ii) showed 
evidence of HRD (i.e., HRD=1). BRCAness cases, on the contrary, were defined as those HRD 
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cases that did not harbour any BRCA1/2 alteration. We used a binary BRCA variable to define 
BRCA (BRCA=1) and BRCAness (BRCA=0) cases. Hereby, we used two different definitions of 
BRCA: Our first BRCA definition assigned all germline, somatic and epigenetic BRCA 
alterations (i.e., germline and somatic BRCA1/2 cases, and hypermethylated BRCA1 promoter 
cases) to be BRCA cases. As somatic mutations, we considered missense, frameshift, stop 
gained, splice acceptor, splice donor, start lost, and inframe deletion mutations. We will refer to 
these BRCA and BRCAness cases as 'gBRCA' and 'gBRCAness', respectively ('g' for 'genetic'). 
Next, we defined 'eBRCA' and 'eBRCAness' cases by using the gBRCA/gBRCAness cases as a 
basis and additionally assigning tumours with strong BRCA1 down-regulation (BRCA1 FPKM ≤ 
0.5) to be BRCA cases ('e' for 'expression'). We considered this additional BRCA variable since 
there has been strong evidence for a relationship between HRD and BRCA1 downregulation 
(Zhou et al., 2003).  
Firstly, we set out to directly identify molecular differences between BRCA and BRCAness 
cases, i.e., between HRD cases with and without known BRCA1/2 alterations. In our altogether 
102 HRD cases, many cancer types were represented only a few times. To keep the analysis 
robust, we decided to restrict the analysis of HRD-positive tumours to breast, ovarian and 
prostate cancers, which (i) showed larger sample sizes (n > 5), and (ii) are also known to be the 
cancer types that are most commonly affected by HRD. This filtering resulted in 83 HRD cases. 
We then classified these cases as either BRCA or BRCAness cases (see above). Altogether, 
the 83 HRD cases contained 46 gBRCA and 58 eBRCA cases.  
We then trained a linear mixed model to associate the BRCA variable with gene expression 
across the 102 HRD cases, taking age, sex, sample purity, cancer type and kinship into 
account. At an FDR threshold of 10%, the gBRCA approach did not result in any significant 
genes. Also no significant deregulation of BRCA1 could be observed. The most significant gene 
was RRAS2 (P=3x10-5, β=-0.844). In the case of eBRCA, we found two genes to be significantly 
deregulated (FDR ≤ 10%), namely BRCA1 (P=7x10-7, β=-1.77) and RRAS2 (P=1x10-5, β=-0.80) 
(Figure 15b). As the downregulation of BRCA1 was expected due to classification of samples 
with low BRCA1 expression as eBRCA, RRAS2 was the only interesting gene that was 
differentially regulated between BRCA and BRCAness cancers. While this analysis might suffer 
from a lack of power due to small sample size and data heterogeneity, the detection of the 
down-regulation of RRAS2 in BRCA cases was of potential interest: RRAS2 is downregulated in 
BRCA cases as BRCA1 is, but unlike BRCA1 it is known as an oncogene: RRAS2 was 
identified as one of the 299 cancer driver genes detected by Bailey et al. (2018). It is a Ras-like 
small GTPase that is involved in signal transduction via association with the plasma membrane, 
and has been shown to be involved in controlling cell proliferation. Mutations and over-
expression of RRAS2 have been linked to the growth of certain tumours, e.g., of breast and 
ovarian cancer (Movilla et al., 1999). Ras signalling has also been linked to HR, BRCA1-
mediated DNA repair and hereditary breast cancer signalling networks (Kalimutho et al., 2017). 
We therefore hypothesised that transcriptome-based differences between BRCA- and 
BRCAness-related HRD might depend on the downregulation of BRCA1 in BRCA cases, and 
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the upregulation of RRAS2 in BRCAness cases, and that the combination of both ultimately 
results in a HRD phenotype. Our gBRCA analyses (see above), however, showed no 
significance of RRAS2 after multiple testing, what may be due to either the lack of statistical 
power or the dependency of RRAS2 expression on BRCA1 downregulation.  
To search for more genes potentially contributing to HRD independently of BRCA, we decided 
to increase our sample size, and set out to analyse all of our PCAWG samples, including HRD-
negative cases.   
 
4.3.2 Dependence of molecular deregulation on BRCA  
We extended our search for BRCA-independent gene associations with HRD to the analysis of 
the entire dataset (n=1,159), assuming increased power to detect BRCAness-specific signal. 
We associated our HRD score with gene expression across all patients while accounting for the 
BRCA variable as a fixed covariate in the linear mixed models (50 gBRCA and 61 eBRCA 
cases, respectively). We hypothesised that model that accounts for any BRCA signal would 
allow detect genes that are associated with HRD beyond BRCA effects.  
When accounting for the gBRCA variable, we found 9 genes to be significantly associated with 
HRD (FDR ≤ 10%); when accounting for the eBRCA covariate, we found 17 genes (FDR ≤ 
10%). None of these gene sets were enriched for any known pathway. A comparison of the 
analyses that accounted for gBRCA or eBRCA (Figure 15c) showed that the results were very 
similar (Pearson correlation coefficient between P-values R=0.808), with no significant 
association between BRCA1 expression and HRD in both analyses.  
We then compared both analyses with our HRD association analysis that did not account for 
BRCA cases (Section 4.2.3). Again, we observed strong correlation of the P-values (Pearson 
correlation coefficient between P-values R=0.627 and R=0.508 for gBRCA and eBRCA, 
respectively). Accordingly, when plotting the P-values against each other, we observed a 
general reduction in statistical power in the analysis the accounted for BRCA, but no strong 
systematic effect of the BRCA factor on the associations between individual genes and HRD 
(Figure 15d for gBRCA). Only a few significant genes including BRCA1, MAPK9, FGFR3, 
ZFAND1, TMEM106B, CHD7, NGRN, TSSC4, DCLRE1A, and ZNF512 were only significant 
when the BRCA variable was not accounted for (i.e., P < 0.001 in the standard HRD analysis, 
and P > 0.1 in the HRD analysis that accounted for gBRCA; genes are highlighted in violet in 
Figure 15d). BRCA1 and DCLRE1A are known players of DNA repair pathways, TSSC4 acts 
as a tumour suppressor, and the remaining genes are involved in cell growth, regulation of 
cellular stress or metastasis. While regulation of these genes seemed to depend on the effect of 
BRCA, we did not detect any genes that were not significantly associated with HRD but gained 
significance when the BRCA covariate was accounted for. We therefore concluded that the 
cancer transcriptome did not show any evidence of alternative molecular processes unique to 
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BRCAness tumours, and that HR-deficient tumours in our dataset were dominantly driven by the 
deregulation of BRCA1/2 processes. 
We repeated the analysis of the effect of the BRCA variable in gene expression-HRD screens (i) 
per cancer type (in cancer types with a sample size n > 10), (ii) only in European samples, (iii) 
only in solid tumours, or (iv) after correcting the gene expression data for 35 instead of 50 peer 
factors. All of these approaches resulted in the same observations, i.e., a decrease of power in 
gene expression-HRD signals when accounting for BRCA cases, but no strong systematic 
effect.  
As directly assessing gene expression associations with BRCAness did not point towards a 
clear mechanism of BRCA-independent HRD, we studied the mutation states of the 110 HRD-
associated genes and how they differed between BRCA and BRCAness cases. We 
hypothesised that if certain genes showed enrichments of somatic mutations in HRD-positive 
tumours, they might have a strong impact on HRD independently of BRCA mechanisms.  
We firstly queried the somatic mutation state of the 110 genes across our 1,159 samples, and 
investigated if their somatic mutagenesis was increased in HR-deficient samples. We would 
then be able to check if these genes also showed different somatic mutational load between 
BRCA and BRCAness cases. As somatic mutations, we considered missense, frameshift, stop 
gained, splice acceptor, splice donor, start lost, and inframe deletion mutations. Altogether 107 
genes were somatically mutated in 405 samples. The somatic mutations of these genes were 
enriched in HR-deficient samples (56 out of 102 HR-deficient patients and 349 out of 1,057 HR-
sufficient patients were mutated in at least one of the genes; P=1x10-5, hypergeometric test). To 
ascertain that the HR-deficient samples did not show enrichment of somatic mutations in any 
set of genes, we randomly sampled 110 genes from our gene set and studied their enrichments 
in HR-deficient samples. We repeated this random sampling 10k times and assessed how often 
enrichments of somatic mutations in HR-deficient samples were significant (Figure 15e). By 
comparing the empiric distribution of P-values with the P-value from our original gene set (green 
line in Figure 15e), we found a marginal significance of enrichment of somatic mutations of 
HRD-related genes in HR-deficient samples (P=0.062). We concluded that somatic 
mutagenesis of the HRD-related genes was to some extent associated with HRD development. 
When repeating the analysis per gene, however, only BRCA1 and SEPP1 showed significant 
enrichment of somatic mutations in HR-deficient tumours (at a significance threshold of α=0.1). 
BRCA1 again pointed towards importance of BRCA factors for HRD, even on a genomic level. 
SEPP1 is known to be involved in oxidative stress, but has not been implicated with HRD yet. 
We still checked if these genes were differentially somatically mutated between BRCA and 
BRCAness cases (based on both definitions of BRCA cases, as gBRCA or eBRCA). However, 
such an approach did not make sense for the BRCA1 gene since our definition of BRCA and 
BRCAness cases was inherently based on the somatic mutation status of BRCA1/2. In the case 
of SEPP1, we saw no significant difference in mutational load between BRCA and BRCAness 
cases, neither in the case of the gBRCA nor in the case of the eBRCA definition. In addition, 
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Welcsh et al., (2002) found that SEPP1 expression is dependent on BRCA1 induction, so 
SEPP1 might just be another player of the complex BRCA-regulated HRD pathways. We 
therefore had to conclude that even on the somatic mutational level, BRCA alone seemed to be 
driving HRD and that we were not able to discover a gene that may contribute to BRCAness 
through somatic mutagenesis.  
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Figure 15. See next page for figure caption. 
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Figure 15. Results of linear mixed models to assess the association between gene expression 
and BRCAness. a. Correlation between P-values (-log10 P) of the linear mixed model 
associating HRD score with gene expression after correcting for 35 (x-axis) or 50 (y-axis) peer 
factors. BRCA1 is highlighted in orange, the five most significant genes per association study 
are annotated, and the FDR threshold of 10% is indicated as dashed grey lines. b. QQ plots of 
the P-values (-log10  P) of the linear mixed model associating expression of 10,959 genes with 
BRCA state across 102 HR-deficient samples. Nominal P-values are shown in blue, permuted 
P-values are shown in red. Gene expression is corrected for 50 peer factors. The ten most 
significant genes are annotated. c. Correlation between P-values (-log10 P) of the linear mixed 
model associating HRD score with gene expression after correcting for gBRCA (x-axis) or 
eBRCA cases (y-axis). BRCA1 is highlighted in orange, the five most significant genes per 
association study are annotated, and the FDR threshold of 10% is indicated as dashed grey 
lines. d. Correlation between P-values (-log10 P) of the linear mixed model associating HRD 
score with gene expression after not accounting for any BRCA cases (x-axis) or after 
accounting for gBRCA cases (y-axis). BRCA1 is highlighted in orange, the five most significant 
genes per association study are annotated, and the FDR threshold of 10% is indicated dashed 
grey lines. Highlighted in violet are the ten genes that were significantly associated with HRD 
only if no BRCA cases were accounted for (P < 0.001 in HRD analysis, and P > 0.1 in HRD 
analysis accounting for gBRCA). e. Histogram showing the frequency of P-values of the 
enrichment of somatic mutations of 110 random genes in HR-deficient samples. The green 
horizontal line represents the enrichment P-value of the set of 110 genes that was associated 
with HRD in our association analysis.  
 
 
4.4 Discussion and conclusion 
To investigate the relevance of gene expression for the development of HRD and BRCAness in 
various cancer types, we set up a gene expression-mutagenesis screen to analyse molecular 
aberrations of HR-deficient tumours in the PCAWG dataset. This section of the thesis extends 
the analysis of the relationship between genetic variation and gene expression to the 
investigation of a clinically relevant genetic signature that is not completely understood yet, 
neither on the level of its genetic determinants nor on the level of its molecular causes and 
consequences. We investigated how a gene expression-mutagenesis screen might be 
leveraged to obtain biologically meaningful and potentially clinically useful information. 
Therefore, we first studied associations between gene expression and HRD in tumours while 
taking differences between cancer types into account. We then used the gene expression-HRD 
associations and corrected for mutational and epigenetic alterations and germline predisposition 
of the BRCA1/2 genes to understand the molecular basis of BRCAness, a postulated BRCA-
independent mechanism of HRD.  
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In the gene expression-HRD screen, we found a strong difference in expression levels of more 
than 800 genes between tumours that did and did not show evidence of HRD. While some of 
these genes were known to play a role in HR-related processes, other known HRD genes were 
not significantly deregulated. Some HRD-related genes might therefore exert their function via 
alternative pathways, including protein activity, translational efficacy, interactive effects with 
other transcripts, or positional regulation.  
Overall, the strongest molecular signal of HRD on the transcriptomic level was the deregulation 
of cell cycle-related processes (when accounting for 35 peer factors in the association analysis). 
This relationship was biologically meaningful considering that cell cycle control during replication 
is an important component in HR. For example, fast replication leads to skipping or diminution of 
HR activity since the faithful repair of DNA double-strand breaks can only take place in the S/G2 
cell cycle states. This finding also confirms the results by Peng et al. (2014) who showed that 
genes deregulated in breast cancer cell lines with inactivated HR functionality were enriched for 
cell cycle and DNA replication control. However, their results were challenged by Wang et al. 
(2016) who contested the study design by Peng et al. (2014) and proved that the gene 
expression changes that were attributed to HRD in Peng et al. (2014) might be a general 
consequence of the reduced proliferation rate of the cell lines after RNA-mediated inactivation. 
As our study was based on in vivo tumour tissues and not on perturbed artificial systems, we 
were, on the contrary, able to confirm the biological importance of cell cycle regulation for the 
development of HRD.  
Moreover, we found RAD17 to be downregulated in HR-deficient tumours, an interesting cell 
cycle-associated gene. This cell cycle checkpoint gene is required for eventually activating 
cell cycle arrest in G2 upon DNA damage. We therefore hypothesised that cell cycle arrest 
might be disrupted in the case of downregulation of RAD17, leading to the accumulation of 
more DNA damage instead of regulated cell death or senescence.  
Another molecular signal we found to be associated with HRD was the enrichment of ETS-
TFBSs in HR-deficient tumours, a finding that we replicated in two more homogeneous 
datasets. However, only ETS TF ELF5 was associated with HRD on the transcriptomic level. 
Due to the weak signal of this association and the generally complicated role of ELF5 in tumour 
progression, we decided to assess the estimated activity of ETS TFs instead of their gene 
expression. While we did not find an association between HRD and ELF5 activity, we 
discovered a significant relationship between HRD and activity of ETV6, a gene with a 
recurrently rearranged genomic region in breast cancers and a known tandem duplicator 
hotspot across various cancer types. As our analyses detected a differential activity of ETV6 
binding between HRD-positive and HRD-negative tumours, we hypothesised that the activity 
change might be attributable to an increase in tandem duplications captured by our HRD score, 
an effect that would ultimately culminate in duplicator hotspots like the one located in the ETV6 
gene itself. In addition, both the breast cancer dataset from Nik-Zainal et al. (2016) and the 
PCAWG dataset pointed towards an association between genomic rearrangements of ETV6 
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and HRD. However, as we lacked a substantial number of rearrangement events in our datasets 
and longitudinal data of cancer progression, we could not infer if these rearrangement had 
contributed to HRD, or if HRD had led to the accumulation of these mutations.  
While these ETS TFBS enrichments were of potential interest to understand HRD, we were not 
able to assess their functional significance. A possible experiment to elucidate their role in HRD 
would be to modulate ETS expression or activity via knockdowns in cell lines and investigate the 
molecular consequences. A candidate could be the ETS TF ERG, which has been shown to 
have vast effects on the molecular composition of the prostate cancer cell line VCaP (Tomlins et 
al., 2008).  
In summary, this first gene expression-mutagenesis screen predicted that genes segregating 
HRD-positive and -negative patients were enriched in general cell cycle regulatory processes. 
Many canonical HRD-related genes were not deregulated, and we did also not discover an 
involvement of direct DNA repair or HR pathways. To ensure that we captured true HRD-
associated gene expression changes, we extended our association analyses to assess the 
effect of the number of hidden factors we adjusted for. We showed that the estimated number of 
confounders had a substantial impact on the association studies, and proposed a systematic 
approach to detect the optimal number of hidden factors that takes into account prior knowledge 
of investigated biological processes. We concluded that biological inferences strongly depend 
on the choice of both, the number of confounding factors and the significance threshold. We 
chose to account for more hidden factors (increasing the number of peer factors in our analysis 
from 35 to 50) since we thus discovered a clear molecular signal of HRD and DNA repair 
deregulation in our associated genes. However, by correcting for more hidden factors, we might 
have accounted for biologically meaningful associations that were linked to cell cycle 
deregulation in HR-deficient tumours. Whereas many association studies like QTL mapping 
approaches rely on estimating the number of confounders by maximising the power of their 
analyses, finding a biologically meaningful way of determining the optimal number of hidden 
factors in highly heterogeneous data still poses a difficult problem: If the number of hidden 
factors is too large, important molecular signal might be adjusted for. If not enough hidden 
factors are accounted for, spurious associations explain sub-structure of the data and not the 
true biological association. We propose that this important topic should be discussed in every 
statistical analysis of heterogeneous datasets. 
We then used our gene expression-mutagenesis screen (firstly based on 50 peer factors, and 
then replicated with the analysis based on 35 peer factors) to study the BRCA-independent 
association between HRD and gene expression changes. Our first analysis was based on only 
HRD-positive patients. This revealed RRAS2 and BRCA1 to be downregulated in BRCA cases 
as compared to BRCAness cases. RRAS2 is a known cancer driver gene that is involved in Ras 
signalling which in turn has already been linked to HR. A hypothesis to describe transcriptome-
based differences between BRCA- and BRCAness-dependent HRD might therefore postulate 
the downregulation of BRCA1 in BRCA cases, and the upregulation of RRAS2 in BRCAness 
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cases, both molecular processes that ultimately result in a HRD phenotype. Again, to obtain a 
deeper understanding of the role of RRAS2, experimental studies like functional knockdowns 
would be necessary to confirm or reject our findings.  
In an analysis of all PCAWG tumours including HR-sufficient patients that accounted for BRCA-
dependent effects on HRD-gene expression associations, we only detected few significant 
genes. These genes were neither enriched for any biological function nor - as far as we know - 
functionally important on their own (except for BRCA1). This pointed towards a strong and 
possibly prerequisite role of BRCA1/2 alterations in HRD development. As we aimed to find 
BRCA-independent molecular signal, we conducted more analyses to ensure the correctness of 
our findings: We conducted the same analyses  (i) per cancer type (in cancer types with a 
sample size n > 10), (ii) only in European samples, (iii) only in solid tumours, or (iv) after 
correcting the gene expression data for 35 instead of 50 peer factors. All of these approaches 
resulted in the same strong decrease of power in gene expression-HRD signals after accounting 
for BRCA cases. Altogether, we concluded that HR-deficient tumours in our dataset were 
dominantly driven by the deregulation of BRCA1/2 processes. Other pathways which 
aberrations have previously been associated with HRD (e.g., Polak et al., 2017) may ultimately 
act by impairing BRCA activity in ways that are not detectable from DNA sequence and gene 
expression data. Indeed, most previously detected genes act upstream of BRCA1/2 in double-
strand break recognition or HR-related pathways (e.g., PALB2 and RAD51C). Also ETS TFs 
have previously been linked to BRCA1 activity: The BRCA1 promoter contains an ETS TFBS 
(Suen & Goss, 1999) and Atlas et al. (2000) showed that ETS TFs transcriptionally activate 
BRCA1.  
We note that the presented analyses of BRCA-independent HRD are exploratory studies, 
involving repeated testing on the same fixed dataset. This means that the P-values of significant 
associations would have to be corrected for multiple testing across all analyses, and that - if we 
had found more than negative results - further validation of these associations would have to be 
performed to achieve high confidence in these results.  
A repetition of our analyses in more homogenous and larger datasets might, however, lead to 
different results. At the time that this thesis is being written, the TCGA program (Cancer 
Genome Atlas Research Network et al., 2013) has assembled various large datasets for many 
cancer types. However, the sole focus on exonic regions of most of their studies did not allow us 
to query this data to replicate our results. We conducted preliminary pre-processing and 
analyses of the TCGA-BRCA breast cancer cohort (n=1,098 patients; Cancer Genome Atlas 
Network et al., 2012), which showed us that the quantity of large indels what we used to define 
HRD in the PCAWG dataset did not correlate with known HRD-related processes like BRCA1 
downregulation or promoter hypermethylation in this dataset. This might be due to an uneven 
distribution of large indels between exonic and non-exonic regions of the genome, 
demonstrating that we would not be able to repeat our analyses on exon-based datasets.  
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Finally, we would like to point towards a general problem of association studies between gene 
expression changes and genetic variation, namely the impact of time. In our analyses, genetic 
signatures that are predictive of HRD, including Signature 3, large indels and BRCA1 promoter 
methylation status, might have been inherited from ancestor cells but might not be signs of on-
going deregulation associated with HRD. Hence, in certain tumours, no gene expression 
alterations due to HRD might be expected despite the detection of genetic or epigenetic 
evidence. Notably, PARPi resistance has developed in originally HR-deficient tumours through 
demethylation of BRCA1 or RAD51C promoters (Montoni et al., 2013). In such cases, we might 
erroneously define a tumour as HR-deficient which would bias our association studies. 
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5 Concluding remarks 
In this thesis, I investigated how functional associations between genetic variation and gene 
expression alterations can be studied in highly heterogeneous molecular genetic datasets using 
statistical models (Section 1). In addition to assessing biologically meaningful associations in 
large-scale data, I showed how causality between genetic and molecular variation can be 
established with the help of germline variation, and how heterogeneity might lead to spurious 
associations. The correction for confounding factors that might be readily available as 
covariates of the dataset (e.g., cancer type in our pan-cancer analysis, Section 2) or that are 
hidden in the data (e.g., effects of tumour sample purity or cancer subtypes, Sections 2 and 4) is 
hereby a prerequisite for all statistical association studies. This includes accounting for inherent 
population structure in genomic datasets, what we achieved by modelling the kinship between 
individuals as a random effect in linear mixed models (Sections 2 and 4). Further statistical 
model regularisation is essential to not over-fit the data and to prevent the effect of multi-
collinearity, a problem we had to deal with in our alternative splicing analyses on single-cell 
transcriptome data: Here, we integrated the genomic features that were highly correlated with 
each other per cassette exon by applying regularised regression, namely ridge regression 
(Section 3). We showed that alternative statistical approaches like CNNs can improve modelling 
non-linear dependencies within complex data (Section 3). These approaches might not only 
improve modelling performance, but also extend the catalogue of biological conclusions we can 
potentially draw from s dataset; in the case of predicting splicing from DNA sequence, we could 
query the model to detect local sequence motifs that are putatively responsible of altered 
splicing rates (Section 3). Finally, we emphasised throughout this thesis that replications in 
independent datasets are a crucial prerequisite for ensuring the credibility of association 
studies, and of scientific findings in general. 
In the first section of this thesis, I introduced statistical methods that have been developed for 
and applied to genomics data to face the described challenges. I introduced concepts 
concerning genetic variation, and gene expression as a proximal readout for molecular 
variability, and presented human cancer as a biological system that can be used to assess the 
applicability and efficiency of these statistical methods. 
In the second section of this thesis, I analysed the highly heterogeneous, cancer type specific 
regulatory landscape of human cancers. This study system allowed us to investigate multi-
dimensional associations between gene expression and genetic variation from various sources, 
including local and genome-wide, germline and somatic, protein-coding and non-coding genetic 
variants. Using joint modelling, we explored the impact of these variants on gene expression.  
Collectively, our analyses of the PCAWG genomic and transcriptomic data provided a 
comprehensive picture of the regulatory landscape of cancer tissue, and of how different 
germline and somatic variations alter gene expression levels in a pan-cancer setting. We 
 106 
showed that co-regulation of the same genes by multiple different types of genetic variants is 
common in cancer, and we simultaneously reported the relative magnitudes of these different 
effects. Previous studies have been limited by the lack of WGS data, which is essential for 
identifying contributions of non-coding variants to gene expression variability. Indeed, our 
analyses of the currently largest cohort of matched tumour WGS and RNA-Seq data of 1,188 
patients identified previously underappreciated associations between somatic regulation in distal 
regulatory elements and gene expression. Besides emphasizing the effect of local non-coding 
variation on gene expression, we established associations between genome-wide mutational 
processes and gene expression, and elucidated cause and consequence of this relationship by 
taking into account the effect of germline variation. Importantly, this allowed us to derive de 
novo functional annotations of mutational signatures with previously known aetiologies. Our 
results hence pointed towards non-coding somatic deregulation as a functional driver of 
carcinogenesis beyond mutations of the coding sequence.  
While these results are a valuable resource to better understand cancer heterogeneity, it will be 
important to conduct similar analyses per cancer type as soon as respective dataset will be 
available. Although we corrected for cancer type specific effects, associations that only occur in 
few cancer types will inherently be confounded by tissue type effects and cannot be anticipated 
in other cancers (PCAWG Transcriptome Core Group et al., 2018). 
In the third section of this thesis, I studied the relationship between genetic and epigenetic 
variation and alternative splicing, and extended the scope of this thesis from associations 
between genetic variation and gene expression (Section 2) by introducing (i) the functionally 
relevant phenotype of alternative splicing, (ii) the study of single-cell instead of bulk data, (iii) the 
impact of epigenetic variation on molecular functions, and (iv) the application of more complex 
(non-linear) machine learning models like deep neural networks. In this project, we conducted 
the first analyses of alternative splicing in single cells while considering the impact of genetic 
and epigenetic factors. Functionally relevant splicing events have been identified in bulk data, 
but variability in splicing between single cells from the same tissue and its relationship with 
epigenetic alterations remained poorly understood.  
Instead of cancer, I studied differentiating iPS cells as a model, and replicated the results in 
mouse ES cells. This allowed us to not only assess the variability of both, alternative splicing 
and the underlying impact of genetic and epigenetic variation across cells, but also on a 
longitudinal scale, namely during the important process of stem cell differentiation. We were 
able to show for the first time that alternative splicing and splicing variability across cells can be 
predicted from genomic and DNA methylation variation in single cells. We studied the impact of 
DNA methylation and cellular features on cassette exon splicing, and characterised splicing 
variation and its determinants. We proved consistency of the detected relationships beyond cell 
type and species boundaries. Importantly, we finally investigated stability and variance of 
splicing during cellular differentiation and we found evidence that DNA methylation primes 
splicing switches during cell differentiation (Linker, Urban et al., 2019). 
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In the fourth section of this thesis, I showed how gene expression-mutagenesis screens could 
be used to understand complex mutational signatures, using the cancer hallmark of DNA repair 
deficiency as an example. This section of the thesis extended the analysis of the relationship 
between genetic variation and gene expression to the investigation of a clinically relevant 
genetic signature: HR-deficient tumours have been shown to be responsive to various inhibition 
therapies, but the molecular cause and consequence and genetic determinants of this repair 
deficiency are not yet fully understood. I investigated genome-wide molecular aberrations 
caused by HRD beyond the few key genes that are known by literature. I therefore firstly set up 
a gene expression-HRD screen and then used it to study the molecular basis of BRCAness, a 
postulated BRCA-independent mechanism of HRD, by correcting for known mutational and 
epigenetic alterations and germline predisposition of the BRCA1/2 genes. My results pointed 
towards a dominant effect of BRCA1 mutagenesis in both, a pan-cancer setting and per cancer 
type. 
This analysis confronted me with two main limitations of gene expression association studies. 
First, estimating the number of confounding factors is not trivial. Whereas many association 
studies like QTL mapping approaches just maximise the power of their analyses across a range 
of confounding factors, this does not ensure finding an optimal number of hidden factors that is 
biologically meaningful in heterogeneous dataset. Hence, association analyses are at risk of 
correcting for important molecular signal if the number of hidden factors is too large, or of 
explaining non-targeted substructure of the data via spurious associations if the number of 
hidden factors is too small. Second, I detected many genes that were putatively associated with 
HRD, but which role in cancer progression has not been described yet. To be able to draw 
functional conclusions from such statistical findings, computational analyses like the ones 
presented in this thesis would have to be complemented and confirmed by functional 
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